Precipio (PRPO) 10-K 27 Mar 20 2019 FY Annual report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Mar. 25, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Entity Registrant Name	PRECIPIO, INC.
Title of 12(b) Security	Common Stock
Trading Symbol	PRPO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 19.8
Entity Common Stock, Shares Outstanding		8,870,129
Entity Central Index Key	0001043961
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash	$ 848,000	$ 381,000
Accounts receivable, net	574,000	690,000
Inventories	184,000	197,000
Other current assets	272,000	525,000
Total current assets	1,878,000	1,793,000
PROPERTY AND EQUIPMENT, NET	431,000	496,000
OTHER ASSETS:
Operating lease right-of-use assets	519,000
Intangibles, net	16,658,000	19,291,000
Other assets	25,000	25,000
Total assets	19,511,000	21,605,000
CURRENT LIABILITIES:
Current maturities of long-term debt, less debt issuance costs	321,000	263,000
Current maturities of convertible notes, less debt discounts and debt issuance costs	142,000	4,377,000
Current maturities of finance lease liabilities	52,000	57,000
Current maturities of operating lease liabilities	209,000
Accounts payable	1,936,000	5,169,000
Accrued expenses	1,639,000	1,940,000
Deferred revenue	35,000	49,000
Other current liabilities		1,910,000
Total current liabilities	4,334,000	13,765,000
LONG TERM LIABILITIES:
Long-term debt, less current maturities and debt issuance costs	198,000	253,000
Finance lease liabilities, less current maturities	119,000	155,000
Operating lease liabilities, less current maturities	317,000
Common stock warrant liabilities	1,338,000	1,132,000
Derivative liabilities		62,000
Deferred tax liability		70,000
Other long-term liabilities		45,000
Total liabilities	6,306,000	15,482,000
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS' EQUITY:
Preferred stock - $0.01 par value, 15,000,000 shares authorized at December 31, 2019 and December 31, 2018, 47 shares issued and outstanding at December 31, 2019 and December 31, 2018, liquidation preference of $42 at December 31, 2019
Common stock, $0.01 par value, 150,000,000 shares authorized at December 31, 2019 and December 31, 2018, 7,898,117 and 2,298,738 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively	79,000	23,000
Additional paid-in capital	74,065,000	53,796,000
Accumulated deficit	(60,939,000)	(47,696,000)
Total stockholders' equity	13,205,000	6,123,000
Total liabilities and stockholders? equity	$ 19,511,000	$ 21,605,000

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	47	47
Preferred stock, shares outstanding (in shares)	47	47
Preferred stock, liquidation preference	$ 42
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Shares issued (in shares)	7,898,117	2,298,738
Common stock, shares outstanding (in shares)	7,898,117	2,298,738

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue, net of contractual allowances and adjustments	$ 4,095	$ 3,448
less allowance for doubtful accounts	(968)	(584)
Net sales	3,127	2,864
Total cost of sales	2,908	2,639
Gross profit	219	225
OPERATING EXPENSES:
Operating expenses	9,623	9,452
Impairment of intangible assets and goodwill	1,590	4,685
TOTAL OPERATING EXPENSES	11,213	14,137
OPERATING LOSS	(10,994)	(13,912)
OTHER INCOME (EXPENSE):
Interest expense, net	(473)	(269)
Warrant revaluation	416	1,918
Loss on modification of warrants	(1,128)
Derivative revaluation	(415)	267
Gain on settlement of liability, net	1,437	263
(Loss) gain on extinguishment of debt	(20)	376
Loss on extinguishment of convertible notes		(2,903)
Loss on litigation	(266)
Loss on issuance of convertible notes	(1,870)	(1,328)
Loss on settlement of equity instruments		(385)
Total other expenses	(2,319)	(2,061)
LOSS BEFORE INCOME TAXES	(13,313)	(15,973)
INCOME TAX BENEFIT	70	279
NET LOSS	(13,243)	(15,694)
Deemed dividends related to beneficial conversion feature of preferred stock and fair value of consideration issued to induce conversion of preferred stock		(4,222)
TOTAL DIVIDENDS		(4,222)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (13,243)	$ (19,916)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)	$ (2.33)	$ (13.82)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)	5,695,159	1,441,113
Service revenue, net [Member]
Revenue, net of contractual allowances and adjustments	$ 4,051	$ 3,335
less allowance for doubtful accounts	(968)	(584)
Net sales	3,083	2,751
Total cost of sales	2,908	2,549
Clinical research grants [Member]
Revenue, net of contractual allowances and adjustments		100
Total cost of sales		90
Other [Member]
Revenue, net of contractual allowances and adjustments	$ 44	$ 13

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Common Stock	Total
Balance at beginning of period at Dec. 31, 2017		$ 7	$ 44,560	$ (31,542)		$ 13,025
Balance at beginning of period (in shares) at Dec. 31, 2017	4,935	679,774
Increase (Decrease) in Stockholders' Equity
Net loss				(15,694)		(15,694)
Conversion of preferred stock into common stock		$ 4	(4)
Conversion of preferred stock into common stock (in shares)	(4,888)	431,022
Conversion of convertible notes into common stock		$ 4	2,352			2,356
Conversion of convertible notes into common stock (in shares)		384,896			252,486
Issuance of common stock in connection with purchase agreements		$ 5	2,003			2,008
Issuance of common stock in connection with purchase agreements (in shares)		428,050
Issuance of common stock in exchange for cancelation of other current liabilities		$ 1	1,896			1,897
Issuance of common stock in exchange for cancelation of other current liabilities (in shares)		120,983
Issuance of common stock upon exercise of warrants		$ 2	1,269			1,271
Issuance of common stock upon exercise of warrants (in shares)		252,486
Issuance of common stock for consulting services in connection with the merger			39			39
Issuance of common stock for consulting services in connection with the merger (in shares)		1,527
Warrant modification recorded as debt discount in conjunction with convertible note issuance			11			11
Beneficial conversion feature on issuance of notes			2,118			2,118
Write-off beneficial conversion feature in conjunction with convertible note extinguishment			(1,029)			(1,029)
Write-off debt discounts (net of debt premiums) in conjunction with convertible note conversions			(210)			(210)
Write-off debt derivative liability in conjunction with convertible note conversions			301			301
Liability recorded related to equity purchase agreement repricing				(460)		(460)
Non-cash stock-based compensation			490			490
Balance at end of period at Dec. 31, 2018		$ 23	53,796	(47,696)		6,123
Balance at end of period (in shares) at Dec. 31, 2018	47	2,298,738
Increase (Decrease) in Stockholders' Equity
Net loss				(13,243)		(13,243)
Conversion of convertible notes into common stock		$ 25	7,528			7,553
Conversion of convertible notes into common stock (in shares)		2,511,173			310,200
Issuance of common stock in connection with purchase agreements		$ 28	6,600			6,628
Issuance of common stock in connection with purchase agreements (in shares)		2,778,077
Proceeds upon issuance of common stock from exercise of warrants		$ 3	1,572			1,575
Write-off warrant liability in conjunction with warrant exercises			2,364			2,364
Issuance of common stock upon exercise of warrants (in shares)		310,200
Beneficial conversion feature on issuance of notes			1,792			1,792
Write-off debt discounts (net of debt premiums) in conjunction with convertible note conversions			(731)			(731)
Write-off debt derivative liability in conjunction with convertible note conversions			477			477
Non-cash stock-based compensation			668			668
Payment of fractional common shares in conjunction with reverse stock split			(1)			(1)
Payment of fractional common shares in conjunction with reverse stock split (in shares)		(71)
Balance at end of period at Dec. 31, 2019		$ 79	$ 74,065	$ (60,939)		$ 13,205
Balance at end of period (in shares) at Dec. 31, 2019	47	7,898,117

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,243)	$ (15,694)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	1,118	1,265
Amortization of operating lease right-of-use asset	231
Amortization of finance lease right-of-use asset	63
Amortization (accretion) of deferred financing costs, debt discounts and debt premiums	111	(21)
Loss (gain) on extinguishment of debt	20	(376)
Gain on settlement of liability, net	(1,437)	(263)
Loss on settlement of equity instrument		385
Loss on litigation	266
Loss on issuance of convertible notes	1,870	1,328
Loss on extinguishment of convertible notes		2,903
Stock-based compensation	668	529
Impairment of intangible assets and goodwill	1,590	4,685
Provision for losses on doubtful accounts	966	581
Warrant revaluation	(416)	(1,918)
Loss on modification of warrants	1,128
Derivative revaluation	415	(267)
Changes in operating assets and liabilities:
Accounts receivable	(850)	(541)
Inventories	13	(36)
Other assets	427	127
Accounts payable	(1,884)	309
Operating lease liabilities	(223)
Accrued expenses and other liabilities	26	250
Net cash used in operating activities	(9,141)	(6,754)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(55)	(97)
Net cash used in investing activities	(55)	(97)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on finance lease obligations	(46)	(58)
Payment of deferred financing costs	(120)	(138)
Payment of fractional common shares in conjunction with reverse stock split	(1)
Issuance of common stock, net of issuance costs	6,628	2,008
Proceeds from exercise of warrants	1,575	1,271
Proceeds from long-term debt		300
Proceeds from convertible notes	2,150	3,850
Principal payments on convertible notes	(50)
Principal payments on long-term debt	(473)	(422)
Net cash flows provided by financing activities	9,663	6,811
NET CHANGE IN CASH	467	(40)
CASH AT BEGINNING OF PERIOD	381	421
CASH AT END OF PERIOD	848	381
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the period for interest	36	42
SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY
Purchases of equipment financed through accounts payable	1	38
Equipment financed through finance lease obligations	23	106
Deferred debt issuance cost financed through accounts payable		57
Discount of 9% on issuance of convertible bridge notes	188	405
Other current liabilities canceled in exchange for common shares		1,897
Conversion of convertible debt plus interest into common stock	7,553	2,356
Beneficial conversion feature on issuance of convertible notes	1,792	2,118
Initial valuation of derivative liability recorded in conjunction with issuance of convertible notes		610
Initial valuation of warrant liability recorded in conjunction with issuance of convertible notes	1,858	2,665
Long-term debt exchanged for convertible notes		3,191
Liabilities exchanged for convertible notes	2,150
Prepaid insurance financed with loan	434	375
Accounts payable converted to long-term debt		74
Liability recorded related to equity purchase agreement repricing	$ 460	460
Warrant liability canceled due to settlement of equity instruments		$ 456
Issuance of common stock for consulting services	-	39
Modification of warrant in conjunction with convertible note issuance		$ 11
Proceed from issuance of convertible note recorded through other current assets		250
Write-off of beneficial conversion feature in conjunction with convertible note extinguishment		1,029
Right-of-use assets obtained in exchange for lease obligations	$ 750
Amounts included in measurement of lease liabilities	273
Write-off warrant liability in conjunction with warrant exercises	2,364
Write-off of debt discounts (net of debt premiums) in conjunction with convertible note conversions	731	210
Write-off of derivative liability in conjunction with convertible note conversions	$ 477	$ 310

BUSINESS DESCRIPTION

BUSINESS DESCRIPTION	12 Months Ended
	Dec. 31, 2019
BUSINESS DESCRIPTION [Abstract]
BUSINESS DESCRIPTION	1. BUSINESS DESCRIPTION Business Description. Precipio, Inc., and its subsidiary, (collectively, “we”, “us”, “our”, the “Company” or “Precipio”) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technologies developed within academic institutions, and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with various academic institutions to capture the expertise, experience and technologies developed within academia to provide a better standard of cancer diagnostics and aim to solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which focuses on development of various technologies, among them IV-Cell, HemeScreen and ICE-COLD-PCR, or ICP, the patented technology described further below, which we exclusively licensed from Dana-Farber Cancer Institute, Inc., or Dana-Farber, at Harvard University. The research and development center focuses on the development of these technologies, which we believe will enable us to commercialize these and other technologies developed with our current and future academic partners. The facility in Omaha was also recently certified as a CLIA and CAP facility, and we have begun bringing in house several molecular tests that the Company had previously referenced out to other laboratories. Our platform also connects patients, physicians and diagnostic experts residing within academic institutions . Going Concern. The consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. As of December 31, 2019, the Company had a net loss of $13.2 million, negative working capital of $2.5 million and net cash used in operating activities of $9.1 million. The Company’s ability to continue as a going concern, for the next twelve months from the date the consolidated financial statements were issued, is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has entered into a purchase agreement with Lincoln Park (the “LP Purchase Agreement” or “Equity Line”), pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $10.0 million of common stock of the Company (subject to certain limitations) from time to time over the term of the LP Purchase Agreement. The extent we rely on Lincoln Park as a source of funding will depend on a number of factors including, the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. As of the date of the consolidated financial statements were issued , we have already received approximately $9.3 million in aggregate, including approximately $1.4 million from the sale of 328,590 shares of common stock to Lincoln Park during 2018, $6.6 million from the sale of 2,778,077 shares of common stock to Lincoln Park during 2019 and $1.3 million from the sale of 900,012 shares of common stock to Lincoln Park from January 1, 2020 through the date the consolidated financial statements were issued, leaving the company an additional $0.7 million to draw upon . Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date the consolidated financial statements were issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation. The consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiaries. All inter-company balances and transactions have been eliminated in consolidation. Use of Estimates. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. The most significant estimates and assumptions with regard to these consolidated financial statements relate to the allowance for doubtful accounts, assumptions used within the fair value of debt and equity transactions, contractual allowances and related impairments. These assumptions require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these consolidated financial statements. Risks and Uncertainties. Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the consolidated financial statements. The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. Fair Value. Unless otherwise specified, book value approximates fair value. The common stock warrant liabilities and derivative liabilities are recorded at fair value. See Note 12 - Fair Value for additional information. Other Current Assets. Other current assets of $0.3 million as of December 31, 2019 include prepaid insurance of $0.2 million and prepaid assets and other receivables of $0.1 million. Other current assets of $0.5 million as of December 31, 2018 include prepaid assets of less than $0.1 million, prepaid insurance of $0.2 million and other receivables of $0.3 million. Concentrations of Risk. From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits of up to $250,000 per depositor per financial institution. We have not experienced any losses on such accounts as of December 31, 2019. Service companies in the health care industry typically grant credit without collateral to patients. The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payers. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000‑89398. Inventories. Inventories consist of laboratory supplies and are valued at cost (determined on an average cost basis, which approximates the first-in, first-out method) or net realizable value, whichever is lower. We evaluate inventory for items that are slow moving or obsolete and record an appropriate reserve for obsolescence if needed. We determined that no allowance for slow moving or obsolete inventory was necessary at December 31, 2019 and 2018. Property and Equipment, net. Property and equipment are carried at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Depreciation and amortization are computed by the straight-line method over the estimated useful lives of the related assets as follows: Furniture and fixtures 5 to 7 years Laboratory equipment 3 to 10 years Computer equipment and software 3 to 7 years For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in operations for the period. Expenditures for major betterments that extend the useful lives of property and equipment are capitalized. Goodwill and Intangible Assets. Goodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets of a business acquired and is tested for impairment annually, as of October 1 st , or when impairment triggering events may occur during a quarterly reporting period. Throughout the year ended December 31, 2018, at certain quarterly reporting periods, the Company experienced a decline in its share price and a significant reduction in its market capitalization, indicating that it was more likely than not that the fair value of the Company was less than its carry value. Through valuation analysis of the fair value of the Company using the market capitalization, the discounted cash flow model and market analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment in the amount of $4.7 million was recorded for the year ended December 31, 2018. As of December 31, 2018, goodwill was fully written off and no balance remained. Intangibles We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair value of the asset to the carrying amount of the asset (group). There were no impairment charges on our amortizable long-lived assets during the years ended December 31, 2019 and 2018. In-process research and development (“IPR&D”) represents the fair value assigned to research and development assets that were not fully developed when acquired. Until the IPR&D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. The IPR&D principally related to research projects that were not related to IV-Cell, HemeScreen or ICP. During 2019, the Company made a determination to suspend further research and analysis of these projects, and, as a result, it was more likely than not that the IPR&D was fully impaired, resulting in an impairment charge of $1.6 million in 2019. There was no impairment of IPR&D during the year ended December 31, 2018. Debt Issuance Costs, Debt Discounts and Debt Premiums. Debt issuance costs, debt discounts and debt premiums are being amortized or accreted over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt and premiums are presented as an increase to the related debt in the accompanying balance sheets. The amortization amount recorded was expense, net of income, of $0.1 million in 2019 and income, net of expense, of less than $0.1 million in 2018. Debt discounts and debt premiums are amortized or accreted to interest expense and interest income on the consolidated statement of operations, respectively. See Note 5 – Long Term Debt and Note 6 – Convertible Notes for further discussion. Stock-Based Compensation. All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Stock-based compensation cost is based on the fair value of the portion of stock-based awards that is ultimately expected to vest. The Company utilizes the Black-Scholes option pricing model for determining the estimated fair value for stock-based awards. Unvested awards as of December 31, 2019 had vesting periods of up to four years from the date of grant. At December 31, 2019, 53,334 unvested awards outstanding are subject to performance vesting conditions and no awards are subject to market-based vesting conditions. No awards outstanding at December 31, 2018 were subject to performance or market-based vesting. Net Sales Recognition. Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services. The Company derives its revenues from diagnostic testing - histology, flow cytometry, cytology and molecular testing; clinical research from bio-pharma customers, state and federal grant programs; and from biomarker testing from bio-pharma customers. All sources of revenue are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See more detailed information on revenue in Note 14 – Sales Service Revenue, Net And Accounts Receivable. The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient’s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payers. Provisions for third-party payer settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance sheet as deferred revenue was approximately $0.1 million as of December 31, 2019 and 2018. Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement. Accounts Receivable Accounts Receivable result from diagnostic services provided to self-pay and insured patients, project based testing services and clinical research. The payment for services provided by the Company are generally due within 30 days from the invoice date. Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the collectability of accounts receivable, the Company analyzes and identifies trends for each of its sources of revenue to estimate the appropriate allowance for doubtful accounts. For receivables associated with self-pay patients, including patients with insurance and a deductible and copayment, the Company records an allowance for doubtful accounts in the period of services on the basis of past experience of patients unable or unwilling to pay for service fee for which they are financially responsible. For receivables associated with services provided to patients with third-party coverage, the Company analyzes contractually due amounts and provides an allowance, if necessary. The difference between the standard rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged against the allowance for doubtful accounts. Presentation of Insurance Claims and Related Insurance Recoveries. The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities. There were no insurance claims or insurance recoveries recorded during the years ended December 31, 2019 and 2018. Advertising Costs. Advertising costs are expensed as incurred and are included in operating expenses on the consolidated statement of operations. Advertising costs charged to operations totaled less than $0.1 million in 2019 and 2018, respectively. Research and Development Costs. All costs associated with internal research and development are expensed as incurred. These costs include salaries and employee related expenses, operating supplies and facility-related expenses. Research and development costs charged to operations totaled $1.2 million and $1.1 million for the years ended December 31, 2019 and 2018, respectively. Income Taxes. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in the period when the change in tax rates is enacted. A valuation allowance is established when it is determined that it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance has been applied against the Company’s net deferred tax assets as of December 31, 2019 and 2018, due to projected losses and because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of, or changes in tax laws, regulations and interpretations thereof as well as other factors. The Company’s policy is to record interest and penalties directly related to income taxes as income tax expense in the accompanying consolidated statements of operations, of which there was none for the years ended December 31, 2019 and 2018. Common Stock Warrants. The Company classifies the issuance of common stock warrants as equity any contracts that (i) require physical settlement or net-stock settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own stocks (physical settlement or net-stock settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside of the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in stock (physical settlement or net-stock settlement). Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. Beneficial Conversion Features. The intrinsic value of a beneficial conversion feature (“BCF”) inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the first conversion date using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the BCF is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. When the preferred shares are non-redeemable the BCF is fully amortized into additional paid-in capital and preferred discount. If the preferred shares are redeemable, the discount is amortized from the commitment date to the first conversion date. Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 2,281,701 and 2,517,675 shares of our common stock have been excluded from the computation of diluted loss per share at December 31, 2019 and 2018, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: December 31, 2019 2018 Stock options 490,330 224,895 Warrants 909,189 917,573 Preferred stock 20,888 20,888 Convertible notes 861,294 1,354,319 Total 2,281,701 2,517,675 Recently Adopted Accounting Pronouncements. In February 2016, the FASB issued ASU No. 2016‑02, Leases-Topic 842 . The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard was adopted effective January 1, 2019, using a modified retrospective transition, and thus did not adjust comparative periods. The new standard provides a number of optional practical expedients in transition. The Company has elected the “package of practical expedients”, which permits it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. As a result of the adoption of Topic 842 the Company recognized approximately $0.7 million of lease liabilities and corresponding right-of-use (“ROU”) assets in its consolidated balance sheet on the date of initial application. See Note 8 – Leases for additional information. In June 2018, the FASB issued ASU 2018-07 “ Compensation—Stock Compensation (Topic 718) ”, which expands the scope of Topic 718 to include share based payment transactions for acquiring goods and services from non-employees. The Company adopted this guidance on January 1, 2019. The adoption of this guidance was not material to our consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted. In December 2019, the FASB issued ASU 2019-12 “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ”, which is intended to improve consistent application and simplify the accounting for income taxes. This ASU removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. This standard is effective for annual reporting periods beginning after December 15, 2020, including interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact of adoption of this ASU and does not expect the adoption of this new standard to have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-13 “ Fair Value Measurement (Topic 820) ”, which modifies certain disclosure requirements in Topic 820, such as the removal of the need to disclose the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy, and several changes related to Level 3 fair value measurements. This ASU is effective for reporting periods beginning after December 15, 2019. We are currently assessing the potential impact that the adoption of this ASU will have on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-15 “ Intangibles—Goodwill and Other—Internal Use Software (Subtopic 350-40) ”, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software. This ASU is effective for reporting periods beginning after December 15, 2019. We are currently assessing the potential impact that the adoption of this ASU will have on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13 “ Measurement of Credit Losses on Financial Instruments ”, which replaces current methods for evaluating impairment of financial instruments not measured at fair value, including trade accounts receivable and certain debt securities, with a current expected credit loss model. This ASU is effective for the Company for reporting periods beginning after December 15, 2022. We are currently assessing the potential impact that the adoption of this ASU will have on our consolidated financial statements.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2019
PROPERTY AND EQUIPMENT [Abstract]
PROPERTY AND EQUIPMENT, NET	3 . PROPERTY AND EQUIPMENT, NET A summary of property and equipment at December 31, 2019 and 2018 is as follows: 2019 2018 Furniture and fixtures $ 12 $ 12 Laboratory equipment 299 299 Computer equipment and software 463 369 Equipment under finance leases 425 402 Construction in process 23 67 1,222 1,149 Less—accumulated depreciation and amortization (791) (653) Total $ 431 $ 496 Depreciation expense was approximately $0.1 million for both the years ended December 31, 2019 and 2018. Depreciation expense during each year includes depreciation related to equipment acquired under finance leases.

INTANGIBLES

INTANGIBLES	12 Months Ended
	Dec. 31, 2019
INTANGIBLES [Abstract]
INTANGIBLES	4 . INTANGIBLES Intangible assets consist of the following: Dollars in Thousands December 31, 2019 Accumulated Impairment Net Book Cost Amortization Charge Value Technology $ 18,990 $ 2,374 $ — $ 16,616 Customer relationships 250 208 — 42 Backlog 200 200 — — Covenants not to compete 30 30 — — Trademark 40 40 — — IPR&D 1,590 — 1,590 — $ 21,100 $ 2,852 $ 1,590 $ 16,658 Dollars in Thousands December 31, 2018 Accumulated Impairment Net Book Cost Amortization Charge Value Technology $ 18,990 $ 1,424 $ — $ 17,566 Customer relationships 250 125 — 125 Backlog 200 200 — — Covenants not to compete 30 30 — — Trademark 40 30 — 10 IPR&D 1,590 — — 1,590 $ 21,100 $ 1,809 $ — $ 19,291 Estimated Useful Life Technology 20 years Customer relationships 3 years Backlog 1 year Covenants not to compete 1 year Trademark 2 years Our IPR&D projects were accounted for as indefinite-lived intangible assets and subject to impairment testing. During 2019, the Company reviewed its IPR&D for impairment and determined that it was more likely than not that the IPR&D was fully impaired, resulting in an impairment charge of $1.6 million in 2019. For the year ended December 31, 2018, there was no impairment of IPR&D. Amortization expense for intangible assets was $1.0 million during the year ended December 31, 2019 and $1.2 million during the year ended December 31, 2018. Amortization expense for intangible assets is expected to be $1.0 million, $0.9 million, $0.9 million, $0.9 million and $0.9 million for each of the years ending December 31, 2020, 2021, 2022, 2023 and 2024, respectively.

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2019
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	5 . LONG-TERM DEBT Long-term debt consists of the following: Dollars in Thousands December 31, 2019 December 31, 2018 Department of Economic and Community Development (DECD) $ 249 $ 274 DECD debt issuance costs (24) (28) Financed insurance loan 260 204 September 2018 Settlement 34 66 Total long-term debt 519 516 Current portion of long-term debt (321) (263) Long-term debt, net of current maturities $ 198 $ 253 Department of Economic and Community Development On January 8, 2018, the Company received gross proceeds of $400,000 when it entered into an agreement with DECD by which the Company received a grant of $100,000 and a loan of $300,000 secured by substantially all of the Company’s assets (the “DECD 2018 Loan”.) For the year ended December 31, 2018, $100,000 has been recorded as clinical research grant revenue in the consolidated statements of operations. The DECD 2018 Loan is a ten-year loan due on December 31, 2027 and includes interest paid monthly at 3.25%. Debt issuance costs associated with the DECD 2018 Loan were approximately $31,000. Amortization of the debt issuance cost was approximately $3,000 for the years ended December 31, 2019 and 2018, respectively. Net debt issuance costs were approximately $24,000 and $28,000 at December 31, 2019 and 2018, respectively, and are presented as a reduction of the related debt in the accompanying consolidated balance sheets. Amortization for each of the next five years is expected to be approximately $3,000. Financed Insurance Loan. The Company finances certain of its insurance premiums (the “Financed Insurance Loans”). In July 2018, the Company financed $0.4 million with a 4.89% interest rate and fully paid off such loan as of July 2019. In July 2019, the Company financed $0.4 million with a 5.0% interest rate and will make monthly payments through May of 2020. As of December 31, 2019 and 2018, the Financed Insurance Loan outstanding balance of $0.3 million and $0.2 million, respectively, was included in current maturities of long-term debt in the Company’s consolidated balance sheets. A corresponding prepaid asset was included in other current assets. Settlement Agreement. On September 21, 2018, the Company entered into a settlement and forbearance agreement with a creditor (the “September 2018 Settlement”) pursuant to which, the Company agreed to make monthly principal and interest payments to the creditor over a two year period, from November 1, 2018 to November 1, 2020, in full and final settlement of $0.1 million of indebtedness that was owed to the creditor on the date of the September 2018 Settlement. The settlement amount will accrue interest at the rate of 10% per annum until paid in full. The September 2018 Settlement outstanding balance of approximately $0.1 million was included in current maturities of long-term debt in the Company’s consolidated balance sheet as of December 31, 2019 and in long-term debt and accounts payable in the Company’s consolidated balance sheet as of December 31, 2018. The aggregate future maturities required on gross long-term debt at December 31, 2019 are as follows: 2020 2021 2022 2023 2024 2025 and thereafter Total DECD loan $ 30 $ 28 $ 30 $ 30 $ 31 $ 100 $ 249 Financed Insurance Loan 260 — — — — — 260 September 2018 Settlement 34 — — — — — 34 $ 324 $ 28 $ 30 $ 30 $ 31 $ 100 $ 543

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2019
LONG-TERM DEBT [Abstract]
CONVERTIBLE NOTES	6 . CONVERTIBLE NOTES. Convertible notes consists of the following: Dollars in Thousands December 31, 2019 December 31, 2018 Convertible bridge notes $ 1,938 $ 4,294 Convertible bridge notes discount and debt issuance costs (1,796) (1,111) Convertible bridge notes premiums — 647 Convertible promissory notes - Exchange Notes — 630 Convertible promissory notes - Exchange notes debt issuance costs — (83) Total convertible notes 142 4,377 Current portion of convertible notes (142) (4,377) Convertible notes, net of current maturities $ — $ — Convertible Bridge Notes. On April 20, 2018, the Company entered into a securities purchase agreement (the “2018 Note Agreement”) with certain investors (the “April 2018 Investors”), pursuant to which the Company would issue up to approximately $3,296,703 in Senior Secured Convertible Promissory Notes along with warrants (the “Transaction”). The number of warrants is equal to the number of shares of common stock issuable upon conversion of the notes based on the conversion price at the time of issuance. Some of the warrants were issued with a one-year term and some with a five-year term. The 2018 Note Agreement includes customary representations, warranties and covenants by the Company and customary closing conditions. The Transaction consisted of a series unregistered Senior Secured Convertible Notes (the “Bridge Notes”), bearing interest at a rate of 8% annually and an original issue discount of 9%. The Bridge Notes are convertible at a price of $7.50 per share, provided that if the notes are not repaid within 180 days of the note’s issuance date, the conversion price shall be adjusted to 80% of the lowest volume weighted average price during the prior 10 days, subject to a minimum conversion price of $4.50 per share. The Transaction consisted of a number of drawdowns. The initial closing on April 20, 2018 provided the Company with proceeds of $1,660,000, net of an original issue discount of 9% and before debt issuance costs, for the issuance of notes with an aggregate principal of $1,824,176 (the “April 2018 Bridge Notes”). The Company completed three additional drawdowns for aggregate proceeds of $1.3 million, net of an original issue discount of 9% and before debt issuance cost, for the issuance of notes with an aggregate principal of $1.5 million, during the third quarter 2018. Drawdowns included the following funding from the April 2018 Investors (i) $348,104 in July 2018 for Bridge Notes with an aggregate principal of $382,526, (ii) $495,955 in August 2018 for Bridge Notes with an aggregate principal of $545,005 and (iii) $495,941 in September 2018 for Bridge Notes with an aggregate principal of $544,990 (collectively, the “Q3 2018 Bridge Notes”). The Bridge Notes are payable by the Company on the earlier of (i) the one year anniversary after each closing date or (ii) upon the closing of a qualified offering, namely the Company raising gross proceeds of at least $7,000,000 (the “Maturity Date”). At any time, provided that the Company gives 5 business days written notice, the Company has the right to redeem the outstanding principal amount of the Bridge Notes, including accrued but unpaid interest, all liquidated damages and all other amounts due under the Bridge Notes, for cash as follows: (i) an amount which is equal to the sum of 105% if the Company exercises its right to redeem the Bridge Notes within 90 days of the initial closing, (ii) 110% if the Company exercises its right to redeem the Bridge Notes within 180 days of the initial closing, or (iii) 115% if the Company exercises its right to redeem 180 days from the initial closing. The terms of the 2018 Note Agreement also stipulate that upon written demand by one of the April 2018 Investors, for any of their draws throughout the year associated with the 2018 Note Agreement after a period of time as defined within the 2018 Note Agreement, the Company shall file a registration statement within thirty (30) days after written demand covering the resale of all or such portion of the conversion shares for an offering to be made on a continuous basis pursuant to Rule 415. The registration statement filed shall be on Form S-3 or Form S-1, at the option of the Company. If the Company does not file a registration statement in accordance with the terms of the 2018 Note Agreement, then on the business day following the applicable filing date and on each monthly anniversary of the business day following the applicable filing date (if no registration statement shall have been filed by the Company in accordance herewith by such date), the Company shall pay to the April 2018 Investors an amount in cash, as partial liquidated damages, equal to 1% per month (pro-rata for partial months) based upon the gross purchase price of the Bridge Notes (calculated on a daily basis) under the 2018 Note Agreement. As requested by certain April 2018 Investors, conversion shares related to the April 2018 Note Agreement were included in a registration statement on Form S-3 that the Company filed with the SEC on February 6, 2019 and which became effective with the SEC on February 13, 2019. The obligations under the Bridge Notes are secured, subject to certain exceptions and other permitted payments by a perfected security interest on the assets of the Company. The 9% discount associated with the April 2018 Bridge Notes was approximately $164,000 and was recorded as a debt discount. The Company also incurred legal and advisory fees associated with the April 2018 Bridge Notes of approximately $164,000 and these were recorded as debt issuance costs. The 9% discount associated with the Q3 2018 Bridge Notes was approximately $133,000 and was recorded as a debt discount. As part of the initial closing, the April 2018 Investors received 243,224 warrants to purchase shares of common stock of the Company (the “April 2018 Warrants”) that are exercisable at a 150% premium to the April 2018 Bridge Notes conversion price or $11.25. Half of such April 2018 Warrants had a five-year term and half had a one-year term. The Company reviewed the provisions of the April 2018 Warrants to determine the balance sheet classification of the April 2018 Warrants. The Company concluded that there is an obligation to repurchase the April 2018 Warrants by transferring assets and accordingly the warrants were classified as a liability. The April 2018 Warrants were valued using a Black-Scholes option pricing model with an initial value of approximately $1.1 million at the date of issuance and were recorded as a liability with an offset to debt discount. The April 2018 Investors received 196,340 warrants to purchase shares of common stock of the Company in connection with the Q3 Bridge Note issuances (the “Q3 2018 Warrants”) with an initial exercise price of $11.25. Half of such Q3 2018 Warrants had a five-year term and half had a one-year term. The terms of the Q3 2018 Warrants are the same as the April 2018 Warrants and, as such, were classified as liabilities. The Q3 2018 Warrants were valued using a Black-Scholes option pricing model with an initial value of approximately $0.7 million at the date of issuance and were recorded as a liability with an offset to debt discount. See Note 12 – Fair Value for further discussion. On September 20, 2018, immediately after the final drawdown of the Bridge Notes, the Company entered into an agreement with the April 2018 Investors whereby the exercise price of all warrants issued to the April 2018 Investors in connection with both the 2018 Note Agreement and the Q3 Bridge Notes were amended from $11.25 to $7.50. The Company reviewed this repricing to determine the appropriate accounting treatment and concluded that the repricing would be treated as a modification of the warrant agreements. As the warrants related to the Bridge Notes are classified as liabilities, the change in fair value attributable to the repricing would be reflected in the subsequent measurement on the warrants. Management calculated the change in fair value due to repricing to be an expense of approximately $0.1 million which is included in warrant revaluation in the consolidated statements of operations. Pursuant to a letter agreement, dated as of April 20, 2018 (the “Letter Agreement”), the Company engaged a registered broker dealer as a financial advisor (the “Financial Advisor”). Pursuant to the Letter Agreement, the Company paid the Financial Advisor a fee of $116,000, approximately 7% of the proceeds from the sale of the April 2018 Bridge Notes. This is included in the debt issuance costs discussed above. Per the Letter Agreement, the Company also issued to the Financial Advisor 15,466 warrants to purchase shares of common stock of the Company with an exercise price of $11.25 (the “Advisor Warrants”). The Advisor Warrants are exercisable at any time and from time to time, in whole or in part, during the four-year period commencing six months from the date of the Letter Agreement. Like the April 2018 Warrants and like the Q3 2018 Warrants, the Advisor Warrants met the criteria to be classified as a liability. The Advisor Warrants were valued using a Black-Scholes option pricing model with an initial value of approximately $0.1 million at the date of issuance and were recorded as a liability with an offset to debt discount. See Note 12 – Fair Value for further discussion. The Company reviewed the conversion option of the April 2018 Bridge Notes and determined that there was a beneficial conversion feature in connection with the issuance of the April 2018 Bridge Notes since the calculated effective conversion price was at a discount to the fair market value of the Company's common stock at issuance date. For purposes of calculating the beneficial conversion feature, the proceeds of $1.7 million from the April 2018 Bridge Notes were allocated to the notes and warrants based on their relative fair values at the date of issuance. The portion allocated to the April 2018 Bridge Notes was $0.6 million with the remaining $1.1 million allocated to the April 2018 Warrants. As a result of the allocation of the proceeds, the Company calculated a beneficial conversion feature of approximately $1.1 million which was recorded as a debt discount with an offset to additional paid in capital. The Q3 2018 Bridge Notes also contained beneficial conversion features. For purposes of calculating the beneficial conversion features, the net proceeds of $1.3 million from the Q3 2018 Bridge Notes were allocated to the notes and warrants based on their relative fair values at the date of issuance. The portion allocated to the Q3 2018 Bridge Notes was $0.6 million with the remaining $0.7 million allocated to the Q3 2018 Warrants. As a result of the allocation of the proceeds, the Company calculated a beneficial conversion feature of approximately $0.5 million which was recorded as a debt discount with an offset to additional paid in capital. The Company reviewed the redemption features of the Bridge Notes and determined that there is a redemption feature (the “Bridge Notes Redemption Feature”) that qualifies as an embedded derivative instrument which is required to be separated from the debt host contract and accounted for separately as a derivative. For the April 2018 Bridge Notes, the Company determined the initial fair value of the derivative at the time of issuance to be approximately $0.1 million which was recorded as a debt discount with an offset to derivative liability. For the Q3 2018 Bridge Notes, the Company determined the initial fair value of the derivatives at the time of issuance to be approximately $0.1 million which was recorded as a debt discount with an offset to derivative liability. The valuations were performed using the “with and without” approach, whereby the Bridge Notes were valued both with the embedded derivative and without, and the difference in values was recorded as the derivative liability. See Note 12 – Fair Value for further discussion. As detailed above, debt discounts and debt issuance costs related to the April 2018 Bridge Notes totaled $2.7 million. Since the costs exceeded the $1.8 million face amount of the debt, the Company recorded $1.8 million of debt discount and debt issuance costs as a reduction of the related debt with the excess $0.9 million expensed as a loss on issuance of convertible notes in the consolidated statements of operations. The total debt discounts and debt issuance costs related to the Q3 2018 Bridge Notes totaled $1.4 million, of which the Company recorded $1.3 million of debt discount and debt issuance costs as a reduction of the related debt with $0.1 million expensed as a loss on issuance of convertible notes in the consolidated statements of operations. The $0.1 million recorded as a loss on issuance of convertible notes was due to the fact that one of the drawdowns during the third quarter of 2018 had debt discount and debt issuance costs in excess of the face amount of the related debt. The debt discount and debt issuance costs will be amortized to interest expense over the life of the respective April 2018 Bridge Notes and Q3 2018 Bridge Notes on a basis that approximates the effective interest method. On November 29, 2018, the Company entered into an amendment and restatement agreement (the “Amendment Agreement”) amending and restating the terms of the 2018 Note Agreement. The Amendment Agreement provided for the issuance of up to $1,318,681 of additional Bridge Notes together with applicable warrants, in one or more tranches, with substantially the same terms and conditions as the previously issued Bridge Notes and related warrants. The conversion price of the notes was amended so that it shall be equal to the greater of $3.75 or $0.75 above the closing bid price of our common stock on the date prior to the original issue date. In the event the notes are not paid in full prior to 180 days after the original issue date, the conversion price shall be equal to 80% of the lowest volume weighted average price (“VWAP”) in the 10 trading days prior to the date of the notice of conversion, but in no event below the floor price of $2.25. In connection with the Amendment Agreement, during the fourth quarter of 2018, the Company completed two additional drawdowns for aggregate proceeds of $1.1 million, net of an original issue discount of 9% and before debt issuance costs, for the issuance of notes with an aggregate principal of $1.2 million (collectively, the “Q4 2018 Bridge Notes”). Approximately $0.3 million of the $1.1 million of proceeds was received after December 31, 2018 and is included in other current assets on our consolidated balance sheet at December 31, 2018. The 9% discount associated with the Q4 2018 Bridge Notes was approximately $108,000 and was recorded as a debt discount. In connection with the Q4 2018 Bridge Note issuances, the Company issued to the investors 300,115 warrants to purchase shares of common stock of the Company (the “Q4 2018 Warrants”) with an initial exercise price of $5.40 and a five-year term. The terms of the Q4 2018 Warrants are the same as the April 2018 Warrants and, as such, were classified as liabilities. The Q4 2018 Warrants were valued using a Black-Scholes option pricing model with an initial value of approximately $0.7 million at the date of issuance and were recorded as a liability with an offset to debt discount. See Note 12 – Fair Value for further discussion. The Company reviewed the conversion option of the Q4 2018 Bridge Notes and determined that there was a beneficial conversion feature in connection with the issuance of the Q4 2018 Bridge Notes, as there was with the previously issued Bridge Notes. For purposes of calculating the beneficial conversion features, the net proceeds of $1.1 million from the Q4 2018 Bridge Notes were allocated to the notes and warrants based on their relative fair values at the date of issuance. The portion allocated to the Q4 2018 Bridge Notes was $0.4 million with the remaining $0.7 million allocated to the Q4 2018 Warrants. As a result of the allocation of the proceeds, the Company calculated a beneficial conversion feature of approximately $0.5 million which was recorded as a debt discount with an offset to additional paid in capital. The Q4 2018 Bridge Notes contain the Bridge Notes Redemption Feature that qualifies as an embedded derivative instrument which is required to be separated from the debt host contract and accounted for separately as a derivative. For the Q4 2018 Bridge Notes, the Company determined the initial fair value of the derivatives at the time of issuance to be approximately $15,000 which was recorded as a debt discount with an offset to derivative liability. See Note 12 – Fair Value for further discussion. The total debt discounts and debt issuance costs related to the Q4 2018 Bridge Notes totaled $1.4 million, of which the Company recorded $1.1 million of debt discount and debt issuance costs as a reduction of the related debt in the accompanying consolidated balance sheet with $0.3 million expensed as a loss on issuance of convertible notes in the consolidated statements of operations. The $0.3 million recorded as a loss on issuance of convertible notes was due to the fact that one of the drawdowns during the fourth quarter of 2018 had debt discount and debt issuance costs in excess of the face amount of the related debt. At the time of the Amendment Agreement, the conversion price related to $3.3 million of previously issued Bridge Notes, the April 2018 Bridge Notes and Q3 2018 Bridge Notes, was amended. The Company reviewed the modification to the conversion price and concluded that the amendment will be treated as an extinguishment of the related Bridge Notes. The difference between the carrying value of the notes just prior to modification (the “Old Debt”) and the fair value of the notes just after modification (the “New Debt”) would be recorded as a gain or loss on extinguishment in the consolidated statements of operations. The Company removed the carrying value of the Old Debt which included $3.1 million of unamortized debt discounts, beneficial conversion features of $1.0 million and less than $0.1 million in derivative liabilities. The Company calculated the fair value of the New Debt to be $4.2 million. The Company reviewed whether or not a beneficial conversion feature existed on the New Debt but the calculation resulted in zero intrinsic value to the conversion options so no new beneficial conversion feature was recorded. Management also reviewed the Bridge Notes Redemption Feature of the New Notes but their fair value was zero so no derivative liability was recorded at the time of modification, however this will be reassessed at the end of each reporting period. As a result, the Company recorded a debt premium on the New Debt of $0.9 million and a loss on extinguishment of convertible notes of $2.9 million in the consolidated statements of operations during the year ended December 31, 2018. On April 16, 2019, the Company entered into an amendment and restatement agreement (“Amendment No.2 Agreement”) amending and restating the terms of the 2018 Note Agreement (as first amended pursuant to the amendment agreement in November 2018 (the Amendment Agreement”)). The Amendment No. 2 Agreement provided the Company with approximately $0.9 million of gross proceeds for the issuance of notes with an aggregate principal of $1.0 million (the “April 2019 Bridge Notes”) together with applicable warrants, with substantially the same terms and conditions as the previously issued Bridge Notes and related warrants. The 9% discount associated with the April 2019 Bridge Notes was approximately $0.1 million and was recorded as a debt discount. In connection with the April 2019 Bridge Note issuances, the Company issued to the investors 147,472 warrants to purchase shares of common stock of the Company with a five year term and exercise price of $5.40 (the “April 2019 Warrants”). The April 2019 Warrants had an initial value of approximately $1.0 million at the date of issuance and were recorded as a liability with an offset to debt discount. See Note 12 – Fair Value for further discussion. The April 2019 Bridge Notes were issued to investors that previously participated in the 2018 Note Agreement. The conversion price of the April 2019 Bridge Notes shall be equal to the greater of $3.75 or $0.75 above the closing bid price of our common stock on the date prior to the original issue date. In the event the notes are not paid in full prior to 180 days after the original issue date, the conversion price shall be equal to 80% of the lowest volume weighted average price (“VWAP”) in the 10 trading days prior to the date of the notice of conversion, but in no event below the floor price of $2.25. The Company reviewed the conversion option of the April 2019 Bridge Notes and determined that there was a beneficial conversion feature with a value of approximately $0.9 million which was recorded as a debt discount with an offset to additional paid in capital. The April 2019 Bridge Notes also contain the Bridge Notes Redemption Feature and the Company performed a valuation at the time of issuance which resulted in zero value, at that time, due to the high value of the conversion feature and a limited upside from the redemption premium. Debt discounts and debt issuance costs related to the April 2019 Bridge Notes totaled $2.0 million. Since the costs exceeded the $1.0 million face amount of the debt at issuance, the Company recorded $1.0 million of debt discount and debt issuance costs as a reduction of the related debt in the accompanying consolidated balance sheet with the excess $1.0 million expensed as a loss on issuance of convertible notes in the consolidated statements of operations during the year ended December 31, 2019. Pursuant to the Amendment No.2 Agreement, previously issued warrants were amended such that the exercise price of such warrants was amended from $7.50 to $5.40 and any warrant that had a one-year term was amended to have a five-year term. The Company reviewed the amendments to the warrants and determined that they will be treated as a modification of an outstanding equity instrument at the time of the Amendment No.2 Agreement. Management calculated the change in fair value due to the modifications to be an expense of approximately $1.1 million which is included in loss on modification of warrants in the consolidated statements of operations. On May 14, 2019, the Company entered into a securities purchase agreement pursuant to which, the Company was provided with $1.0 million of gross proceeds for the issuance of notes with an aggregate principal of $1.1 million (the “May 2019 Bridge Notes”) together with applicable warrants, with substantially the same terms and conditions as the previously issued Bridge Notes and related warrants. The 9% discount associated with the May 2019 Bridge Notes was approximately $0.1 million and was recorded as a debt discount. In connection with the May 2019 Bridge Note issuances, the Company issued to the investors 154,343 warrants to purchase shares of common stock of the Company with a five year term and exercise price of $9.56 (the “May 2019 Warrants”). The May 2019 Warrants had an initial value of approximately $0.9 million at the date of issuance and were recorded as a liability with an offset to debt discount. See Note 12 – Fair Value for further discussion. The May 2019 Bridge Notes were issued to investors that previously participated in the 2018 Note Agreement. The conversion price of the May 2019 Bridge Notes is $7.12, provided that a) in the event the notes are not paid in full prior to 180 days after the original issue date or b) upon a registration statement (as defined in the purchase agreement) being declared effective, whichever occurs earlier, the conversion price shall be equal to 80% of the lowest VWAP in the 10 trading days prior to the date of the notice of conversion, but in no event below the floor price of $2.25. The Company reviewed the conversion option of the May 2019 Bridge Notes and determined that there was a beneficial conversion feature with a value of approximately $0.9 million which was recorded as a debt discount with an offset to additional paid in capital. The May 2019 Bridge Notes also contain the Bridge Notes Redemption Feature and the Company performed a valuation at the time of issuance which resulted in zero value, at that time, due to the high value of the conversion feature and a limited upside from the redemption premium. Debt discounts and debt issuance costs related to the May 2019 Bridge Notes totaled $2.0 million. Since the costs exceeded the $1.1 million face amount of the debt, the Company recorded $1.1 million of debt discount and debt issuance costs as a reduction of the related debt in the accompanying consolidated balance sheet with the excess $0.9 million expensed as a loss on issuance of convertible notes in the consolidated statements of operations during the year ended December 31, 2019. During the years ended December 31, 2019 and 2018, $4.4 million and $0.2 million, respectively, of Bridge Notes, plus interest, were converted into 1,900,766 and 93,334 shares of common stock of the Company, respectively. As a result of the conversions, the Company wrote-off approximately $0.5 million of derivative liability, with an offset to additional paid-in capital, during the year ended December 31, 2019 and approximately $0.1 million of debt premium with an offset to additional paid in capital during the year ended December 31, 2018. During the years ended December 31, 2019 and 2018, the change in Bridge Note debt discounts and debt premiums was as follows: For the Year Ended December 31, 2019 2018 Debt Discounts Debt Premiums Debt Discounts Debt Premiums Beginning balance at January 1 $ (1,111) $ 647 $ — $ — Additions: (2,088) — (4,275) 879 Deductions: Amortization (accretion) (1) 273 (167) 118 (170) Write-off related to note conversions (2) 1,130 (480) — (62) Write-off related to note extinguishment (3) — — 3,046 — Balance at December 31 $ (1,796) $ — $ (1,111) $ 647 (1) Amortization/accretion is recognized as interest expense/income within the consolidated statements of operations based on the effective interest method. (2) Write-offs associated with note conversions are recognized as an offset to additional paid-in capital at the time of the conversion. (3) Write-offs associated with note extinguishment are recognized as a loss and included in loss on extinguishment of convertible notes in the consolidated statements of operations. The remaining debt discounts of $1.8 million, as of December 31, 2019, are expected to be fully amortized by the end of the second quarter of 2020. Convertible Promissory Notes – Exchange Notes. In 2017, the Company entered into Debt Settlement Agreements (the “Settlement Agreements”) with certain of its accounts payable and accrued liability vendors (the “Creditors”) pursuant to which the Creditors, who were owed $6.3 million (the “Debt Obligations”) by the Company, agreed to reduce and exchange the Debt Obligations for a secured obligation in the amount of $3.2 million, $1.9 million in shares of the Company’s common stock and warrants, with a fair value of approximately $0.2 million, to purchase shares of the Company’s common stock. The Debt Obligations were restructured as follows: · The Company entered into a scheduled long-term debt repayment agreement of approximately $3.2 million, which includes interest of approximately $0.6 million, to be paid in forty-eight equal monthly installments beginning in July 2018 (the “Secured Debt Obligations”). · Debt Obligations of $1.9 million were canceled in exchange for 120,983 shares of the Company’s common stock with a weighted average price per share of $15.60 (the “Settlement Common Shares”). The stock was issued in February 2018. · Warrants to purchase 7,207 shares of the Company’s common stock at an exercise price of $112.50 per share (the “Creditor Warrants”) were issued to certain Creditors. The Creditor Warrants were issued in February 2018. During 2018, the Company entered into an Exchange Agreement (the “Exchange Agreements”) with three institutional investors (the “Holders”) pursuant to which the Company issued convertible promissory notes, due January 1, 2021 (the “Exchange Notes”) in exchange (the “Exchange”) for amounts owed to the Holders pursuant to certain debt settlement agreements, dated October 31, 2017. For the year ended December 31, 2018, $3.2 million of Secured Debt Obligations were exchanged for $2.8 million of Exchange Notes. The Company considered the appropriate accounting treatment of the Exchange and determined that the Exchange will be treated as a debt extinguishment and the difference between the carrying amount of the Secured Debt Obligations and the face value of the Exchange Notes will be treated as a gain on extinguishment. The Company recorded a $0.4 million gain on extinguishment of debt in the consolidated statements of operations for the year ending December 31, 2018. Pursuant to the terms of the Exchange Notes, the Company shall pay to the Holders the aggregate principal amount of the Exchange Notes in eighteen equal installments beginning on August 1, 2019 and ending on January 1, 2021. In accordance with the terms of the Exchange Notes, the Holder shall have the right, to convert at the then applicable conversion price any amount of the Exchange Notes up to $300,000 on any given Trading Day, with a maximum conversion amount up to $500,000 during a period of five Trading Days (the “Conversion Option”). The conversion price shall be the lesser of (i) the average volume weighted average price for the five trading days prior to the date of conversion multiplied by 1.65 and (ii) $15.00 (the “Conversion Price”). At any time at which there is no Equity Conditions Failure, as defined in the terms of the Exchange Note, and only once every ten trading days, the Company shall have the right, but not the obligation, to direct the Holders to convert up to 20% of the then outstanding principal amount of the Exchange Notes under specified conditions (the “Company Put Option”). The Company will be subject to certain restrictive covenants pursuant to the Notes, including limitations on (i) amending its certificate of incorporation and bylaws (ii) indebtedness, (iii) asset sales or leases, (iv) restricted payments and investments, (v) redemptions or repurchases of capital stock and (vi) transactions with affiliates, and the conversion price of the Exchange Notes shall be subject to certain customary adjustments in the event of stock splits, dividends, rights offerings or other pro rata distributions to holders of the Company’s common stock. The Company reviewed the Conversion Option and concluded that it meets the criteria for derivative accounting and requires bifurcation and separate accounting as a derivative. The Company determined the initial fair value of the derivative at the time of issuance to be approximately $0.4 million which was recorded as a debt discount with an offset to derivative liability. The valuation was performed using a Monte Carlo Simulation. See Note 12 – Fair Value for further discussion. The Company reviewed the Company Put Option and concluded that it meets the criteria for derivative accounting and requires bifurcation and separate accounting as a derivative. The Company determined the initial fair value of the derivative at the time of issuance to be immaterial. The valuation was performed using a Monte Carlo Simulation. The Company also reviewed certain redemption provisions and call options that exist in the terms of the Exchange Notes and determined that neither require bifurcation or separate accounting. During the year ended December 31, 2019 and 2018, Exchange Notes of approximately $0.6 million and $2.2 million, respectively, were converted into 155,351 and 291,562 shares of common stock of the Company, respectively. As of December 31, 2019 and 2018, the outstanding balance of the Exchange Notes, net of discounts, was zero and $0.6 million, respectively, and was presented within convertible notes in the Company’s consolidated balance sheet. During the year ended December 31, 2019 and 2018, the change in Exchange Note debt discounts was as follows: (Dollars in thousands) For the Year Ended December 31, 2019 2018 Beginning balance at January 1 $ (83) $ — Additions: — (383) Deductions: Amortization (1) 2 28 Write-off related to note conversions (2) 81 272 Balance at December 31 $ — $ (83) (1) Amortization is recognized as intere

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	7 . ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. Accrued expenses at December 31, 2019 and 2018 are as follows: (dollars in thousands) December 31, 2019 December 31, 2018 Accrued expenses $ 1,268 $ 1,583 Accrued compensation 247 118 Accrued interest 124 239 $ 1,639 $ 1,940 The Company was able to reduce certain accrued expense and accounts payable amounts through negotiations with certain vendors to settle outstanding liabilities and the Company recorded these amounts as gains which are included in gain on settlement of liability, net in the consolidated statements of operations. During the years ended December 31, 2019 and 2018, approximately $1.4 million and $0.3 million, respectively, was recorded as a gain. Other current liabilities at December 31, 2019 and 2018 are as follows: (dollars in thousands) December 31, 2019 December 31, 2018 Liability related to equity purchase agreement — 460 Liability for settlement of equity instrument — 1,450 $ — $ 1,910 On February 20, 2018, Crede Capital Group LLC (“Crede”) filed a lawsuit against the Company in the Supreme Court of the State of New York for Summary Judgment in Lieu of Complaint requiring the Company to pay cash owed to Crede. Crede claimed that Precipio had breached a Securities Purchase Agreement and Warrant that Crede entered into in connection with an investment in Transgenomic and that pursuant to those agreements, Precipio owed Crede approximately $2.2 million. On March 12, 2018, Precipio entered into a settlement agreement (the “Crede Agreement”) with Crede pursuant to which Precipio agreed to pay Crede a total sum of $1.925 million over a period of 16 months payable in cash, or at the Company’s discretion, in stock, in accordance with terms contained in the Crede Agreement. In accordance with the terms of the agreement and in addition to the agreement to pay, we also executed and delivered to Crede an affidavit of confession of judgment. As of the date of the Crede Agreement, the fair value of the common stock warrant liability related to Crede was revalued to approximately $0.4 million, resulting in a gain of $0.2 million included in warrant revaluation in the consolidated statement of operations during the year ended December 31, 2018. See Note 12 – Fair Value for further discussion. At the time of the Crede Agreement, the Company recorded an additional loss of $0.4 million, which is included in loss on settlement of equity instruments in the consolidated statement of operations during the year ended December 31, 2018. During 2018, the Company paid approximately $0.5 million to Crede, with a remaining balance of $1.45 million as of December 31, 2018. On January 15, 2019, the $1.45 million liability was replaced with the Crede Note . As of December 31, 2018, the Company had recorded a liability of approximately $0.5 million related to an equity purchase agreement with Leviston, which is included in other current liabilities on our consolidated balance sheet. On January 29, 2019, the Company entered into the Leviston Settlement pursuant to which the Company issued the Leviston Note in full satisfaction of the $0.5 million discussed above along with approximately $0.2 million of other obligations owed to Leviston which are included in accrued expenses in our consolidated balance sheet at December 31, 2018. See Note 6 – Convertible Notes.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	8 . LEASES On January 1, 2019, the Company recorded initial ROU assets and corresponding operating lease liabilities of approximately $750,000 and a reversal of deferred rent and prepaid expenses of approximately $6,000 resulting in no cumulative effect adjustment upon adoption of Topic 842. The Company leases administrative facilities and laboratory equipment through operating lease agreements. In addition we rent various equipment used in our diagnostic lab and in our administrative offices through finance lease arrangements. Our operating leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common area or other maintenance costs). The facility leases include one or more options to renew, from 1 to 5 years or more. The exercise of lease renewal options is typically at our sole discretion, therefore, the renewals to extend the lease terms are not included in our ROU assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and, when they are reasonably certain of exercise, we include the renewal period in our lease term. As our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. Operating leases result in the recognition of ROU assets and lease liabilities on the balance sheet. ROU assets represent our right to use the leased asset for the lease term and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The primary leases we enter into with initial terms of 12 months or less are for equipment. Upon the adoption of Topic 842, our accounting for finance leases, previously referred to as capital leases, remains substantially unchanged from prior guidance. The balance sheet presentation of our operating and finance leases is as follows: (dollars in thousands) Classification on the Condensed Consolidated Balance Sheet December 31, 2019 Assets: Operating lease assets Operating lease right-of-use assets, net $ 519 Finance lease assets Property and equipment, net 184 Total lease assets $ 703 Liabilities: Current: Operating lease obligations Current maturities of operating lease liabilities $ 209 Finance lease obligations Current maturities of finance lease liabilities 52 Noncurrent: Operating lease obligations Operating lease liabilities, less current maturities 317 Finance lease obligations Finance lease liabilities, less current maturities 119 Total lease liabilities $ 697 As of December 31, 2019, the estimated future minimum lease payments, excluding non-lease components, are as follows: (dollars in thousands) Operating Leases Finance Leases Total 2020 $ 242 $ 62 $ 304 2021 241 38 279 2022 48 32 80 2023 35 28 63 2024 17 27 44 Thereafter — 13 13 Total lease obligations 583 200 783 Less: Amount representing interest (57) (29) (86) Present value of net minimum lease obligations 526 171 697 Less, current portion (209) (52) (261) Long term portion $ 317 $ 119 $ 436 Other information as of December 31, 2019: Weighted-average remaining lease term (years): Operating leases 2.8 Finance leases 4.3 Weighted-average discount rate: Operating leases Finance leases During the year ended December 31, 2019, operating cash flows from operating leases was $144,000 and ROU assets obtained in exchange for operating lease liabilities was $750,000. Operating Lease Costs Operating lease costs were $0.3 million during the year ended December 31, 2019 and 2018, respectively. These costs are primarily related to long-term operating leases for the Company’s facilities and laboratory equipment. Short-term and variable lease costs were less than $0.1 million for the years ended December 31, 2019 and 2018, respectively. Finance Lease Costs Finance leases are included in property and equipment, net and finance lease liabilities, less current maturities on the consolidated balance sheets. The associated amortization expense and interest included in the consolidated statements of operations for the year ended December 31, 2019 and 2018 is less than $0.1 million, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES PURCHASE COMMITMENTS The Company has entered into purchase commitments for reagents from suppliers. These agreements started in 2011 and run through 2025. The Company and the suppliers will true up the amounts on an annual basis. The future minimum purchase commitments under these and other purchase agreements are as follows: Years ending December 31, (dollars in thousands) 2020 $ 341 2021 242 2022 228 2023 219 2024 149 Thereafter 50 $ 1,229 LITIGATIONS The Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. On February 21, 2017, XIFIN, Inc. (“XIFIN”) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately $0.27 million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. A liability of $0.1 million was reflected in accounts payable within the accompanying consolidated balance sheet at December 31, 2018. On April 19, 2019, the Company executed a settlement agreement with XIFIN pursuant to which the Company paid to XIFIN an agreed amount of $40,000 as settlement in consideration for total release from all outstanding amounts due and payable by the Company to XIFIN. The settlement amount was paid in full by the Company on April 19, 2019 . CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of less than $0.1 million has been recorded and is reflected in accounts payable within the accompanying consolidated balance sheet at December 31, 2019 and 2018. On February 17, 2017, Jesse Campbell (“Campbell”) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we had a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement’s deal protection provisions deter superior offers. As a result, Campbell alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a‑9 promulgated thereafter. The Company filed a motion to dismiss all claims, which motion was fully briefed on November 27, 2017. The Court granted the Company’s motion in full on May 3, 2018 and dismissed the lawsuit. The Eighth Circuit reversed the decision of the District Court and remanded the case back to the District Court. The parties filed a notice with the Court on May 22, 2019, announcing that they had reached a settlement in principle. On June 21, 2019, the parties filed a stipulation of settlement, in which defendants are released from all claims and expressly deny that that they have committed any act or omission giving rise to any liability. The stipulation includes a settlement payment of $1.95 million, which will be primarily funded by our insurance. On July 10, 2019, the Court entered an order preliminarily approving the settlement. The settlement remains subject to final approval by the Court. The Company’s insurance policy includes a deductible of approximately $0.8 million and the Company has previously paid approximately $0.5 million in legal fees in connection with the litigation which have been applied to the deductible leaving approximately $0.3 million to be paid by the Company and approximately $1.7 million to be paid by the insurance company. During the third quarter of 2019, both the Company and the insurance company paid their respective amounts to an escrow account where the funds will be held until they are approved for distribution at a fairness hearing of the Court which took place on November 4, 2019. As of the date the consolidated financial statements were issued, the Company is waiting for the Court to render its judgement which is still outstanding. On March 21, 2018, Bio-Rad Laboratories filed a lawsuit against us in the Superior Court Judicial Branch of the State of Connecticut for Summary Judgment in Lieu of Complaint requiring us to pay cash owed to Bio-Rad in the amount of $39,000 that was recorded in accounts payable within the accompanying consolidated balance sheet at December 31, 2018. The obligation was paid in full during the second quarter 2019, resulting in no remaining amount due to Bio-Rad. LEGAL AND REGULATORY ENVIRONMENT The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES The Company recorded a deferred tax liability of $0.1 million as of December 31, 2018, related to the acquisition of IPR&D through the Merger. This deferred tax liability was recorded to account for the book versus tax basis difference related to the IPR&D intangible asset. This deferred tax liability was excluded from sources of future taxable income, as the timing of its reversal cannot be predicted due to the indefinite life of this IPR&D. As such, this deferred tax liability cannot be used to offset the valuation allowance. As a result of the write-off of the IPR&D in 2019, the related deferred tax liability of $0.1 million was eliminated and is included in income tax benefit in the consolidated statements of operations for the year ended December 31, 2019. Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s net deferred tax assets relate primarily to its net operating loss carryforwards and stock based compensation, offset by property and equipment and intangible assets. With the exception of the IPR&D, the Company has recorded a full valuation allowance to offset the net deferred tax assets, because it is not more likely than not that the Company will realize future benefits associated with these net deferred tax assets at December 31, 2019 and 2018. At December 31, 2019 and 2018, the Company had net deferred tax assets of $10.7 million and $8.7 million, respectively, against which a valuation allowance of $10.7 million and $8.8 million, respectively, had been recorded. The valuation allowance excluded the deferred tax liability for IPR&D assigned as an indefinite life intangible asset for book purposes, also known as a “naked credit” in the amount of $0.1 million at December 31, 2018. The increase in the valuation allowance for the year ended December 31, 2019 is $1.9 million, resulting from additional net operating losses generated in the year. The deferred tax liabilities associated with the book versus tax basis difference of intangible assets are the result of an asset step-up pursuant to the Merger. Significant components of the Company’s deferred tax assets at December 31, 2019 and 2018 are as follows: Dollars in Thousands 2019 2018 Deferred tax assets: Net operating loss and credit carryforwards $ 13,989 $ 10,202 Stock-based compensation 292 192 Other 666 426 Gross deferred tax assets 14,947 10,820 Deferred tax liabilities: Property and equipment (95) 42 Intangible assets (4,148) (2,084) IPR&D intangible assets — (70) Gross deferred tax liabilities (4,243) (2,112) Net deferred tax assets 10,704 8,708 Less valuation allowance (10,704) (8,778) Net deferred liability $ — $ (70) The Company’s provision for income taxes for the year ended December 31, 2019 and December 31, 2018 relates to income taxes in states and other jurisdictions and differs from the amounts determined by applying the statutory federal income tax rate to the loss before income taxes for the following reasons: Dollars in Thousands 2019 2018 Benefit at federal rate $ (2,796) $ (3,354) Increase (decrease) resulting from: State income taxes—net of federal benefit (517) (633) Miscellaneous permanent differences 78 — Warrant liability revaluation (104) (479) Impairment of goodwill — 1,170 Impairment of in-process research and development (70) — Other — 14 Change in valuation allowance 3,339 3,003 Total income tax benefit $ (70) $ (279) The income tax expense consists of the following at December 31, 2019 and 2018. Dollars in Thousands 2019 2018 Federal: Current $ — $ — Deferred (70) (279) Total Federal $ (70) $ (279) State: Current $ — $ — Deferred — — Total State $ — $ — Foreign: Current $ — $ — Deferred — — Total Foreign $ — $ — Total Tax Provision $ (70) $ (279) The Company had approximately $61 million and $39 million of available gross federal and state net operating loss (“NOL”) carryforwards as of December 31, 2019 and 2018, respectively. B eginning in 2018, under the Act, federal loss carryforwards have an unlimited carryforward period, however such losses can only offset 80% of taxable income in any one year. Included in the total NOLs for 2019 are $31 million of federal losses that fall under these new rules. Section 382 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited. The Company reduced its tax attributes (NOLs and tax credits) and generated a limitation on utilization of such attributes resulting from the Merger. At December 31, 2019 and 2018, and as a result of the limitations under Section 382 of the Internal Revenue Code, the Company had a total of unused federal tax net operating loss carryforwards with expiration dates as follows: Dollars in Thousands 2019 2018 2036 $ 13,470 $ 13,470 2037 3,441 3,441 Unlimited life 42,100 21,138 Total Federal $ 59,011 $ 38,049 The Company has adopted guidance on accounting for uncertainty in income taxes which clarified the accounting for income taxes by prescribing the minimum threshold a tax position is required to meet before being recognized in the financial statements as well as guidance on de-recognition, measurement, classification and disclosure of tax positions. There are no material uncertain tax positions that would require recognition in the financial statements. The Company is obligated to file income tax returns in the U.S. federal jurisdiction and various U.S. states. Since the Company had losses in the past, all prior years that generated NOLs are open and subject to audit examination in relation to the NOL generated from those years. Our evaluation of uncertain tax positions was performed for the tax years ended December 31, 2014 and forward.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	11. STOCKHOLDERS’ EQUITY Common Stock Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance. On December 20, 2018, the Company’s shareholders approved the proposal to authorize the Company’s Board of Directors to, in its discretion, to amend the Company’s Third Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 150,000,000 shares to 250,000,000 shares. The Company has not yet affected this increase. On February 12, 2018, the Company issued 120,983 shares of its common stock in exchange for approximately $1.9 million of debt obligations. See Note 6 – Convertible Notes. During the year ended December 31, 2018, the Company issued 208,000 shares of its common stock in connection with conversions of its Series B Preferred Stock and 223,022 shares of its common stock in connection with conversions of its Series C Preferred Stock. Aside from 4,000 shares of common stock issued in connection with conversions of its Series C Preferred Stock, all of the shares of common stock issued for the year ended December 31, 2018 in connection with conversions of its Series B Preferred Stock and Series C Preferred Stock (together the “Preferred Stock”) were issued after the Company induced the holders of its Preferred Stock to convert their shares of Preferred Stock to shares of the company’s common stock (see below - Preferred Stock induced conversions). During the years ended December 31, 2019 and 2018, the Company issued 310,200 and 252,486 shares of its common stock, respectively, in connection with the exercise of 310,200 and 252,486 warrants, respectively. The warrant exercises resulted in net cash proceeds to the Company of approximately $1.6 million and $1.3 million during the years ended December 31, 2019 and 2018, respectively. Also during the years ended December 31, 2019 and 2018, the Company issued 2,511,173 and 384,896 shares of its common stock, respectively, in connection with the conversion of convertible notes, plus interest, totaling $7.6 million and $2.4 million, respectively. See Note 6 – Convertible Notes. 2018 Purchase Agreement On February 8, 2018 the Company entered into an equity purchase agreement (the “2018 Purchase Agreement”) with Leviston for the purchase of up to $8,000,000 (the “Aggregate Amount”) of shares (the “Shares”) of the Company’s common stock from time to time, at the Company’s option. Shares offered and sold prior to February 13, 2018 were issued pursuant to the Company’s shelf registration statement on Form S-3 (and the related prospectus) that the Company filed with the Securities and Exchange Commission (the “SEC”) and which was declared effective by the SEC on February 13, 2015 (the “Shelf Registration Statement”). Leviston purchased 48,076 shares (the “Investor Shares”) of the Company’s common stock following the close of business on February 9, 2018, subject to customary closing conditions, at a price per share of $15.60 for approximately $750,000. The shares were sold pursuant to the Shelf Registration Statement. The Company incurred approximately $132,000 in costs which have been treated as issuance costs within additional paid-in capital in the accompanying consolidated balance sheet. As required by the terms of the 2018 Purchase Agreement, the Company timely filed an S-1 on April 16, 2018. The S-1 Registration Statement was not declared effective by the SEC and on August 10, 2018 the Company filed a withdrawal request with the SEC. No securities had been issued or sold under this Registration Statement. The Company determined not to proceed with the offering as the Company sought to re-negotiate the terms of the equity purchase agreement in order to comply with the requirements of the SEC pursuant to a letter from the SEC dated August 7, 2018. In consideration of Leviston’s agreement to enter into the 2018 Purchase Agreement, the Company agreed to pay to Leviston a commitment fee in shares of the Company’s common stock equal in value to 5.25% of the total Aggregate Amount (the “Leviston Commitment Shares”), payable in three installments upon achieving certain milestones. The first installment of 1.75% was due on or before February 12, 2018 and this amount, of $140,000, was paid to Leviston through the issuance of 11,381 shares of the Company’s common stock on February 12, 2018. In accordance with the terms of the 2018 Purchase Agreement, the Company provided Leviston with a price protection provision, if the Company issues any warrants in connection with issuances, sales or an agreement in writing to issue common stock or common stock equivalents of the Company, Leviston will have the right to receive a proportionate amount of such warrants, cash or shares, at Leviston’s sole election, valued using the Black Scholes formula. As a result of 2018 Note Agreement and the April 2018 Warrants issued, the Company was required to provide Leviston with a proportionate and equivalent coverage in the form of warrants, stock or cash in the amount of approximately $460,000. As Leviston has the ability to elect the form of compensation, the Company has recorded the $460,000 as a liability as of December 31, 2018, within the other current liabilities line of the accompanying consolidated balance sheet. As of December 31, 2018, the Company had a total of $0.7 million in accruals (see Note 7 – Accrued Expenses and Other Current Liabilities) for potential obligations to Leviston, but had not issued any additional shares or made any payments to Leviston. On January 29, 2019, the Company entered into the Leviston Settlement pursuant to which the Company issued to Leviston the Note in full satisfaction of all obligations owed to Leviston. See Note 6 – Convertible Notes for further details of the Leviston Note. LP Purchase Agreement On September 7, 2018, the Company entered the LP Purchase Agreement, pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $10,000,000 of common stock of the Company (subject to certain limitations) from time to time over the term of the LP Purchase Agreement. Pursuant to the terms of the LP Purchase Agreement, on the agreement date, the Company issued 40,000 shares of its common stock to Lincoln Park as consideration for its commitment to purchase shares of common stock of the Company under the LP Purchase Agreement (the “LP Commitment Shares”). Also on September 7, 2018, the Company entered into a registration rights agreement with Lincoln Park (the “LP Registration Rights Agreement”), pursuant to which on September 14, 2018, the Company filed with the SEC a registration statement on Form S-1 to register for resale under the Securities Act of 1933, as amended, or the Securities Act, 466,667 shares of common stock, which includes the LP Commitment Shares, that have been or may be issued to Lincoln Park under the LP Purchase Agreement. The Form S-1 was declared effective by the SEC on September 28, 2018. As of January 16, 2019, all shares registered under this S-1 had been sold and/or issued to Lincoln Park. On February 1, 2019, the Company filed with the SEC a registration statement on Form S-1 to register for resale under the Securities Act of 1933, as amended, or the Securities Act, an additional 1,000,000 shares of common stock that have been or may be issued to Lincoln Park under the LP Purchase Agreement. The Form S-1 was declared effective by the SEC on February 12, 2019. As of August 5, 2019, all shares registered under this S-1 had been sold and/or issued to Lincoln Park. On August 9, 2019, the Company filed with the SEC a registration statement on Form S-1 to register for resale under the Securities Act of 1933, as amended, or the Securities Act, an additional 1,800,000 shares of common stock that have been or may be issued to Lincoln Park under the LP Purchase Agreement. As of December 31, 2019, 1,680,000 shares registered under this S-1 had been sold and/or issued to Lincoln Park and 120,000 were sold and/or issued to Lincoln Park in January 2020. On January 14, 2020, the Company filed with the SEC a registration statement on Form S-1 to register for resale under the Securities Act of 1933, as amended, or the Securities Act, an additional 920,654 shares of common stock that have been or may be issued to Lincoln Park under the LP Purchase Agreement. From January 1, 2020 through the date the consolidated financial statements were issued, 780,012 shares registered under this S-1 had been sold and/or issued to Lincoln Park. Under the LP Purchase Agreement, the Company may, from time to time and at its sole discretion, on any single business day on which the closing price of its common stock is not less than the Floor Price, defined as the lower of (i) $1.50 per share (subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the LP Purchase Agreement) and (ii) $0.10 per share, direct Lincoln Park to purchase shares of its common stock in amounts up to 30,000 shares, which amounts may be increased to up to 36,666 shares depending on the market price of its common stock at the time of sale and subject to a maximum commitment by Lincoln Park of $1,000,000 per single purchase, which the Company refers to as “regular purchases”, plus other “accelerated amounts” and/or “additional accelerated amounts” under certain circumstances. The Company will control the timing and amount of any sales of its common stock to Lincoln Park. The purchase price of the shares that may be sold to Lincoln Park in regular purchases under the LP Purchase Agreement will be based on the market price of the common stock of the Company preceding the time of sale as computed under the LP Purchase Agreement. The purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business days used to compute such price. The Company may at any time in its sole discretion terminate the LP Purchase Agreement without fee, penalty or cost upon one business day notice. There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the LP Purchase Agreement or LP Registration Rights Agreement, other than a prohibition on the Company entering into certain types of transactions that are defined in the LP Purchase Agreement as “Variable Rate Transactions”. Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement. Under applicable rules of The Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the LP Purchase Agreement more than 19.99% of the shares of its common stock outstanding immediately prior to the execution of the LP Purchase Agreement (which is 308,590 shares based on 1,543,724 shares outstanding immediately prior to the execution of the LP Purchase Agreement), which limitation the Company refers to as the Exchange Cap, unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of the Company’s common stock to Lincoln Park under the LP Purchase Agreement equals or exceeds $7.05 (which represents the closing consolidated bid price of the Company’s common stock on September 7, 2018, plus an incremental amount to account for the issuance of the LP Commitment Shares to Lincoln Park), such that issuances and sales of the Company’s common stock to Lincoln Park under the LP Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules. In any event, the LP Purchase Agreement specifically provides that the Company may not issue or sell any shares of its common stock under the LP Purchase Agreement if such issuance or sale would breach any applicable NASDAQ rules. The Company received shareholder approval on December 20, 2018. The LP Purchase Agreement also prohibits the Company from directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of the Company’s common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of the Company’s common stock, as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 13d-3 thereunder, which limitation the Company refers to as the Beneficial Ownership Cap as defined in the LP Agreement. As of the date the consolidated financial statements were issued, we have already received $9.3 million in aggregate, including approximately $1.4 million from the sale of 328,590 shares of common stock to Lincoln Park during 2018, $6.6 million from the sale of 2,778,077 shares of common stock to Lincoln Park during 2019, and $1.3 million from the sale of 900,012 shares of common stock to Lincoln Park from January 1, 2020 through the date the consolidated financial statements were issued. Preferred Stock The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i) the number of shares; (ii) the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii) whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv) whether shares shall be convertible and, if so, the terms and provisions thereof; (v) what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi) whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends. We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock. Series B Preferred Stock The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (“Series B Preferred Stock”) with the State of Delaware which designates 6,900 shares of our preferred stock as Series B Preferred Stock. The Series B Preferred Stock has a stated value of $1,000 per share and a par value of $0.01 per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering (the “August 2017 Offering”) consisting of the Company’s Series B Preferred Stock and warrants. The conversion price of the Series B Preferred Stock contains a down round feature. The Company will recognize the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation. The 2018 Purchase Agreement triggered the down round feature of the Series B Preferred Stock and, as a result, the conversion price of the Company’s Series B Convertible Preferred Stock was automatically adjusted to $15.60 per share. In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $1.4 million which was recognized as a deemed dividend at time of the down round adjustment (“Deemed Dividend A”). The 2018 Inducement Agreement, discussed below, triggered the down round feature of the Series B Preferred Stock and , as a result, the conversion price of the Company’s Series B Convertible Preferred Stock was automatically adjusted from $15.60 per share to $11.25 per share. In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $40,000 which was recognized as a deemed dividend at time of the down round adjustment (“Deemed Dividend B”). The 2018 Note Agreement, see Note 6 – Convertible Notes, triggered the down round feature of the Series B Preferred Stock and , as a result, the conversion price of the Company’s Series B Convertible Preferred Stock was automatically adjusted from $11.25 per share to $4.50 per share. In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $0.2 million which was recognized as a deemed dividend at time of the down round adjustment (“Deemed Dividend C”). On November 29, 2018, the Amendment Agreement triggered the down round feature of the Series B Preferred Stock and , as a result, the conversion price of the Company’s Series B Convertible Preferred Stock was automatically adjusted from $4.50 per share to $2.25 per share. In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $0.3 million which was recognized as a deemed dividend at time of the down round adjustment (“Deemed Dividend D”). During the year ended December 31, 2018, 2,340 shares of Series B Preferred Stock, that were outstanding, were converted into 208,000 shares of our common stock. At December 31, 2019 and 2018, the Company had 6,900 shares of Series B designated and issued and 47 shares of Series B outstanding. Series C Preferred Stock The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (“Series C Preferred Stock”) with the State of Delaware which designates 2,748 shares of our preferred stock as Series C Preferred Stock. The Series C Preferred Stock has a stated value of $1,000 per share and a par value of $0.01 per share. On November 2, 2017, the Company completed a registered direct offering consisting of the Company’s Series C Preferred Stock and warrants (the “Series C Preferred Offering”). The conversion price of the Series C Preferred Stock contains a down round feature. The 2018 Purchase Agreement triggered the down round feature of the Series C Preferred Stock and , as a result, the conversion price of the Company’s Series C Convertible Preferred Stock was automatically adjusted from $21.00 per share to $15.60 per share. In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $0.8 million which was recognized as a deemed dividend at time of the down round adjustment (“Deemed Dividend E”). There were no further adjustments to the conversion price of the Series C Preferred stock because all of the Series C Preferred Stock was converted in 2018. During the year ended December 31, 2018, 2,548 shares of Series C Preferred Stock were converted into 223,022 shares of our common stock. At December 31, 2019 and 2018, the Company had 2,748 shares of Series C designated and issued and zero shares of Series C outstanding. Liquidation Preferences The following is the liquidation preferences for the Company’s preferred stock; The Series B Preferred Stock and Series C Preferred Stock have identical terms regarding liquidation preferences. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, the holders shall be entitled to receive out of the assets of the Corporation an amount equal to the par value, plus any accrued and unpaid dividends thereon, for each share of Preferred Stock before any distribution or payment shall be made to the holders of the Common Stock, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares. If all amounts were paid in full; and thereafter, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Preferred Stock were fully converted to Common Stock which amount shall be paid pari passu with all holders of Common Stock. Preferred Stock induced conversions On March 21, 2018, the Company entered into a letter agreement (the “2018 Inducement Agreement”) with certain holders of shares of the Company’s Series B Preferred Stock and Series C Preferred Stock (together the “Preferred Stock”), and warrants (the “Warrants”) to purchase shares of the Company’s common stock, issued in the Company’s public offering in August 2017 and registered direct offering in November 2017. Pursuant to the 2018 Inducement Agreement, the Company and the Investors agreed that, as a result of the issuance of shares of common stock pursuant to that Purchase Agreement, dated February 8, 2018, by and between the Company and the investor named therein, and effective as of the time of execution of the 2018 Inducement Agreement, the exercise price of the Warrants was reduced to $11.25 per share (the “Exercise Price Reduction”) and the conversion price of the Preferred Stock was reduced to $11.25 (the “Conversion Price Reduction”). As consideration for the Company’s agreement to the Exercise Price Reduction and the Conversion Price Reduction, (i) each investor agreed to convert the shares of Preferred Stock held by such investor into shares of Common Stock in increments of up to 4.99% of the shares of common stock outstanding as of the date of the 2018 Inducement Agreement and (ii) one investor agreed to exercise 44,444 Warrants and another investor agreed to exercise 33,333 Warrants in increments of up to 4.99% of the shares of common stock outstanding as of the date of the 2018 Inducement Agreement, in each case in accordance with the beneficial ownership limitations set forth in the Company’s Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, the Company’s Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock and the Warrants. As discussed above, as of December 31, 2019, all shares of Preferred Stock, except 47 shares of Series B Preferred Stock, were converted to shares of our common stock pursuant to the terms of the 2018 Inducement Agreement and 20,000 Warrants were exercised at the $11.25 exercise price. The 2018 Inducement Agreement represented an inducement by the Company to convert shares of the Preferred Stock. The conversion price of the Preferred Stock and the exercise price of the Warrants were reduced from $15.60 per share to $11.25 per share, respectively. The Company calculated the fair value of the additional securities and consideration to be approximately $1.2 million (“Deemed Dividend F”). During the year ended December 31, 2018, this amount was recorded as a charge to additional paid-in-capital and as a deemed dividend resulting in a reduction of income available to common shareholders in our basic earnings per share calculation. The $1.2 million is comprised of two components: 1) $1.1 million related to the fair value of the additional common shares issued upon conversion of the Preferred Stock due to the reduced conversion price and 2) $0.1 million in incremental fair value of the Warrants resulting from the reduction of the exercise price. Common Stock Warrants . The following represents a summary of the warrants outstanding as of December 31, 2019: Underlying Exercise Issue Year Expiration Shares Price Warrants (1) 2014 April 2020 832 $ 1,800.00 (2) 2015 February 2020 1,588 $ 1,008.00 (3) 2015 December 2020 272 $ 747.00 (4) 2016 January 2021 596 $ 544.50 (5) 2017 June 2022 2,540 $ 41.25 (5) 2017 June 2022 500 $ 7.50 (6) 2017 June 2022 6,095 $ 105.00 (7) 2017 August 2022 25,201 $ 2.25 (8) 2017 August 2022 4,000 $ 46.88 (9) 2017 August 2022 47,995 $ 150.00 (9) 2017 August 2022 9,101 $ 7.50 (10) 2017 August 2022 16,664 $ 2.25 (10) 2017 August 2022 7,335 $ 2.25 (11) 2017 October 2022 666 $ 2.25 (12) 2017 May 2023 — $ 2.25 (13) 2018 October 2022 7,207 $ 112.50 (14) 2018 April 2023 69,964 $ 5.40 (14) 2018 April 2023 121,552 $ 5.40 (15) 2018 October 2022 15,466 $ 11.25 (16) 2018 July 2023 14,671 $ 5.40 (16) 2018 July 2023 14,672 $ 5.40 (16) 2018 August 2023 36,334 $ 5.40 (16) 2018 August 2023 36,334 $ 5.40 (16) 2018 September 2023 19,816 $ 5.40 (16) 2018 September 2023 20,903 $ 5.40 (17) 2018 November 2023 75,788 $ 5.40 (17) 2018 December 2023 51,282 $ 5.40 (18) 2019 April 2024 147,472 $ 5.40 (19) 2019 May 2024 154,343 $ 9.56 909,189 (1) These warrants were issued in connection with a private placement which was completed in October 2014. (2) These warrants were issued in connection with an offering which was completed in February 2015. (3) These warrants were issued in connection with an offering which was completed in July 2015. (4) These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding warrants as of December 31, 2019, 357 warrants are recorded as liability, See Note 12 – Fair Value for further discussion, and 239 warrants are treated as equity. (5) These warrants were issued in connection with a June 2017 merger transaction (the “Merger”) and are the 2017 New Bridge Warrants. (6) These warrants were issued in connection with the Merger and are considered the Side Warrants. (7) These warrants were issued in connection with an underwritten public offering consisting of the Company’s Series B Preferred Stock and warrants (the “August 2017 Offering”) and are the August 2017 Offering Warrants discussed below. (8) These warrants were issued in connection with the August 2017 Offering and are the Representative Warrants discussed below. (9) These warrants were issued 2017 and are the Series A Conversion Warrants discussed below. (10) These warrants were issued in connection with the conversion of convertible bridge notes, at the time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below. (11) These warrants were issued in connection with a waiver of default the Company received in the fourth quarter of 2017 in connection with certain convertible promissory notes and are the Convertible Promissory Note Warrants discussed below. (12) These warrants (the “Series C Warrants’) were issued in connection with the Series C Preferred Offering and are discussed below. (13) These warrants were issued in connection with the Settlement Agreements and are the Creditor Warrants discussed below. (14) These warrants were issued in connection with the 2018 Note Agreement and are the April 2018 Warrants discussed below. (15) These warrants were issued in connection with the 2018 Note Agreement and are the Advisor Warrants discussed below. (16) These warrants were issued in connection with the 2018 Note Agreement and are the Q3 2018 Warrants discussed below. (17) These warrants were issued in connection with the 2018 Note Agreement, and subsequent Amendment Agreement, and are the Q4 2018 Warrants discussed below. (18) These warrants were issued in connection with the 2018 Note Agreement and subsequent Amendment No. 2 Agreement and are the April 2019 Warrants discussed below. (19) These warrants were issued in connection with the May 2019 Bridge Notes and are the May 2019 Warrants discussed below. 2017 New Bridge Warrants The initial exercise price of the 2017 New Bridge Warrants was $112.50 (subject to adjustments). These warrants had a one-time down round provision. As a result of the August 2017 Offering, the exercise price of the 2017 New Bridge Warrants was adjusted to $41.25 per share, and the down round provision for these warrants no longer exists after this adjustment. At the time of the Amendment Agreement in 2018, the exercise price of 500 of the 2017 New Bridge Warrants was modified so that the exercise price became $7.50 per share. The fair value of this warrant modification was calculated to be less than $1,000 which was recorded as a debt discount in conjunction with the issuance of the Q4 2018 Bridge Notes with an offset to additional paid-in-capital. Side Warrants The Company issued warrants to purchase an aggregate of 6,095 shares of the Company’s common stock at an exercise price of $105.00 per share (subject to adjustment). The warrants (“Side Warrants”) have a term of 5 years. August 2017 Offering Warrants In connection with the August 2017 Offering, the Company issued 178,667 warrants at an exercise price of $45.00, which contain a down round provision. The August 2017 Offering Warrants were exercisable immediately and expire 5 years from date of issuance. In February 2018, as a result of 2018 Purchase Agreement, the exercise price of the August 2017 Offering Warrants was adjusted to $15.60. At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately $62,000 and recorded this as a deemed dividend (“Deemed Dividend G”) during 2018 . In addition, as a result of the 2018 Inducement Agreement, the exercise price of the August 2017 Offering Warrants was further adjusted to $11.25 as a result of the Exercise Price Reduction discussed above. In April 2018, as a result of the 2018 Note Agreement, the exercise price of the August 2017 Offering Warrants was adjusted to $4.50. At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately $63,000 and recorded this as a deemed dividend (“Deemed Dividend H”) . In November 2018, as a result of the Amendment Agreement, the exercise price of the August 2017 Offering Warrants was adjusted to $2.25. At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately $5,000 and recorded this as a deemed dividend (“Deemed Dividend I”). There were 6,800 and 146,666 August 2017 Offering Warrants exercised during the year ended December 31, 2019 and 2018, respectively, for proceeds to the Company of approximately $15,000 and $795,000, respectively. During the year ended December 31, 2019 and 2018, the intrinsic value of the August 2017 Offering Warrants exercised was approximately $36,000 and $420,000. Representative Warrants The Representative Warrants are exercisable beginning one year after the date of the prospectus for the August 2017 Offering and expiring on a date which is no more than five years from the date of the prospectus for the August 2017 Offering. Series A Conversion Warrants These warrants were issued in connection with the conversion of our Series A Senior stock, at the time of the closing of the August 2017 Offering, and have a term of 5 years. At the time of the Amendment Agreement in 2018, the exercise price of 9,101 of the Series A Conversion Warrants was modified so that the exercise price became $7.50 per share. The fair value of this warrant modification was calculated to be approximately $10,000 which was recorded as a debt discount in conjunction with the issuance of the Q4 2018 Bridge Notes with an offset to additional paid-in-capital. Note Conversion Warrants Upon the closing of the August 2017 Offering, the Company issued 23,999 warrants to purchase the Company's common stock (the “Note Conversion Warrants”). The Note Conversion Warrants have an exercise price of $45.00 per share, a five year term and contain a down round provision. As a result of the Series C Preferred Offering in 2017, the exercise price of the Note Conversion Warrants was adjusted to $21.00 per share. In February 2018, as a result of 2018 Purchase Agreement, the exercise price of the Note Conversion Warrants was a

FAIR VALUE

FAIR VALUE	12 Months Ended
	Dec. 31, 2019
FAIR VALUE [Abstract]
FAIR VALUE	12. FAIR VALUE FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements. FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows: Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability. Common Stock Warrant Liabilities. Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our consolidated statement of operations. 2016 Warrant Liability The Company has a warrant liability related to warrants issued in January 2016 (the “2016 Warrant Liability”) and it represents the fair value of such warrants, of which, 357 warrants remain outstanding as of December 31, 2019. In March 2018, a portion of the 2016 Warrant Liability was part of a settlement agreement pursuant to a lawsuit that was filed against the Company by one of the warrant holders. As such, approximately $0.4 million of the warrant liability, representing 1,347 warrants, was canceled on the date of the settlement agreement and replaced by amounts that were recorded as other current liabilities. For further detail, see discussion of the Crede Agreement in Note 8 – Accrued Expenses and Other Current Liabilities. The 2016 Warrant Liability is considered a Level 3 financial instrument and was valued using the Monte Carlo methodology. As of December 31, 2019, assumptions and inputs used in the valuation of the common stock warrants include: remaining life to maturity of one year; annual volatility of 140%; and a risk-free interest rate of 1.59%. As of December 31, 2018, assumptions and inputs used in the valuation of the 2016 Warrant Liability include: remaining life to maturity of two years; annual volatility of 176%; and a risk-free interest rate of 2.48% Bridge Note Warrant Liabilities During 2019 and 2018, the Company issued 154,343 of May 2019 Warrants, 147,472 of April 2019 Warrants, 243,224 of April 2018 Warrants, 15,466 of Advisor Warrants, 196,340 of Q3 2018 Warrants and 300,115 of Q4 2018 Warrants. All of these warrants issuances were classified as warrant liabilities (the “Bridge Note Warrant Liabilities”). See Note 6 - Convertible Notes for further discussion of each warrant. The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black Scholes model. As of December 31, 2019, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 2.3 to 4.4 years; annual volatility of 141% to 163%; and risk free rate of 1.58% to 1.65%. As of December 31, 2018, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 5.0 years; annual volatility of 85% to 162%; and risk free rate of 2.45% to 2.63%. During the years ended December 31, 2019 and 2018, the change in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were comprised of the following: Dollars in Thousands Year Ended December 31, 2019 2016 Warrant Bridge Note Total Warrant Liability Warrant Liabilities Liabilities Beginning balance at January 1 $ 116 $ 1,016 $ 1,132 Additions: – 1,858 1,858 Total (gains) losses: Revaluation recognized in earnings (46) (370) (416) Modification recognized in earnings – 1,128 1,128 Deductions – warrant exercises – (2,364) (2,364) Balance at December 31 $ 70 $ 1,268 $ 1,338 Year Ended December 31, 2018 2016 Warrant Bridge Note Total Warrant Liability Warrant Liabilities Liabilities Beginning balance at January 1 $ 841 $ – $ 841 Additions: – 2,665 2,665 Total (gains) losses: Revaluation recognized in earnings (269) (1,792) (2,061) Modification recognized in earnings – 143 143 Deductions – warrant liability settlement (456) – (456) Balance at December 31 $ 116 $ 1,016 $ 1,132 Derivative Liabilities. Certain of our issued and outstanding convertible notes contain features that are considered derivative instruments and are required to bifurcated from the debt host and accounted for separately as derivative liabilities. The estimated fair value of the derivatives will be remeasured at each reporting date and any change in estimated fair value of the derivatives will be recorded as non-cash adjustments to earnings. The gains or losses included in earnings are reported in other income (expense) in our consolidated statement of operations. Bridge Notes Redemption Feature At the time of the Bridge Note issuances, the Company recorded derivative instruments as liabilities with an initial fair value of approximately $0.3 million. The valuations were performed using the “with and without” approach, whereby the Bridge Notes were valued both with the embedded derivative and without, and the difference in values was recorded as the derivative liability. In November 2018, the conversion price of the April 2018 Bridge Note and the Q3 2018 Bridge Note was amended. The amendment was treated as an extinguishment which resulted in less than $0.1 million of derivative liabilities being written off in November 2018. See Note 6 - Convertible Notes for further discussion. Conversion Option The Company recorded derivative liabilities related to the Conversion Option of the Exchange Notes issued during the year ended December 31, 2018 with an initial fair value of approximately $0.4 million. The valuations were performed using the Monte Carlo methodology. Approximately $0.1 million and $0.3 million of Conversion Option derivative liabilities were written off due to Exchange Note conversions during the years ended December 31, 2019 and 2018, respectively. See Note 6 - Convertible Notes for further discussion. During the years ended December 31, 2019 and 2018, the change in the fair value of the derivative liabilities was comprised of the following: Year Ended December 31, 2019 Bridge Notes Redemption Conversion Total Derivative Feature Option Liabilities Beginning balance at January 1 $ 30 $ 32 $ 62 Deductions - write-off in conjunction with convertible note conversions (438) (39) (477) Total loss: Revaluation recognized in earnings 408 7 415 Balance at December 31 $ — $ — $ — Year Ended December 31, 2018 Bridge Notes Redemption Conversion Total Derivative Feature Option Liabilities Beginning balance at January 1 $ — $ — $ — Additions: 269 383 652 Deductions - write-off in conjunction with convertible note conversions — (301) (301) Total gain: Extinguishment recognized in earnings (22) — (22) Revaluation recognized in earnings (217) (50) (267) Balance at December 31 $ 30 $ 32 $ 62

EQUITY INCENTIVE PLAN

EQUITY INCENTIVE PLAN	12 Months Ended
	Dec. 31, 2019
EQUITY INCENTIVE PLAN [Abstract]
EQUITY INCENTIVE PLAN	13. EQUITY INCENTIVE PLAN The Company’s 2006 Equity Incentive Plan (the "2006 Plan") was terminated as to future awards on July 12, 2016. The Company’s 2017 Stock Option and Incentive Plan (the "2017 Plan") was adopted by the Company’s stockholders on June 5, 2017 and there were 44,444 shares of common stock reserved for issuance under the 2017 Plan. The 2017 Plan will expire on June 5, 2027. The Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”), which has the authority to set the number, exercise price, term and vesting provisions of the awards granted under the Plan, subject to the terms thereof. Either incentive or non-qualified stock options may be granted to employees of the Company, but only non-qualified stock options may be granted to non-employee directors and advisors. However, in either case, the Plan requires that stock options must be granted at exercise prices not less than the fair market value of the common stock on the date of the grant. Options issued under the plan vest over periods as determined by the Committee and expire 10 years after the date the option was granted. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value and expenses the benefit in operating expense in the consolidated statements of operations over the service period of the awards. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. Amendment of the 2017 Stock Option and Incentive Plan On January 31, 2018, at a special meeting of the stockholders of the Company, the stockholders approved an amendment and restatement of the Company’s 2017 Stock Option and Incentive Plan (the “2017 Plan”) to: · increase the aggregate number of shares authorized for issuance under the 2017 Plan by 359,300 shares to 403,744 shares; · increase the maximum number of shares that may be granted in the form of stock options or stock appreciation rights to any one individual in any one calendar year and the maximum number of shares underlying any award intended to qualify as performance-based compensation to any one individual in any performance cycle, in each case to 66,667 shares of common stock; and · add an “evergreen” provision, pursuant to which the aggregate number of shares authorized for issuance under the 2017 Plan will be automatically increased each year on January 1 st , beginning on January 1, 2019, by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31 st , or such lesser number of shares determined by the Company’s Board of Directors or Compensation Committee. Stock Options. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the condensed consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. During the year ended December 31, 2019, The Company granted stock options to employees and directors to purchase up to 292,604 shares of common stock at a weighted average exercise price of $2.36. These awards have vesting periods of up to four years and had a weighted average grant date fair value of $2.15. The fair value calculation of options granted during 2019 used the follow assumptions: risk free interest rates of 1.60% to 2.53%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 133% to 139% based on historical volatility of the Company’s common stock over a time that is consistent with the expected life of the option. The following table summarizes stock option activity under our plans during the year ended December 31, 2019: Number of Weighted-Average Options Exercise Price Outstanding at January 1, 2019 224,895 $ 15.90 Granted 292,604 2.36 Forfeited (27,169) 6.03 Outstanding at December 31, 2019 490,330 $ 8.30 Exercisable at December 31, 2019 181,705 $ 13.48 As of December 31, 2019, there were 413,174 options that were vested or expected to vest with an aggregate intrinsic value of zero and a remaining weighted average contractual life of 8.7 years. During the year ended December 31, 2018, there were 224,365 options granted with a weighted average exercise price of $10.50 and 15,236 options forfeited with a weighted average exercise price of $29.94. During the years ended December 31, 2019 and 2018, we recorded compensation expense for all stock awards of $0.7 million and $0.5 million, respectively, within operating expense in the accompanying statements of operations. As of December 31, 2019, the unrecognized compensation expense related to unvested stock awards was $1.7 million, which is expected to be recognized over a weighted-average period of 2.0 years.

SALES SERVICE REVENUE, NET AND

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2019
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	14. SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE ASC Topic 606, “Revenue from contracts with customers” On January 1, 2018, the Company adopted ASC 606 that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model: Step 1: Identification of the contract with the customer. Sub-steps include determining the customer in a contract; Initial contract identification and determine if multiple contracts should be combined and accounted for as a single transaction. Step 2: Identify the performance obligation in the contract. Sub-steps include identifying the promised goods and services in the contract and identifying which performance obligations within the contract are distinct. Step 3: Determine the transaction price. Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer. Step 4: Allocate transaction price. Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. Step 5: Satisfaction of performance obligations. Sub-steps include ascertaining the point in time when an asset is transferred to the customer and the customer obtains control of the asset upon which time the Company recognizes revenue. Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance (ASC 605). Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. Accordingly, the initial application of the new revenue standard did not result in the recognition of a cumulative effect adjustment to the opening balance of accumulated deficit as of January 1, 2018. Nature of Contracts and Customers T he Company’s contracts and related performance obligations are similar for its customers and the sales process for all customers starts upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research. Payment terms for the services provided are 30 days, unless separately negotiated. Diagnostic testing Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient’s laboratory report, per the contract. Clinical research grants Control of the clinical research services are transferred to the customer over time. The Company will recognize revenue utilizing the “effort based” method, measuring its progress toward complete satisfaction of the performance obligation. Biomarker testing and clinical project services Control of the biomarker testing and clinical project services are transferred to the customer over time. The Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results. The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical research grants funded by both bio-pharma customers and government health programs. Disaggregation of Revenues by Transaction Type We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Service revenue, net for the years ended December 31, 2019 and 2018 was as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption): For the Year Ended December 31, (dollars in thousands) Diagnostic Testing Biomarker Testing Total 2019 2018 2019 2018 2019 2018 Medicaid $ 28 $ 50 $ — $ — $ 28 $ 50 Medicare 1,669 1,000 — — 1,669 1,000 Self-pay 34 138 — — 34 138 Third party payers 1,725 960 — — 1,725 960 Contract diagnostics — — 595 1,187 595 1,187 Service revenue, net $ 3,456 $ 2,148 $ 595 $ 1,187 $ 4,051 $ 3,335 Revenue from the Medicare and Medicaid programs account for a portion of the Company’s patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. The Company derives its revenues from three types of transactions: diagnostic testing (“Diagnostic”), and clinical research grants from state and federal research programs, and other revenues from the Company’s ICP technology and bio-pharma projects encompassing genetic diagnostics (collectively “Biomarker”). Deferred revenue Deferred revenue, or unearned revenue, refers to advance payments for products or services that are to be delivered in the future. The Company records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or services that are owed to a customer. As the product or service is delivered over time, the Company recognizes the appropriate amount of revenue from deferred revenue. As of December 31, 2019 and 2018, the deferred revenue was $35,000 and $49,000, respectively. Contractual Allowances and Adjustments We are reimbursed by payers for services we provide. Payments for services covered by payers average less than billed charges. We monitor revenue and receivables from payers and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payers. Accordingly, the total revenue and receivables reported in our consolidated financial statements are recorded at the amounts expected to be received from these payers. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts. The following table presents our revenues initially recognized for each associated payer class during the year ended December 31, 2019 and 2018. (dollars in thousands) For the Year Ended December 31, Contractual Allowances and Revenues, net of Contractual Gross Revenues adjustments Allowances and adjustments 2019 2018 2019 2018 2019 2018 Medicaid $ 31 $ 86 $ (3) $ (36) $ 28 $ 50 Medicare 1,686 1,019 (17) (19) 1,669 1,000 Self-pay 34 138 — — 34 138 Third party payers 5,785 2,358 (4,060) (1,398) 1,725 960 Contract diagnostics 595 1,187 — — 595 1,187 8,131 4,788 (4,080) (1,453) 4,051 3,335 Clinical research grants and other 44 113 — — 44 113 $ 8,175 $ 4,901 $ (4,080) $ (1,453) $ 4,095 $ 3,448 Allowance for Doubtful Accounts The Company provides for a general allowance for collectability of services when recording net sales. The Company has adopted the policy of recognizing net sales to the extent it expects to collect that amount. Reference FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debt, and the Allowance for Doubtful Accounts. The change in the allowance for doubtful accounts is directly related to the increase in patient service revenues. The following table presents our reported revenues net of the collection allowance and adjustments for the year ended December 31, 2019 and 2018. For the Year Ended December 31, Revenues, net of (dollars in thousands) Contractual Allowances Allowances for doubtful and adjustments accounts Total 2019 2018 2019 2018 2019 2018 Medicaid $ 28 $ 50 $ (28) $ (50) $ — $ — Medicare 1,669 1,000 (251) (150) 1,418 850 Self-pay 34 138 — — 34 138 Third party payers 1,725 960 (689) (384) 1,036 576 Contract diagnostics 595 1,187 — — 595 1,187 4,051 3,335 (968) (584) 3,083 2,751 Clinical research grants and other 44 113 — — 44 113 $ 4,095 $ 3,448 $ (968) $ (584) $ 3,127 $ 2,864 Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in operating expenses in the consolidated statements of operations. Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the consolidated statements of operations. Accounts Receivable The Company has provided an allowance for potential credit losses, which has been determined based on management’s industry experience. The Company grants credit without collateral to its patients, most of who are insured under third party payer agreements. The following summarizes the mix of receivables for the years ended December 31, 2019 and 2018: (dollars in thousands) December 31, 2019 December 31, 2018 Medicaid $ 107 $ 82 Medicare 814 633 Self-pay 88 108 Third party payers 2,203 1,382 Contract diagnostic services 36 193 $ 3,248 $ 2,398 Less allowance for doubtful accounts (2,674) (1,708) Accounts receivable, net $ 574 $ 690 The following table presents the roll-forward of the allowance for doubtful accounts for the year ended December 31, 2019: Allowance for Doubtful (dollars in thousands) Accounts Balance, January 1, 2019 $ (1,708) Collection Allowance: Medicaid $ (28) Medicare (251) Third party payers (689) (968) Bad debt expense $ 2 Total charges (966) Balance, December 31, 2019 $ (2,674) Customer Revenue and Accounts Receivable Concentration Customer revenue and accounts receivable concentration amounted to the following for the identified periods. Year Ended December 31, 2019 2018 Percentage of net sales by customer: Customer A % % Customer B * Customer C * * * represents less than 10% December 31, December 31, 2019 2018 Percentage of total accounts receivable by customer: Customer A * % Customer B % * Customer C % * * represents less than 10%

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	15. SUBSEQUENT EVENTS The Company has evaluated events and transactions subsequent to December 31, 2019 through the date the consolidated financial statements were issued. Strategic Partnership On March 16, 2020, the Company announced that it had completed a non-cash transaction with Poplar Healthcare to establish a strategic partnership that includes the acquisition of the customer base OncoMetrix, Poplar’s hematopathology division. Precipio will assume responsibility for OncoMetrix’s customer base and associated revenues which should provide a substantial improvement to the Company’s laboratory economies of scale. As part of the transaction, three sales representatives of OncoMetrix have transitioned to Precipio. The transition of the customer based involved no exchange of cash or equity with Poplar Healthcare. Purchase Agreement On March 26, 2020, the Company entered into a purchase agreement (the “LP 2020 Purchase Agreement”) and a registration rights agreement (the “LP 2020 Registration Rights Agreement”) with Lincoln Park pursuant to which Lincoln Park has agreed to purchase from us, from time to time, up to $10,000,000 of our common stock, subject to certain limitations, during the 24 month term of the LP 2020 Purchase Agreement. Pursuant to the terms of the LP 2020 Registration Rights Agreement, we will file with the SEC the registration statement on form S-1 in order to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the LP 2020 Purchase Agreement. As consideration for its commitment to purchase shares of our common stock under the LP 2020 Purchase Agreement, we agreed to issue 250,000 commitment shares to Lincoln Park as a commitment fee . We do not have the right to commence any sales to Lincoln Park under the LP 2020 Purchase Agreement until certain conditions set forth in the LP 2020 Purchase Agreement, all of which are outside of Lincoln Park’s control, have been satisfied, including the registration statement on form S-1 being declared effective by the SEC. Thereafter, under the LP 2020 Purchase Agreement, on any business day selected by us, we may direct Lincoln Park to purchase up to 50,000 shares of our common stock on any such business day, which we refer to as a Regular Purchase in the LP 2020 Purchase Agreement, provided, however, that (i) the Regular Purchase may be increased to up to 80,000 shares, provided that the closing sale price is not below $1.00 on the purchase date and (ii) the Regular Purchase may be increased to up to 100,000 shares, provided that the closing sale price is not below $1.50 on the purchase date. In each case, the maximum amount of any single Regular Purchase may not exceed $1,000,000 per purchase. Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as we direct, subject to certain conditions. The purchase price for Regular Purchases shall be equal to the lesser of: (i) the lowest sale price of the common shares during the purchase date, or (ii) the average of the three (3) lowest closing sale prices of the common shares during the ten (10) business days prior to the purchase date. Convertible Note Amendment On March 26, 2020, the Company entered into an amendment agreement (the “March 2020 Amendment”) amending the terms of that certain Amendment No. 2 Agreement dated April 16, 2019 and the securities purchase agreement dated May 14, 2019. As a result of the March 2020 amendment, (i) the maturity date of the April 2019 Bridge Notes and the May 2019 Bridge Notes was extended three months from April 16, 2020 to July 16, 2020, (ii) the floor price at which conversions may occur under the April 2019 Bridge Notes and the May 2019 Bridge Notes was amended from $2.25 to $0.40, and (iii) guaranteed interest on the April 2019 Bridge Notes and the May 2019 Bridge Notes was amended from twelve months to eighteen months. The Company is currently reviewing the appropriate accounting treatment related to the March 2020 Amendment and will record the necessary accounting in the first quarter 2020.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Principles of Consolidation	Principles of Consolidation. The consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiaries. All inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. The most significant estimates and assumptions with regard to these consolidated financial statements relate to the allowance for doubtful accounts, assumptions used within the fair value of debt and equity transactions, contractual allowances and related impairments. These assumptions require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these consolidated financial statements.
Risks and Uncertainties	Risks and Uncertainties. Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the consolidated financial statements. The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.
Fair Value	Fair Value. Unless otherwise specified, book value approximates fair value. The common stock warrant liabilities and derivative liabilities are recorded at fair value. See Note 12 - Fair Value for additional information.
Other Current Assets	Other Current Assets. Other current assets of $0.3 million as of December 31, 2019 include prepaid insurance of $0.2 million and prepaid assets and other receivables of $0.1 million. Other current assets of $0.5 million as of December 31, 2018 include prepaid assets of less than $0.1 million, prepaid insurance of $0.2 million and other receivables of $0.3 million.
Concentrations of Risk	Concentrations of Risk. From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits of up to $250,000 per depositor per financial institution. We have not experienced any losses on such accounts as of December 31, 2019. Service companies in the health care industry typically grant credit without collateral to patients. The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payers. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000‑89398.
Inventories	Inventories. Inventories consist of laboratory supplies and are valued at cost (determined on an average cost basis, which approximates the first-in, first-out method) or net realizable value, whichever is lower. We evaluate inventory for items that are slow moving or obsolete and record an appropriate reserve for obsolescence if needed. We determined that no allowance for slow moving or obsolete inventory was necessary at December 31, 2019 and 2018.
Property and Equipment, Net	Property and Equipment, net. Property and equipment are carried at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Depreciation and amortization are computed by the straight-line method over the estimated useful lives of the related assets as follows: Furniture and fixtures 5 to 7 years Laboratory equipment 3 to 10 years Computer equipment and software 3 to 7 years For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in operations for the period. Expenditures for major betterments that extend the useful lives of property and equipment are capitalized.
Goodwill and Intangible Assets	Goodwill and Intangible Assets. Goodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets of a business acquired and is tested for impairment annually, as of October 1 st , or when impairment triggering events may occur during a quarterly reporting period. Throughout the year ended December 31, 2018, at certain quarterly reporting periods, the Company experienced a decline in its share price and a significant reduction in its market capitalization, indicating that it was more likely than not that the fair value of the Company was less than its carry value. Through valuation analysis of the fair value of the Company using the market capitalization, the discounted cash flow model and market analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment in the amount of $4.7 million was recorded for the year ended December 31, 2018. As of December 31, 2018, goodwill was fully written off and no balance remained. Intangibles We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair value of the asset to the carrying amount of the asset (group). There were no impairment charges on our amortizable long-lived assets during the years ended December 31, 2019 and 2018. In-process research and development (“IPR&D”) represents the fair value assigned to research and development assets that were not fully developed when acquired. Until the IPR&D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. The IPR&D principally related to research projects that were not related to IV-Cell, HemeScreen or ICP. During 2019, the Company made a determination to suspend further research and analysis of these projects, and, as a result, it was more likely than not that the IPR&D was fully impaired, resulting in an impairment charge of $1.6 million in 2019. There was no impairment of IPR&D during the year ended December 31, 2018.
Debt Issuance Costs and Debt Discounts	Debt Issuance Costs, Debt Discounts and Debt Premiums. Debt issuance costs, debt discounts and debt premiums are being amortized or accreted over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt and premiums are presented as an increase to the related debt in the accompanying balance sheets. The amortization amount recorded was expense, net of income, of $0.1 million in 2019 and income, net of expense, of less than $0.1 million in 2018. Debt discounts and debt premiums are amortized or accreted to interest expense and interest income on the consolidated statement of operations, respectively. See Note 5 – Long Term Debt and Note 6 – Convertible Notes for further discussion.
Stock-Based Compensation	Stock-Based Compensation. All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Stock-based compensation cost is based on the fair value of the portion of stock-based awards that is ultimately expected to vest. The Company utilizes the Black-Scholes option pricing model for determining the estimated fair value for stock-based awards. Unvested awards as of December 31, 2019 had vesting periods of up to four years from the date of grant. At December 31, 2019, 53,334 unvested awards outstanding are subject to performance vesting conditions and no awards are subject to market-based vesting conditions. No awards outstanding at December 31, 2018 were subject to performance or market-based vesting.
Net Sales Recognition	Net Sales Recognition. Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services. The Company derives its revenues from diagnostic testing - histology, flow cytometry, cytology and molecular testing; clinical research from bio-pharma customers, state and federal grant programs; and from biomarker testing from bio-pharma customers. All sources of revenue are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See more detailed information on revenue in Note 14 – Sales Service Revenue, Net And Accounts Receivable. The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient’s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payers. Provisions for third-party payer settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance sheet as deferred revenue was approximately $0.1 million as of December 31, 2019 and 2018. Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.
Accounts Receivable	Accounts Receivable Accounts Receivable result from diagnostic services provided to self-pay and insured patients, project based testing services and clinical research. The payment for services provided by the Company are generally due within 30 days from the invoice date. Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the collectability of accounts receivable, the Company analyzes and identifies trends for each of its sources of revenue to estimate the appropriate allowance for doubtful accounts. For receivables associated with self-pay patients, including patients with insurance and a deductible and copayment, the Company records an allowance for doubtful accounts in the period of services on the basis of past experience of patients unable or unwilling to pay for service fee for which they are financially responsible. For receivables associated with services provided to patients with third-party coverage, the Company analyzes contractually due amounts and provides an allowance, if necessary. The difference between the standard rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged against the allowance for doubtful accounts.
Presentation of Insurance Claims and Related Insurance Recoveries	Presentation of Insurance Claims and Related Insurance Recoveries. The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities. There were no insurance claims or insurance recoveries recorded during the years ended December 31, 2019 and 2018.
Advertising Costs	Advertising Costs. Advertising costs are expensed as incurred and are included in operating expenses on the consolidated statement of operations. Advertising costs charged to operations totaled less than $0.1 million in 2019 and 2018, respectively.
Research and Development Costs	Research and Development Costs. All costs associated with internal research and development are expensed as incurred. These costs include salaries and employee related expenses, operating supplies and facility-related expenses. Research and development costs charged to operations totaled $1.2 million and $1.1 million for the years ended December 31, 2019 and 2018, respectively.
Income Taxes	Income Taxes. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in the period when the change in tax rates is enacted. A valuation allowance is established when it is determined that it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance has been applied against the Company’s net deferred tax assets as of December 31, 2019 and 2018, due to projected losses and because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of, or changes in tax laws, regulations and interpretations thereof as well as other factors. The Company’s policy is to record interest and penalties directly related to income taxes as income tax expense in the accompanying consolidated statements of operations, of which there was none for the years ended December 31, 2019 and 2018.
Common Stock Warrants	Common Stock Warrants. The Company classifies the issuance of common stock warrants as equity any contracts that (i) require physical settlement or net-stock settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own stocks (physical settlement or net-stock settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside of the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in stock (physical settlement or net-stock settlement). Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings.
Beneficial Conversion Feature	Beneficial Conversion Features. The intrinsic value of a beneficial conversion feature (“BCF”) inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the first conversion date using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the BCF is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. When the preferred shares are non-redeemable the BCF is fully amortized into additional paid-in capital and preferred discount. If the preferred shares are redeemable, the discount is amortized from the commitment date to the first conversion date.
Loss Per Share	Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 2,281,701 and 2,517,675 shares of our common stock have been excluded from the computation of diluted loss per share at December 31, 2019 and 2018, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: December 31, 2019 2018 Stock options 490,330 224,895 Warrants 909,189 917,573 Preferred stock 20,888 20,888 Convertible notes 861,294 1,354,319 Total 2,281,701 2,517,675
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements. In February 2016, the FASB issued ASU No. 2016‑02, Leases-Topic 842 . The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard was adopted effective January 1, 2019, using a modified retrospective transition, and thus did not adjust comparative periods. The new standard provides a number of optional practical expedients in transition. The Company has elected the “package of practical expedients”, which permits it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. As a result of the adoption of Topic 842 the Company recognized approximately $0.7 million of lease liabilities and corresponding right-of-use (“ROU”) assets in its consolidated balance sheet on the date of initial application. See Note 8 – Leases for additional information. In June 2018, the FASB issued ASU 2018-07 “ Compensation—Stock Compensation (Topic 718) ”, which expands the scope of Topic 718 to include share based payment transactions for acquiring goods and services from non-employees. The Company adopted this guidance on January 1, 2019. The adoption of this guidance was not material to our consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted. In December 2019, the FASB issued ASU 2019-12 “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ”, which is intended to improve consistent application and simplify the accounting for income taxes. This ASU removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. This standard is effective for annual reporting periods beginning after December 15, 2020, including interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact of adoption of this ASU and does not expect the adoption of this new standard to have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-13 “ Fair Value Measurement (Topic 820) ”, which modifies certain disclosure requirements in Topic 820, such as the removal of the need to disclose the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy, and several changes related to Level 3 fair value measurements. This ASU is effective for reporting periods beginning after December 15, 2019. We are currently assessing the potential impact that the adoption of this ASU will have on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-15 “ Intangibles—Goodwill and Other—Internal Use Software (Subtopic 350-40) ”, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software. This ASU is effective for reporting periods beginning after December 15, 2019. We are currently assessing the potential impact that the adoption of this ASU will have on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13 “ Measurement of Credit Losses on Financial Instruments ”, which replaces current methods for evaluating impairment of financial instruments not measured at fair value, including trade accounts receivable and certain debt securities, with a current expected credit loss model. This ASU is effective for the Company for reporting periods beginning after December 15, 2022. We are currently assessing the potential impact that the adoption of this ASU will have on our consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Estimated Useful Lives of Property and Equipment	Depreciation and amortization are computed by the straight-line method over the estimated useful lives of the related assets as follows: Furniture and fixtures 5 to 7 years Laboratory equipment 3 to 10 years Computer equipment and software 3 to 7 years
Outstanding Securities not Included in the Computation of Diluted Net Loss	The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: December 31, 2019 2018 Stock options 490,330 224,895 Warrants 909,189 917,573 Preferred stock 20,888 20,888 Convertible notes 861,294 1,354,319 Total 2,281,701 2,517,675

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2019
PROPERTY AND EQUIPMENT [Abstract]
Summary of Property and Equipment	A summary of property and equipment at December 31, 2019 and 2018 is as follows: 2019 2018 Furniture and fixtures $ 12 $ 12 Laboratory equipment 299 299 Computer equipment and software 463 369 Equipment under finance leases 425 402 Construction in process 23 67 1,222 1,149 Less—accumulated depreciation and amortization (791) (653) Total $ 431 $ 496

INTANGIBLES (Tables)

INTANGIBLES (Tables)	12 Months Ended
	Dec. 31, 2019
INTANGIBLES [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following: Dollars in Thousands December 31, 2019 Accumulated Impairment Net Book Cost Amortization Charge Value Technology $ 18,990 $ 2,374 $ — $ 16,616 Customer relationships 250 208 — 42 Backlog 200 200 — — Covenants not to compete 30 30 — — Trademark 40 40 — — IPR&D 1,590 — 1,590 — $ 21,100 $ 2,852 $ 1,590 $ 16,658 Dollars in Thousands December 31, 2018 Accumulated Impairment Net Book Cost Amortization Charge Value Technology $ 18,990 $ 1,424 $ — $ 17,566 Customer relationships 250 125 — 125 Backlog 200 200 — — Covenants not to compete 30 30 — — Trademark 40 30 — 10 IPR&D 1,590 — — 1,590 $ 21,100 $ 1,809 $ — $ 19,291
Intangible Assets, Estimated Useful Life	Estimated Useful Life Technology 20 years Customer relationships 3 years Backlog 1 year Covenants not to compete 1 year Trademark 2 years

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2019
LONG-TERM DEBT [Abstract]
Schedule of debt	Long-term debt consists of the following: Dollars in Thousands December 31, 2019 December 31, 2018 Department of Economic and Community Development (DECD) $ 249 $ 274 DECD debt issuance costs (24) (28) Financed insurance loan 260 204 September 2018 Settlement 34 66 Total long-term debt 519 516 Current portion of long-term debt (321) (263) Long-term debt, net of current maturities $ 198 $ 253
Schedule of Maturities of Long-term Debt [Table Text Block]	The aggregate future maturities required on gross long-term debt at December 31, 2019 are as follows: 2020 2021 2022 2023 2024 2025 and thereafter Total DECD loan $ 30 $ 28 $ 30 $ 30 $ 31 $ 100 $ 249 Financed Insurance Loan 260 — — — — — 260 September 2018 Settlement 34 — — — — — 34 $ 324 $ 28 $ 30 $ 30 $ 31 $ 100 $ 543

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Instrument [Line Items]
Schedule of debt	Long-term debt consists of the following: Dollars in Thousands December 31, 2019 December 31, 2018 Department of Economic and Community Development (DECD) $ 249 $ 274 DECD debt issuance costs (24) (28) Financed insurance loan 260 204 September 2018 Settlement 34 66 Total long-term debt 519 516 Current portion of long-term debt (321) (263) Long-term debt, net of current maturities $ 198 $ 253
Convertible Bridge Loan
Debt Instrument [Line Items]
Summary of change in Bridge Note debt discounts and debt premiums	For the Year Ended December 31, 2019 2018 Debt Discounts Debt Premiums Debt Discounts Debt Premiums Beginning balance at January 1 $ (1,111) $ 647 $ — $ — Additions: (2,088) — (4,275) 879 Deductions: Amortization (accretion) (1) 273 (167) 118 (170) Write-off related to note conversions (2) 1,130 (480) — (62) Write-off related to note extinguishment (3) — — 3,046 — Balance at December 31 $ (1,796) $ — $ (1,111) $ 647 (1) Amortization/accretion is recognized as interest expense/income within the consolidated statements of operations based on the effective interest method. (2) Write-offs associated with note conversions are recognized as an offset to additional paid-in capital at the time of the conversion. Write-offs associated with note extinguishment are recognized as a loss and included in loss on extinguishment of convertible notes in the consolidated statements of operations.
Convertible promissory notes - Exchange Notes
Debt Instrument [Line Items]
Summary of change in Bridge Note debt discounts and debt premiums	During the year ended December 31, 2019 and 2018, the change in Exchange Note debt discounts was as follows: (Dollars in thousands) For the Year Ended December 31, 2019 2018 Beginning balance at January 1 $ (83) $ — Additions: — (383) Deductions: Amortization (1) 2 28 Write-off related to note conversions (2) 81 272 Balance at December 31 $ — $ (83) (1) Amortization is recognized as interest expense within the condensed consolidated statements of operations based on the effective interest method. Write-offs associated with note conversions are recognized as an offset to additional paid-in capital at the time of the conversion.
Convertible Debt [Member]
Debt Instrument [Line Items]
Schedule of debt	Dollars in Thousands December 31, 2019 December 31, 2018 Convertible bridge notes $ 1,938 $ 4,294 Convertible bridge notes discount and debt issuance costs (1,796) (1,111) Convertible bridge notes premiums — 647 Convertible promissory notes - Exchange Notes — 630 Convertible promissory notes - Exchange notes debt issuance costs — (83) Total convertible notes 142 4,377 Current portion of convertible notes (142) (4,377) Convertible notes, net of current maturities $ — $ —

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued expenses	Accrued expenses at December 31, 2019 and 2018 are as follows: (dollars in thousands) December 31, 2019 December 31, 2018 Accrued expenses $ 1,268 $ 1,583 Accrued compensation 247 118 Accrued interest 124 239 $ 1,639 $ 1,940
Other current liabilities	Other current liabilities at December 31, 2019 and 2018 are as follows: (dollars in thousands) December 31, 2019 December 31, 2018 Liability related to equity purchase agreement — 460 Liability for settlement of equity instrument — 1,450 $ — $ 1,910

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Summary of balance sheet presentation of our operating and finance leases	(dollars in thousands) Classification on the Condensed Consolidated Balance Sheet December 31, 2019 Assets: Operating lease assets Operating lease right-of-use assets, net $ 519 Finance lease assets Property and equipment, net 184 Total lease assets $ 703 Liabilities: Current: Operating lease obligations Current maturities of operating lease liabilities $ 209 Finance lease obligations Current maturities of finance lease liabilities 52 Noncurrent: Operating lease obligations Operating lease liabilities, less current maturities 317 Finance lease obligations Finance lease liabilities, less current maturities 119 Total lease liabilities $ 697
Summary of estimated future minimum lease payments for finance leases	As of December 31, 2019, the estimated future minimum lease payments, excluding non-lease components, are as follows: (dollars in thousands) Operating Leases Finance Leases Total 2020 $ 242 $ 62 $ 304 2021 241 38 279 2022 48 32 80 2023 35 28 63 2024 17 27 44 Thereafter — 13 13 Total lease obligations 583 200 783 Less: Amount representing interest (57) (29) (86) Present value of net minimum lease obligations 526 171 697 Less, current portion (209) (52) (261) Long term portion $ 317 $ 119 $ 436
Schedule of other information	Weighted-average remaining lease term (years): Operating leases 2.8 Finance leases 4.3 Weighted-average discount rate: Operating leases Finance leases

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Purchase Obligations	Years ending December 31, (dollars in thousands) 2020 $ 341 2021 242 2022 228 2023 219 2024 149 Thereafter 50 $ 1,229

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets And Liabilities	Dollars in Thousands 2019 2018 Deferred tax assets: Net operating loss and credit carryforwards $ 13,989 $ 10,202 Stock-based compensation 292 192 Other 666 426 Gross deferred tax assets 14,947 10,820 Deferred tax liabilities: Property and equipment (95) 42 Intangible assets (4,148) (2,084) IPR&D intangible assets — (70) Gross deferred tax liabilities (4,243) (2,112) Net deferred tax assets 10,704 8,708 Less valuation allowance (10,704) (8,778) Net deferred liability $ — $ (70)
Reconciliation of the Provision for Income Taxes	Dollars in Thousands 2019 2018 Benefit at federal rate $ (2,796) $ (3,354) Increase (decrease) resulting from: State income taxes—net of federal benefit (517) (633) Miscellaneous permanent differences 78 — Warrant liability revaluation (104) (479) Impairment of goodwill — 1,170 Impairment of in-process research and development (70) — Other — 14 Change in valuation allowance 3,339 3,003 Total income tax benefit $ (70) $ (279)
Schedule of Income Taxes by Jurisdiction	Dollars in Thousands 2019 2018 Federal: Current $ — $ — Deferred (70) (279) Total Federal $ (70) $ (279) State: Current $ — $ — Deferred — — Total State $ — $ — Foreign: Current $ — $ — Deferred — — Total Foreign $ — $ — Total Tax Provision $ (70) $ (279)
Summary of Operating Loss Carryforwards	Dollars in Thousands 2019 2018 2036 $ 13,470 $ 13,470 2037 3,441 3,441 Unlimited life 42,100 21,138 Total Federal $ 59,011 $ 38,049

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of stockholders' equity, including warrants and rights	The following represents a summary of the warrants outstanding as of December 31, 2019: Underlying Exercise Issue Year Expiration Shares Price Warrants (1) 2014 April 2020 832 $ 1,800.00 (2) 2015 February 2020 1,588 $ 1,008.00 (3) 2015 December 2020 272 $ 747.00 (4) 2016 January 2021 596 $ 544.50 (5) 2017 June 2022 2,540 $ 41.25 (5) 2017 June 2022 500 $ 7.50 (6) 2017 June 2022 6,095 $ 105.00 (7) 2017 August 2022 25,201 $ 2.25 (8) 2017 August 2022 4,000 $ 46.88 (9) 2017 August 2022 47,995 $ 150.00 (9) 2017 August 2022 9,101 $ 7.50 (10) 2017 August 2022 16,664 $ 2.25 (10) 2017 August 2022 7,335 $ 2.25 (11) 2017 October 2022 666 $ 2.25 (12) 2017 May 2023 — $ 2.25 (13) 2018 October 2022 7,207 $ 112.50 (14) 2018 April 2023 69,964 $ 5.40 (14) 2018 April 2023 121,552 $ 5.40 (15) 2018 October 2022 15,466 $ 11.25 (16) 2018 July 2023 14,671 $ 5.40 (16) 2018 July 2023 14,672 $ 5.40 (16) 2018 August 2023 36,334 $ 5.40 (16) 2018 August 2023 36,334 $ 5.40 (16) 2018 September 2023 19,816 $ 5.40 (16) 2018 September 2023 20,903 $ 5.40 (17) 2018 November 2023 75,788 $ 5.40 (17) 2018 December 2023 51,282 $ 5.40 (18) 2019 April 2024 147,472 $ 5.40 (19) 2019 May 2024 154,343 $ 9.56 909,189 (1) These warrants were issued in connection with a private placement which was completed in October 2014. (2) These warrants were issued in connection with an offering which was completed in February 2015. (3) These warrants were issued in connection with an offering which was completed in July 2015. (4) These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding warrants as of December 31, 2019, 357 warrants are recorded as liability, See Note 12 – Fair Value for further discussion, and 239 warrants are treated as equity. (5) These warrants were issued in connection with a June 2017 merger transaction (the “Merger”) and are the 2017 New Bridge Warrants. (6) These warrants were issued in connection with the Merger and are considered the Side Warrants. (7) These warrants were issued in connection with an underwritten public offering consisting of the Company’s Series B Preferred Stock and warrants (the “August 2017 Offering”) and are the August 2017 Offering Warrants discussed below. (8) These warrants were issued in connection with the August 2017 Offering and are the Representative Warrants discussed below. (9) These warrants were issued 2017 and are the Series A Conversion Warrants discussed below. (10) These warrants were issued in connection with the conversion of convertible bridge notes, at the time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below. (11) These warrants were issued in connection with a waiver of default the Company received in the fourth quarter of 2017 in connection with certain convertible promissory notes and are the Convertible Promissory Note Warrants discussed below. (12) These warrants (the “Series C Warrants’) were issued in connection with the Series C Preferred Offering and are discussed below. (13) These warrants were issued in connection with the Settlement Agreements and are the Creditor Warrants discussed below. (14) These warrants were issued in connection with the 2018 Note Agreement and are the April 2018 Warrants discussed below. (15) These warrants were issued in connection with the 2018 Note Agreement and are the Advisor Warrants discussed below. (16) These warrants were issued in connection with the 2018 Note Agreement and are the Q3 2018 Warrants discussed below. (17) These warrants were issued in connection with the 2018 Note Agreement, and subsequent Amendment Agreement, and are the Q4 2018 Warrants discussed below. (18) These warrants were issued in connection with the 2018 Note Agreement and subsequent Amendment No. 2 Agreement and are the April 2019 Warrants discussed below. (19) These warrants were issued in connection with the May 2019 Bridge Notes and are the May 2019 Warrants discussed below.
Summary of dividends recorded	There were no dividends recorded in 2019. The following represents a summary of the dividends recorded for the year ended December 31, 2018: Amount Recorded Deemed Dividends (in thousands) Dividends resulting from the 2018 Purchase Agreement Deemed Dividend A $ 1,358 Deemed Dividend E 829 Deemed Dividend G 62 Deemed Dividend J 8 Deemed Dividend N * Deemed Dividend R 58 Dividends resulting from the 2018 Inducement Agreement Deemed Dividend B 40 Deemed Dividend F 1,154 Deemed Dividend K 5 Deemed Dividend O * Dividends resulting from the 2018 Note Agreement Deemed Dividend C 216 Deemed Dividend H 63 Deemed Dividend L 10 Deemed Dividend P * Deemed Dividend S 45 Dividends resulting from the Amendment Agreement Deemed Dividend D 361 Deemed Dividend I 5 Deemed Dividend M 4 Deemed Dividend Q * Deemed Dividend T 4 Total 2018 Deemed Dividends $ 4,222 * Represents less than one thousand dollars

FAIR VALUE (Tables)

FAIR VALUE (Tables)	12 Months Ended
	Dec. 31, 2019
FAIR VALUE [Abstract]
Schedule of Changes in Fair Value of Liability	During the years ended December 31, 2019 and 2018, the change in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were comprised of the following: Dollars in Thousands Year Ended December 31, 2019 2016 Warrant Bridge Note Total Warrant Liability Warrant Liabilities Liabilities Beginning balance at January 1 $ 116 $ 1,016 $ 1,132 Additions: – 1,858 1,858 Total (gains) losses: Revaluation recognized in earnings (46) (370) (416) Modification recognized in earnings – 1,128 1,128 Deductions – warrant exercises – (2,364) (2,364) Balance at December 31 $ 70 $ 1,268 $ 1,338 Year Ended December 31, 2018 2016 Warrant Bridge Note Total Warrant Liability Warrant Liabilities Liabilities Beginning balance at January 1 $ 841 $ – $ 841 Additions: – 2,665 2,665 Total (gains) losses: Revaluation recognized in earnings (269) (1,792) (2,061) Modification recognized in earnings – 143 143 Deductions – warrant liability settlement (456) – (456) Balance at December 31 $ 116 $ 1,016 $ 1,132
Schedule of Change in the Fair Value of the Derivative Liabilities	During the years ended December 31, 2019 and 2018, the change in the fair value of the derivative liabilities was comprised of the following: Year Ended December 31, 2019 Bridge Notes Redemption Conversion Total Derivative Feature Option Liabilities Beginning balance at January 1 $ 30 $ 32 $ 62 Deductions - write-off in conjunction with convertible note conversions (438) (39) (477) Total loss: Revaluation recognized in earnings 408 7 415 Balance at December 31 $ — $ — $ — Year Ended December 31, 2018 Bridge Notes Redemption Conversion Total Derivative Feature Option Liabilities Beginning balance at January 1 $ — $ — $ — Additions: 269 383 652 Deductions - write-off in conjunction with convertible note conversions — (301) (301) Total gain: Extinguishment recognized in earnings (22) — (22) Revaluation recognized in earnings (217) (50) (267) Balance at December 31 $ 30 $ 32 $ 62

EQUITY INCENTIVE PLAN (Tables)

EQUITY INCENTIVE PLAN (Tables)	12 Months Ended
	Dec. 31, 2019
EQUITY INCENTIVE PLAN [Abstract]
Summary of stock option activity	The following table summarizes stock option activity under our plans during the year ended December 31, 2019: Number of Weighted-Average Options Exercise Price Outstanding at January 1, 2019 224,895 $ 15.90 Granted 292,604 2.36 Forfeited (27,169) 6.03 Outstanding at December 31, 2019 490,330 $ 8.30 Exercisable at December 31, 2019 181,705 $ 13.48

SALES SERVICE REVENUE, NET AN_2

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2019
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
Schedule of Net Revenues	Service revenue, net for the years ended December 31, 2019 and 2018 was as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption): For the Year Ended December 31, (dollars in thousands) Diagnostic Testing Biomarker Testing Total 2019 2018 2019 2018 2019 2018 Medicaid $ 28 $ 50 $ — $ — $ 28 $ 50 Medicare 1,669 1,000 — — 1,669 1,000 Self-pay 34 138 — — 34 138 Third party payers 1,725 960 — — 1,725 960 Contract diagnostics — — 595 1,187 595 1,187 Service revenue, net $ 3,456 $ 2,148 $ 595 $ 1,187 $ 4,051 $ 3,335
Schedule of Gross to Net Sales Adjustments	The following table presents our revenues initially recognized for each associated payer class during the year ended December 31, 2019 and 2018. (dollars in thousands) For the Year Ended December 31, Contractual Allowances and Revenues, net of Contractual Gross Revenues adjustments Allowances and adjustments 2019 2018 2019 2018 2019 2018 Medicaid $ 31 $ 86 $ (3) $ (36) $ 28 $ 50 Medicare 1,686 1,019 (17) (19) 1,669 1,000 Self-pay 34 138 — — 34 138 Third party payers 5,785 2,358 (4,060) (1,398) 1,725 960 Contract diagnostics 595 1,187 — — 595 1,187 8,131 4,788 (4,080) (1,453) 4,051 3,335 Clinical research grants and other 44 113 — — 44 113 $ 8,175 $ 4,901 $ (4,080) $ (1,453) $ 4,095 $ 3,448
Schedule of Reported Revenues Net of Collection Allowance [Table Text Block]	The following table presents our reported revenues net of the collection allowance and adjustments for the year ended December 31, 2019 and 2018. For the Year Ended December 31, Revenues, net of (dollars in thousands) Contractual Allowances Allowances for doubtful and adjustments accounts Total 2019 2018 2019 2018 2019 2018 Medicaid $ 28 $ 50 $ (28) $ (50) $ — $ — Medicare 1,669 1,000 (251) (150) 1,418 850 Self-pay 34 138 — — 34 138 Third party payers 1,725 960 (689) (384) 1,036 576 Contract diagnostics 595 1,187 — — 595 1,187 4,051 3,335 (968) (584) 3,083 2,751 Clinical research grants and other 44 113 — — 44 113 $ 4,095 $ 3,448 $ (968) $ (584) $ 3,127 $ 2,864
Schedule of Receivables	The following summarizes the mix of receivables for the years ended December 31, 2019 and 2018: (dollars in thousands) December 31, 2019 December 31, 2018 Medicaid $ 107 $ 82 Medicare 814 633 Self-pay 88 108 Third party payers 2,203 1,382 Contract diagnostic services 36 193 $ 3,248 $ 2,398 Less allowance for doubtful accounts (2,674) (1,708) Accounts receivable, net $ 574 $ 690
Schedule of Allowance for Doubtful Accounts	The following table presents the roll-forward of the allowance for doubtful accounts for the year ended December 31, 2019: Allowance for Doubtful (dollars in thousands) Accounts Balance, January 1, 2019 $ (1,708) Collection Allowance: Medicaid $ (28) Medicare (251) Third party payers (689) (968) Bad debt expense $ 2 Total charges (966) Balance, December 31, 2019 $ (2,674)
Schedule of Customer Revenue and Accounts Receivable Concentrations	Customer revenue and accounts receivable concentration amounted to the following for the identified periods. Year Ended December 31, 2019 2018 Percentage of net sales by customer: Customer A % % Customer B * Customer C * * * represents less than 10% December 31, December 31, 2019 2018 Percentage of total accounts receivable by customer: Customer A * % Customer B % * Customer C % * * represents less than 10%

BUSINESS DESCRIPTION (Narrative

BUSINESS DESCRIPTION (Narrative) (Details) - USD ($)	Jan. 01, 2020	Jan. 15, 2019	Sep. 07, 2018	Feb. 11, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Accumulated Net Income (Loss)					$ 13,200,000
Working deficiency					2,500,000
Net cash used in operating activities					(9,141,000)	$ (6,754,000)
Proceeds from issuance of common stock					$ 6,628,000	$ 2,008,000
Lincoln Park [Member]
Business Acquisition [Line Items]
Value of shares issued			$ 10,000,000
Shares sold in offering (in shares)					2,778,077	328,590
Proceeds from issuance of common stock					$ 6,600,000	$ 1,400,000
Equity purchase agreement value remaining available					700,000
Lincoln Park [Member] | Maximum
Business Acquisition [Line Items]
Value of shares issued			$ 1,000,000		$ 10,000,000
Shares sold in offering (in shares)			30,000
Crede Note
Business Acquisition [Line Items]
Proceeds from issuance of common stock		$ 4,000,000
Subsequent Events
Business Acquisition [Line Items]
Shares sold in offering (in shares)	900,012
Proceeds from issuance of common stock	$ 1,300,000
Subsequent Events | Lincoln Park [Member]
Business Acquisition [Line Items]
Shares sold in offering (in shares)				900,012
Proceeds from issuance of common stock	$ 9,300,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Recent Accounting Pronouncements) (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities	$ 526,000	$ 750,000
Right-of-use assets	519,000	750,000
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities	700,000	750,000
Right-of-use assets	$ 700,000	$ 750,000

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Prepaid Insurance	$ 200	$ 200
Amortization expense for intangible assets	$ 1,000	$ 1,200
Awards outstanding	53,334
Securities not included in the computation of diluted net loss per share	2,281,701	2,517,675
Impairment of goodwill		$ 4,700
Other current receivables	$ 100	300
Impairment of intangible assets	0	0
Depreciation expense	100	100
Amortization expense of converted debt issuance costs	(100)	100
Insurance claims, recoveries	0	0
Income tax, interest and penalties	$ 0	0
Share-based compensation arrangement by share-based payment award, expiration period	10 years
Advertising expense	$ 100	100
Research and development expense	1,200	1,100
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 1,600	0
Maximum
Finite-Lived Intangible Assets [Line Items]
Current prepaid expense		$ 100
Stock options, unvested options, vesting period	4 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	2,281,701	2,517,675
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	490,330	224,895
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	909,189	917,573
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	20,888	20,888
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	861,294	1,354,319

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Estimated Useful Lives of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2019
Furniture and Fixtures [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Laboratory Equipment [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Laboratory Equipment [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Equipment and Software [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment and Software [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years

PROPERTY AND EQUIPMENT, NET (Su

PROPERTY AND EQUIPMENT, NET (Summary of Property and Equipment) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,222	$ 1,149
Less-accumulated depreciation and amortization	(791)	(653)
Property, Plant and Equipment, Net, Total	431	496
Depreciation	100	100
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	12	12
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	299	299
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	463	369
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	23	67
Equipment Under Finance Leases [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 425	$ 402

INTANGIBLES (Narrative) (Detail

INTANGIBLES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Impairment of finite lived intangible asset	$ 1.6
Amortization expense for intangible assets	1	$ 1.2
Amortization expense, 2020	1
Amortization expense, 2021	0.9
Amortization expense, 2022	0.9
Amortization expense, 2023	0.9
Amortization expense, 2024	$ 0.9
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of finite lived intangible asset		$ 0

INTANGIBLES (Schedule of Intang

INTANGIBLES (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 21,100	$ 21,100
Accumulated Amortization	2,852	1,809
Impairment Charge	1,590
Net Book Value	16,658	19,291
Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	18,990	18,990
Accumulated Amortization	2,374	1,424
Net Book Value	16,616	17,566
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	250	250
Accumulated Amortization	208	125
Net Book Value	42	125
Backlog [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	200	200
Accumulated Amortization	200	200
Covenants not to Compete [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	30	30
Accumulated Amortization	30	30
Trademark [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	40	40
Accumulated Amortization	40	30
Net Book Value		10
In-Process Research and Development [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	1,590	1,590
Impairment Charge	$ 1,590
Net Book Value		$ 1,590

INTANGIBLES (Intangible Assets,

INTANGIBLES (Intangible Assets, Estimated Useful Life) (Details)	12 Months Ended
	Dec. 31, 2019
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	20 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	3 years
Backlog [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	1 year
Covenants not to Compete [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	1 year
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	2 years

LONG-TERM DEBT (Schedule of Deb

LONG-TERM DEBT (Schedule of Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total debt	$ 519	$ 516
Current portion of long-term debt	(321)	(263)
Long-term debt, net of current maturities	198	253
Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Total debt	249	274
Debt issuance cost	(24)	(28)
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Total debt	260	204
Convertible Debt [Member]
Debt Instrument [Line Items]
Total debt	142	4,377
Current portion of long-term debt	(142)	(4,377)
Long-term debt, net of current maturities
Convertible Debt [Member] | Convertible bridge notes
Debt Instrument [Line Items]
Debt issuance cost	(1,796)	(1,111)
Settlement Agreement [Member]
Debt Instrument [Line Items]
Total debt	$ 34	$ 66

LONG-TERM DEBT (Department of E

LONG-TERM DEBT (Department of Economic and Community Development) (Details) - USD ($)	Jan. 08, 2018	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Proceeds from long-term debt			$ 300,000
Total debt		$ 519,000	516,000
Revenue, net of contractual allowances and adjustments		4,095,000	3,448,000
Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Gross proceeds from grant received and loan	$ 400,000
Proceeds from grant	$ 100,000
Debt instrument, term	10 years
Debt instrument, maturity date	Dec. 31, 2027
Interest rate (as a percent)	3.25%
Total debt		249,000	274,000
Revenue, net of contractual allowances and adjustments		100,000
Term loan | Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Proceeds from long-term debt	$ 300,000
Debt issuance costs, net	$ 31,000	24,000	$ 28,000
Amortization of debt issuance cost		3,000
2020		3,000
2021		3,000
2022		3,000
2023		3,000
2024		$ 3,000

LONG-TERM DEBT (Financed Insura

LONG-TERM DEBT (Financed Insurance Loan) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jul. 31, 2019	Dec. 31, 2018	Jul. 31, 2018
Debt Instrument [Line Items]
Total debt	$ 519		$ 516
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 400		$ 400
Interest rate (as a percent)		5.00%		4.89%
Total debt	$ 260		$ 204

LONG-TERM DEBT (Settlement Agre

LONG-TERM DEBT (Settlement Agreement) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 21, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total debt	$ 519	$ 516
Settlement Agreements
Debt Instrument [Line Items]
Total debt				$ 3,200
Settlement Agreement [Member]
Debt Instrument [Line Items]
Total debt	$ 34	66
Settlement Agreement [Member] | Settlement Agreements
Debt Instrument [Line Items]
Frequency of periodic payment	monthly
Debt instrument, term	2 years
Date of first required payment	Nov. 1, 2018
Maturity date	Nov. 1, 2020
Debt instrument, face amount			$ 100
Interest rate (as a percent)	10.00%
Total debt	$ 100	$ 100

LONG-TERM DEBT (Aggregate Futur

LONG-TERM DEBT (Aggregate Future Maturities on Long-Term Debt) (Details) $ in Thousands	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
2020	$ 324
2021	28
2022	30
2023	30
2024	31
2025 and thereafter	100
Total	543
Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
2020	30
2021	28
2022	30
2023	30
2024	31
2025 and thereafter	100
Total	249
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
2020	260
Total	260
Settlement Agreement [Member]
Debt Instrument [Line Items]
2020	34
Total	$ 34

CONVERTIBLE NOTES (Details)

CONVERTIBLE NOTES (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Current portion of long-term debt	$ (321)	$ (263)
Long-term debt, net of current maturities	198	253
Convertible Debt [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	(142)	(4,377)
Long-term debt, net of current maturities
Convertible bridge notes | Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible notes	1,938	4,294
Debt issuance cost	(1,796)	(1,111)
Convertible bridge notes premiums		647
Convertible promissory notes - Exchange Notes | Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible notes		630
Debt issuance cost		(83)
Long-term debt, net of current maturities	$ 0	$ 600

CONVERTIBLE NOTES - Bridge Note

CONVERTIBLE NOTES - Bridge Notes (Details)	May 14, 2019USD ($)D$ / sharesshares	Apr. 16, 2019USD ($)D$ / sharesshares	Nov. 29, 2018USD ($)D$ / shares	Sep. 17, 2018USD ($)$ / shares	Sep. 17, 2018USD ($)D$ / shares	Sep. 17, 2018USD ($)$ / shares	Sep. 17, 2018USD ($)$ / shares	Apr. 30, 2018USD ($)$ / shares	Apr. 20, 2018USD ($)	Feb. 12, 2018USD ($)shares	Sep. 30, 2018USD ($)item$ / shares	Apr. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)item$ / sharesshares	Sep. 30, 2018USD ($)item$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Apr. 30, 2019$ / shares	Nov. 30, 2018$ / shares	Sep. 20, 2018$ / shares	Sep. 19, 2018$ / shares	Aug. 31, 2018USD ($)$ / shares	Jul. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Oct. 03, 2017$ / shares
Debt Instrument [Line Items]
Proceeds from issuance of debt															$ 2,150,000	$ 3,850,000
Number of additional drawdowns completed | item														1
Total debt													$ 516,000		519,000	516,000
Warrant revaluation															(416,000)	(1,918,000)
Payments of financial advisor fees												$ 116,000
Loss on modification of warrants															(1,128,000)
Proceeds from convertible notes															2,150,000	3,850,000
Derivative asset (liability)													62,000			62,000
Loss on extinguishment of debt																(2,903,000)
Warrant liability canceled due to settlement of equity instruments																456,000
Number of shares converted from debt instrument (in shares) | shares										120,983
Conversion of convertible debt plus interest into common stock										$ 1,900,000					$ 7,553,000	2,356,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															909,189
Wrote-off of debt discount with an offset to additional paid in capital															$ 731,000	210,000
Write-off debt derivative liability in conjunction with convertible note conversions															477,000	301,000
Long-term debt, net of current maturities													253,000		198,000	253,000
Gain (Loss) on Derivative Instruments Held for Trading Purposes, Net															(415,000)	267,000
Bridge Notes Beneficial Conversion Features
Debt Instrument [Line Items]
Derivative asset (liability)													15,000			15,000
Bridge Notes Redemption Feature [Member]
Debt Instrument [Line Items]
Derivative asset (liability)													30,000			30,000
Convertible Promissory Note Warrants
Debt Instrument [Line Items]
Exercise price (in dollars per share) | $ / shares															$ 21									$ 45
April 2018 Warrants, First Half
Debt Instrument [Line Items]
Class of Warrant or Right, Term								5 years				5 years		5 years
April 2018 Warrants, Second Half
Debt Instrument [Line Items]
Class of Warrant or Right, Term								1 year				1 year		1 year
April 2018 Warrants
Debt Instrument [Line Items]
Conversion price per share | $ / shares								$ 11.25				$ 11.25							$ 7.50	$ 11.25
Proceeds from issuance of debt												$ 1,100,000
Stock rights issued (in shares) | shares | shares												243,224
Warrants, fair value								$ 1,100,000				$ 1,100,000
Conversion ratio												150
Exercise price (in dollars per share) | $ / shares								$ 11.25			$ 7.50	$ 11.25		$ 7.50
Warrant revaluation														$ 100,000
Advisor fees as a percentage of proceeds												7.00%
Proceeds from convertible notes												$ 1,100,000
Amended Warrants
Debt Instrument [Line Items]
Exercise price (in dollars per share) | $ / shares																	$ 5.40
Warrants term																	5 years
Advisor Warrants
Debt Instrument [Line Items]
Class of Warrant or Right, Term														4 years
Stock rights issued (in shares) | shares | shares												15,466
Warrants, fair value								$ 100,000				$ 100,000
Senior Secured Convertible Promissory Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 300,000	$ 300,000	$ 300,000	$ 300,000
Convertible debt, threshold consecutive trading days | D					10
Conversion price per share | $ / shares				$ 15	$ 15	$ 15	$ 15
Debt instrument, convertible, threshold trading days | item					5		5
Conversion ratio						1.65
Derivative liability from debt discount															$ 400,000
Conversion of convertible debt plus interest into common stock																2,800,000
Debt instrument, term				18 months
Percentage of principal outstanding						20.00%
Senior Secured Convertible Promissory Notes | Maximum
Debt Instrument [Line Items]
Debt instrument, face amount				$ 500,000	$ 500,000	$ 500,000	$ 500,000
Quarter 3 2018 Warrants
Debt Instrument [Line Items]
Stock rights issued (in shares) | shares | shares														196,340
Exercise price (in dollars per share) | $ / shares																	$ 5.40
Warrants term																	5 years
Quarter 4 2018 Warrants
Debt Instrument [Line Items]
Proceeds from issuance of debt													$ 700,000
Stock rights issued (in shares) | shares | shares													300,115
Proceeds from convertible notes													$ 700,000
2018 Note Agreement
Debt Instrument [Line Items]
Debt instrument, face amount									$ 3,296,703
Exercise price (in dollars per share) | $ / shares								$ 4.50				$ 4.50						$ 2.25
2018 Note Agreement | April 2018 Warrants, First Half
Debt Instrument [Line Items]
Class of Warrant or Right, Term															1 year
2018 Note Agreement | April 2018 Warrants, Second Half
Debt Instrument [Line Items]
Class of Warrant or Right, Term															5 years
2018 Note Agreement | Advisor Warrants
Debt Instrument [Line Items]
Conversion price per share | $ / shares								$ 11.25				$ 11.25
Stock rights issued (in shares) | shares | shares												15,466
Warrants, fair value								$ 100,000				$ 100,000
Exercise price (in dollars per share) | $ / shares								$ 11.25				$ 11.25
Convertible Bridge Loan | Quarter 4 2018 Warrants
Debt Instrument [Line Items]
Warrants, fair value													$ 700,000			$ 700,000
Exercise price (in dollars per share) | $ / shares													$ 5.40			$ 5.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares													300,115			300,115
Warrants term													5 years			5 years
Quarter 3 2018 Bridge Notes
Debt Instrument [Line Items]
Proceeds from issuance of debt														$ 600,000
Derivative liability from debt discount											$ 100,000			100,000
Proceeds from convertible notes														600,000
Quarter 3 2018 Bridge Notes | Quarter 3 2018 Warrants
Debt Instrument [Line Items]
Proceeds from issuance of debt														700,000
Proceeds from convertible notes														700,000
April 2018 Bridge Notes
Debt Instrument [Line Items]
Proceeds from issuance of debt												$ 600,000
Number of additional drawdowns completed | item											3
Derivative liability from debt discount								$ 100,000				100,000
Proceeds from convertible notes												600,000
April 2018 Bridge Notes | Convertible Promissory Note Warrants
Debt Instrument [Line Items]
Discount percentage									9.00%
May 2019 Bridge Notes
Debt Instrument [Line Items]
Stock rights issued (in shares) | shares | shares	154,343
Warrants, fair value	$ 900,000
Exercise price (in dollars per share) | $ / shares	$ 9.56
Warrants term	5 years
Quarter 4 2018 Bridge Notes
Debt Instrument [Line Items]
Proceeds from issuance of debt													$ 400,000
Number of additional drawdowns completed | item													1
Total debt													$ 1,400,000			$ 1,400,000
Debt discount and debt issuance costs as a reduction of the related debt													1,100,000			1,100,000
Beneficial conversion feature													1,100,000
Loss on issuance of convertible notes													300,000
Proceeds from convertible notes													400,000
Write off of debt premium with an offset to additional paid in capital													500,000
Quarter 4 2018 Bridge Notes | Amendment Agreement
Debt Instrument [Line Items]
Proceeds from issuance of debt													$ 1,100,000		$ 300,000
Number of additional drawdowns completed | item													2
Total debt													$ 1,200,000			1,200,000
Debt discount													108,000			108,000
Proceeds from convertible notes													1,100,000		300,000
Quarter 4 2018 Bridge Notes | Amendment Agreement | Other current assets
Debt Instrument [Line Items]
Proceeds from issuance of debt															1,100,000
Proceeds from convertible notes															1,100,000
Convertible Debt [Member]
Debt Instrument [Line Items]
Total debt													4,377,000		142,000	4,377,000
Long-term debt, net of current maturities
Convertible Debt [Member] | Quarter 3 2018 Warrants
Debt Instrument [Line Items]
Debt discount and debt issuance costs as a reduction of the related debt											$ 1,300,000			1,300,000
Warrants, fair value											$ 700,000			$ 700,000
Exercise price (in dollars per share) | $ / shares																					$ 11.25
Warrant revaluation																100,000
Convertible Debt [Member] | Quarter 4 2018 Warrants
Debt Instrument [Line Items]
Warrants, fair value													$ 700,000			$ 700,000
Exercise price (in dollars per share) | $ / shares													$ 5.40			$ 5.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares													300,115			300,115
Warrants term													5 years			5 years
Convertible Debt [Member] | Convertible Bridge Loan
Debt Instrument [Line Items]
Debt instrument, face amount															1,800,000
Interest rate (as a percent)											8.00%			8.00%
Discount percentage														9.00%
Conversion threshold percentage of stock price trigger														80.00%
Convertible debt, threshold consecutive trading days | item														10
Conversion price per share | $ / shares											$ 7.50			$ 7.50
Repayment Period														180 days
Debt discount and debt issuance costs as a reduction of the related debt															1,800,000
Early repayment trigger, amount of gross proceeds														$ 7,000,000
Debt Instrument, Period To File Registration Statement											30 days
Percentage per month charged as damages if registration statement not filed by deadline														1.00%
Debt discount											$ 164,000		$ 1,111,000	$ 164,000	1,796,000	$ 1,111,000
Debt issuance costs, net											$ 164,000			$ 164,000
Beneficial conversion feature															1,100,000
Net debt issuance costs and debt discounts															2,700,000
Loss on issuance of convertible notes															900,000
Debt premium on debt													$ 647,000			$ 647,000
Warrant liability canceled due to settlement of equity instruments															$ 4,400,000
Number of shares converted from debt instrument (in shares) | shares															1,900,766	93,334
Conversion of convertible debt plus interest into common stock																$ 200,000
Amortization of debt discount															$ 273,000	118,000
Amortization of debt premium															$ 167,000	170,000
Convertible Debt [Member] | Convertible Bridge Loan | Amendment Agreement
Debt Instrument [Line Items]
Conversion threshold percentage of stock price trigger			80.00%
Convertible debt, threshold consecutive trading days | D			10
Debt discount			$ 3,100,000
Beneficial conversion feature			1,000,000
Maximum borrowing amount			$ 1,318,681
Conversion price above the closing bid price of common stock | $ / shares			$ 0.75
Floor price | $ / shares			$ 2.25
Debt, carrying amount			$ 3,300,000
Fair value of convertible debt			4,200,000
Debt premium on debt			900,000
Loss on extinguishment of debt			2,900,000
Write off of debt premium with an offset to additional paid in capital																$ 100,000
Convertible Debt [Member] | Convertible Bridge Loan | Amendment Agreement | Bridge Notes Beneficial Conversion Features
Debt Instrument [Line Items]
Beneficial conversion feature			0
Convertible Debt [Member] | Convertible Bridge Loan | Amendment Agreement | Bridge Notes Redemption Feature [Member]
Debt Instrument [Line Items]
Derivative asset (liability)			$ 0
Convertible Debt [Member] | Convertible Bridge Loan | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage															105.00%
Convertible Debt [Member] | Convertible Bridge Loan | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage															110.00%
Convertible Debt [Member] | Convertible Bridge Loan | Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage															115.00%
Convertible Debt [Member] | Convertible Bridge Loan | Minimum
Debt Instrument [Line Items]
Conversion price per share | $ / shares											$ 4.50			$ 4.50
Convertible Debt [Member] | Convertible Bridge Loan | Maximum | Amendment Agreement
Debt Instrument [Line Items]
Conversion price per share | $ / shares			$ 3.75
Derivative liability from debt discount			$ 100,000
Convertible Debt [Member] | Quarter 3 2018 Bridge Notes
Debt Instrument [Line Items]
Debt discount and debt issuance costs as a reduction of the related debt											$ 1,300,000			$ 1,300,000
Debt discount											133,000			133,000
Beneficial conversion feature															$ 500,000
Derivative liability from debt discount											100,000			100,000
Net debt issuance costs and debt discounts											1,400,000			1,400,000
Loss on issuance of convertible notes														100,000
Convertible Debt [Member] | July 2018 Bridge Notes
Debt Instrument [Line Items]
Debt instrument, face amount																						$ 348,104
Total debt																						$ 382,526
Convertible Debt [Member] | August 2018 Bridge Notes
Debt Instrument [Line Items]
Debt instrument, face amount																					$ 495,955
Total debt																					$ 545,005
Convertible Debt [Member] | September 2018 Bridge Notes
Debt Instrument [Line Items]
Debt instrument, face amount											495,941			495,941
Total debt											544,990			544,990
Convertible Debt [Member] | April 2018 Bridge Notes
Debt Instrument [Line Items]
Proceeds from issuance of debt									$ 1,660,000
Total debt									1,824,176		1,500,000			1,500,000
Debt discount and debt issuance costs as a reduction of the related debt											$ 1,300,000			$ 1,300,000
Beneficial conversion feature												$ 1,700,000
Proceeds from convertible notes									$ 1,660,000
Convertible Debt [Member] | April 2019 Bridge Notes
Debt Instrument [Line Items]
Discount percentage		9.00%
Repayment Period		180 days
Proceeds from issuance of debt		$ 900,000
Total debt		1,000,000
Debt discount and debt issuance costs as a reduction of the related debt		1,000,000
Debt discount		$ 100,000
Stock rights issued (in shares) | shares | shares		147,472
Warrants, fair value		$ 1,000,000
Exercise price (in dollars per share) | $ / shares		$ 5.40
Beneficial conversion feature		$ 900,000
Net debt issuance costs and debt discounts		2,000,000
Loss on issuance of convertible notes															$ 1,000,000
Proceeds from convertible notes		$ 900,000
Warrants term		5 years
Convertible Debt [Member] | April 2019 Bridge Notes | Amendment Agreement
Debt Instrument [Line Items]
Conversion threshold percentage of stock price trigger		80.00%
Convertible debt, threshold consecutive trading days | D		10
Conversion price per share | $ / shares		$ 0.75
Floor price | $ / shares		2.25
Convertible Debt [Member] | April 2019 Bridge Notes | Maximum | Amendment Agreement
Debt Instrument [Line Items]
Conversion price per share | $ / shares		$ 3.75
Convertible Debt [Member] | May 2019 Bridge Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,100,000
Conversion threshold percentage of stock price trigger	80.00%
Convertible debt, threshold consecutive trading days | D	10
Conversion price per share | $ / shares	$ 7.12
Repayment Period	180 days
Proceeds from issuance of debt	$ 1,000,000
Debt discount and debt issuance costs as a reduction of the related debt	1,100,000
Debt discount	100,000
Beneficial conversion feature	900,000
Net debt issuance costs and debt discounts	2,000,000
Loss on issuance of convertible notes	$ 900,000
Original issue discount (as a percent)	9
Proceeds from convertible notes	$ 1,000,000
Floor price | $ / shares	$ 2.25

CONVERTIBLE NOTES (Bridge Note

CONVERTIBLE NOTES (Bridge Note debt discounts and debt premiums) (Details) - Convertible Debt [Member] - Convertible Bridge Loan - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt discounts
Beginning balance	$ (1,111)
Additions	(2,088)	(4,275)
Deductions: Amortization/accretion	273	118
Deductions: Write-off related to note conversions	1,130
Deductions: Write-off related to note extinguishment		3,046
Ending balance	(1,796)	(1,111)
Debt premiums
Beginning balance	647
Additions:		879
Deductions: Amortization/accretion	(167)	(170)
Deductions: Write-off related to note conversions	(480)	(62)
Ending balance		$ 647

CONVERTIBLE NOTES (Convertible

CONVERTIBLE NOTES (Convertible Promissory Notes - Exchange Notes) (Details) - USD ($)	Sep. 17, 2018	Feb. 12, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2018
Debt Instrument [Line Items]
Total debt			$ 519,000	$ 516,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			909,189
Original debt amount				456,000
Conversion of convertible debt plus interest into common stock		$ 1,900,000	$ 7,553,000	2,356,000
Number of shares converted from debt instrument (in shares)		120,983
Share Price		$ 15.60
Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, term			48 months
Date of first required payment			Jul. 1, 2018
Original debt amount				3,200,000
Interest Expense, Debt			$ 600,000
Debt Restructured					$ 6,300,000
Creditor Warrants Relating to Secured Debt
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						7,207
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 112.50
Senior Secured Convertible Promissory Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 300,000
Debt instrument, term	18 months
Conversion of convertible debt plus interest into common stock				2,800,000
Write off of derivative liability			100,000	300,000
Settlement Agreements
Debt Instrument [Line Items]
Total debt					3,200,000
Warrants and Rights Outstanding					1,900,000
Warrants, fair value					$ 200,000
Convertible Debt [Member]
Debt Instrument [Line Items]
Total debt			142,000	4,377,000
Convertible Debt [Member] | Convertible promissory notes - Exchange Notes
Debt Instrument [Line Items]
Conversion of convertible debt plus interest into common stock			$ 600,000	$ 2,200,000
Number of shares converted from debt instrument (in shares)			155,351	291,562

CONVERTIBLE NOTES (Exchange Not

CONVERTIBLE NOTES (Exchange Note debt discounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt discounts
Offset by additional paid in capital	$ 477	$ 301
Convertible promissory notes - Exchange Notes | Convertible Debt [Member]
Debt discounts
Beginning balance	(83)
Additions		(383)
Deductions: Amortization/accretion	2	28
Deductions: Write-off related to note conversions	$ 81	272
Ending balance		$ (83)

CONVERTIBLE NOTES (Convertibl_2

CONVERTIBLE NOTES (Convertible Promissory Notes) (Details) $ in Thousands	Apr. 16, 2019USD ($)shares	Jan. 29, 2019USD ($)installmentshares	Jan. 15, 2019USD ($)	Feb. 12, 2018USD ($)shares	Feb. 09, 2018shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Payments on notes						$ 473	$ 422
Conversion of convertible debt plus interest into common stock				$ 1,900		7,553	2,356
Number of shares converted from debt instrument (in shares) | shares				120,983
Outstanding debt						543
Proceeds from issuance of common stock						6,628	2,008
Proceeds from issuance of debt						2,150	3,850
Crede Note
Debt Instrument [Line Items]
Conversion of convertible debt plus interest into common stock	$ 1,450
Number of shares converted from debt instrument (in shares) | shares	270,699
Outstanding debt						0
Issuance of convertible notes			$ 1,450
Conversion price based on closing bid price of common stock on the date prior to each conversion date (as a percent)			90.00%
Proceeds from issuance of common stock			$ 4,000
Beneficial Ownership Cap			4.99%
Leviston Resources LLC
Debt Instrument [Line Items]
Conversion of convertible debt plus interest into common stock						$ 700
Number of shares converted from debt instrument (in shares) | shares						184,357
Outstanding debt						$ 0
Beneficial Ownership Cap		4.99%
New shares issued (in shares) | shares		10,000			48,076
Percentage of daily average composite trading volume		10.00%
Leviston Resources LLC | Other current liabilities
Debt Instrument [Line Items]
Outstanding debt							500
Leviston Resources LLC | Accrued expenses
Debt Instrument [Line Items]
Outstanding debt							$ 200
Settled Litigation | Leviston Resources LLC
Debt Instrument [Line Items]
Issuance of convertible notes		$ 700
Number of equal monthly installments | installment		14
Settled Litigation | Leviston Resources LLC | Crede Note | Accrued expenses
Debt Instrument [Line Items]
Issuance of convertible notes		$ 200
Maximum | Crede Note
Debt Instrument [Line Items]
New shares issued (in shares) | shares						10,000
Percentage of daily average composite trading volume						10.00%
Maximum | Leviston Resources LLC
Debt Instrument [Line Items]
Payments on notes						$ 100
Minimum | Settled Litigation
Debt Instrument [Line Items]
Proceeds from issuance of common stock		$ 4,000

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Accrued Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued expenses	$ 1,268	$ 1,583
Accrued compensation	247	118
Accrued interest	124	239
Accrued expenses	$ 1,639	$ 1,940

ACCRUED EXPENSES AND OTHER CU_4

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details) $ in Thousands	Dec. 31, 2018USD ($)
Payables and Accruals [Abstract]
Liability related to equity purchase agreement	$ 460
Liability for settlement of equity instrument	1,450
Other Liabilities, Current, Total	$ 1,910

ACCRUED EXPENSES AND OTHER CU_5

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Narrative) (Details) - USD ($) $ in Thousands	Mar. 12, 2018	Dec. 31, 2019	Dec. 31, 2018	Jan. 29, 2019	Jan. 15, 2019
Reduction in Certain Accrued Expense and Accounts Payable		$ 1,400	$ 300
Common stock warrant liabilities		1,338	1,132
Gain in warrant revaluation		200
Gain (loss) on settlement of equity instruments		1,437	263
Proceeds from convertible notes		2,150	3,850
Liability related to equity purchase agreement			460
Other current liabilities
Liability related to equity purchase agreement			500
Crede Note
Loss Contingency, Damages Sought, Value		2,200
Warrants, fair value		400
Gain (loss) on settlement of equity instruments		$ (400)
Issuance of convertible notes					$ 1,450
Settled Litigation | Crede Note
Litigation Settlement, Amount Awarded to Other Party	$ 1,925
Liability For Settlement Payment Period		16 months
Damages paid			$ 500
Settled Litigation | Leviston Resources LLC
Issuance of convertible notes				$ 700
Settled Litigation | Leviston Resources LLC | Crede Note | Accrued expenses
Issuance of convertible notes				$ 200

LEASES - Narrative (Details)

LEASES - Narrative (Details)	Jan. 01, 2019USD ($)item	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Lessee, Lease, Description [Line Items]
Right-of-use assets	$ 750,000	$ 519,000
Lease liabilities	$ 750,000	526,000
Operating leases		144,000
Right-of-use assets obtained in exchange for lease obligations		750,000
Minimum
Lessee, Lease, Description [Line Items]
Facility leases | item	1
Renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Current prepaid expense			$ 100,000
Renewal term	5 years
ASU 2016-02
Lessee, Lease, Description [Line Items]
Right-of-use assets	$ 750,000	700,000
Lease liabilities	750,000	$ 700,000
Increase (decrease) in deferred rent and prepaid expenses	(6,000)
Current prepaid expense	6,000
Cumulative effect adjustment	$ 0

LEASES - Operating and Financin

LEASES - Operating and Financing leases (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Balance sheet presentation of our operating and financing leases
Operating lease right-of-use assets	$ 519,000	$ 750,000
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Operating lease right-of-use assets
Finance lease assets	$ 184,000
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Finance lease assets
Total lease assets	$ 703,000
Operating lease obligations, current	$ 209,000
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Operating lease obligations, current
Finance lease obligations	$ 52,000		$ 57,000
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Finance lease obligations
Operating lease liabilities, less current maturities	$ 317,000
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Operating lease liabilities, less current maturities
Finance lease liabilities, less current maturities	$ 119,000		$ 155,000
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Finance lease liabilities, less current maturities
Total lease liabilities	$ 697,000

LEASES - Future Minimum Lease P

LEASES - Future Minimum Lease Payments (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating leases, estimated future minimum lease payments
2020	$ 242,000
2021	241,000
2022	48,000
2023	35,000
2024	17,000
Total lease obligations	583,000
Less: Amount representing interest	(57,000)
Present value of net minimum lease obligations	526,000	$ 750,000
Less, current portion	(209,000)
Long term portion	317,000
Finance leases, estimated future minimum lease payments
2020	62,000
2021	38,000
2022	32,000
2023	28,000
2024	27,000
Thereafter	13,000
Total lease obligations	200,000
Less: Amount representing interest	(29,000)
Finance Lease, Liability, Total	171,000
Less, current portion	(52,000)		$ (57,000)
Long term portion	119,000		$ 155,000
2020	304,000
2021	279,000
2022	80,000
2023	63,000
2024	44,000
Thereafter	13,000
Total lease obligations	783,000
Less: Amount representing interest	(86,000)
Total lease liabilities	697,000
Less, current portion	(261,000)
Long term portion	$ 436,000

LEASES - Operating and Financ_2

LEASES - Operating and Financing Lease Cost (Details) - USD ($) $ in Millions	12 Months Ended		24 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
Operating lease costs	$ 0.3	$ 0.3
Finance leases, amortization expense and interest	$ 0.1	$ 0.1
Minimum
Lessee, Lease, Description [Line Items]
Renewal term				1 year
Maximum
Lessee, Lease, Description [Line Items]
Short-term lease costs			$ 0.1
Renewal term				5 years

LEASES - Other Information (Det

LEASES - Other Information (Details)	Dec. 31, 2019
Leases [Abstract]
Operating leases (in years)	2 years 9 months 18 days
Finance leases (in years)	4 years 3 months 18 days
Operating leases discount rate	8.00%
Finance leases discount rate	7.25%

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Purchase Commitments) (Details) - Inventories [Member]	Dec. 31, 2019USD ($)
2020	$ 341
2021	242
2022	228
2023	219
2024	149
Thereafter	50
Total	$ 1,229

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)	Jul. 10, 2019	Jun. 21, 2019	Apr. 19, 2019	Mar. 21, 2018	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Loss Contingencies [Line Items]
Outstanding debt						$ 543,000
(Loss) gain on extinguishment of debt						(20,000)	$ 376,000
Insurance deductible amount						800,000
XIFIN, Inc.
Loss Contingencies [Line Items]
Loss contingency, damages sought						270,000
Loss contingency accrual							100,000
Litigation settlement in favor of other party, amount			$ 40,000
CPA Global
Loss Contingencies [Line Items]
Loss contingency, damages sought						200,000
Loss contingency accrual						100,000	$ 100,000
Bio-Rad Laboratories
Loss Contingencies [Line Items]
Litigation settlement in favor of other party, amount				$ 39,000
Jesse Cambell
Loss Contingencies [Line Items]
Loss contingency accrual						300,000
Litigation settlement in favor of other party, amount		$ 1,950,000
Loss Contingency Accrual, Payments					$ 0
Legal Fees	$ 500,000
Expected amount to be paid by insurance company						$ 1,700,000

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income tax expense	$ (70)	$ (279)
Income tax, interest and penalties	0	0
Net deferred tax assets	10,704	8,708
Deferred Tax Assets, Valuation Allowance	10,704	8,778
Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs		70
Increase in valuation allowance	1,900
Gross federal and state net operating loss ("NOL") carryforwards		61,000	$ 39,000
Intangible assets	4,148	2,084
Federal losses	(70)	(279)
Federal
Federal losses		31,000
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	$ 59,011	$ 38,049

INCOME TAXES (Schedule of Defer

INCOME TAXES (Schedule of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss and credit carryforwards	$ 13,989	$ 10,202
Stock-based compensation	292	192
Other	666	426
Gross deferred tax assets	14,947	10,820
Property and equipment	(95)	42
Intangible assets	(4,148)	(2,084)
IPR&D intangible assets		(70)
Gross deferred tax liabilities	(4,243)	(2,112)
Net deferred tax assets	10,704	8,708
Less valuation allowance	$ (10,704)	(8,778)
Net deferred liability		$ (70)

INCOME TAXES (Reconciliation of

INCOME TAXES (Reconciliation of the Provision for Income Taxes) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Benefit at federal rate	$ (2,796)	$ (3,354)
State income taxes-net of federal benefit	(517)	(633)
Miscellaneous permanent differences	78
Warrant liability revaluation	(104)	(479)
Impairment of goodwill		1,170
Income Tax Reconciliation Impairment of in-process research and development	(70)
Other		14
Change in valuation allowance	3,339	3,003
Income Tax Expense (Benefit), Total	$ (70)	$ (279)

INCOME TAXES (Schedule of Incom

INCOME TAXES (Schedule of Income Taxes by Jurisdiction) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Current Federal
Deferred Federal	(70)	(279)
Total Federal	(70)	(279)
Current State
Deferred State
Total State
Current Foreign
Deferred Foreign
Total Foreign
Income Tax Expense (Benefit), Total	$ (70)	$ (279)

INCOME TAXES (Summary of Operat

INCOME TAXES (Summary of Operating Loss Carryforwards) (Details) - Internal Revenue Service (IRS) [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards	$ 59,011	$ 38,049
Tax Year 2036 [Member]
Operating Loss Carryforwards	13,470	13,470
Tax Year 2037 [Member]
Operating Loss Carryforwards	3,441	3,441
Unlimited life
Operating Loss Carryforwards	$ 42,100	$ 21,138

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock, 2018 Purchase Agreement and LP Purchase Agreement) (Details) - USD ($)	Jan. 14, 2020	Jan. 01, 2020	Aug. 09, 2019	Feb. 01, 2019	Jan. 29, 2019	Sep. 14, 2018	Sep. 07, 2018	Aug. 10, 2018	Feb. 12, 2018	Feb. 09, 2018	Feb. 08, 2018	Feb. 11, 2020	Jan. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Feb. 11, 2020	Jan. 01, 2019	Dec. 20, 2018	Dec. 19, 2018	Sep. 06, 2018
Class of Stock [Line Items]
Common stock, shares authorized (in shares)															150,000,000	150,000,000		250,000,000	150,000,000	150,000,000
Conversion of convertible notes into common stock (in shares)									120,983
Common stock, shares outstanding (in shares)															7,898,117	2,298,738					1,543,724
Issuance of common stock, net of issuance costs															$ 6,628,000	$ 2,008,000
Conversion of convertible debt plus interest into common stock									$ 1,900,000						7,553,000	2,356,000
Share price (in dollars per share)									$ 15.60
Stock Issued During Period, Value, Issued for Services																39,000
Liability recorded related to equity purchase agreement repricing															460,000	460,000
Liability related to equity purchase agreement																460,000
Number of shares converted from debt instrument (in shares)									120,983
Conversion of debt into stock									$ 1,900,000						7,553,000	2,356,000
Liability for settlement of equity instrument																1,450,000
Other current liabilities																1,910,000
Proceeds from exercise of warrants															$ 1,575,000	$ 1,271,000
Shares issued (in shares)															7,898,117	2,298,738
Common Stock
Class of Stock [Line Items]
Conversion of convertible notes into common stock (in shares)															2,511,173	384,896
Number of shares converted (in shares)																(431,022)
Issuance of common stock for consulting services in connection with the merger (in shares)																1,527
Stock Issued During Period, Shares, Issued for Services																1,527
Number of shares converted from debt instrument (in shares)															2,511,173	384,896
Leviston Resources LLC
Class of Stock [Line Items]
Issuance costs															$ 132,000
Common Stock
Class of Stock [Line Items]
Conversion of convertible notes into common stock (in shares)															310,200	252,486
Conversion of convertible debt plus interest into common stock															$ 7,600,000	$ 2,400,000
Number of shares converted from debt instrument (in shares)															310,200	252,486
Conversion of debt into stock															$ 7,600,000	$ 2,400,000
Warrant exercises in period															310,200	252,486
Proceeds from exercise of warrants															$ 1,600,000	$ 1,300,000
Series B Preferred Stock
Class of Stock [Line Items]
Common stock issued on conversion of preferred shares															208,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares converted (in shares)															2,548
Common stock issued on conversion of preferred shares															223,022
Stock Not Issued, Shares															4,000
Preferred Class B
Class of Stock [Line Items]
Number of shares converted (in shares)															2,340
Subsequent Events
Class of Stock [Line Items]
Shares sold in offering (in shares)		900,012
Issuance of common stock, net of issuance costs		$ 1,300,000
Leviston Resources LLC
Class of Stock [Line Items]
Proceeds from sale of stock										$ 750,000
Conversion of convertible notes into common stock (in shares)															184,357
Issuance of common stock for consulting services in connection with the merger (in shares)										11,381
New shares issued (in shares)					10,000					48,076
Beneficial Ownership Cap					4.99%
Shares sold in offering (in shares)								0
Conversion of convertible debt plus interest into common stock															$ 700,000
Equity Purchase Agreement											$ 8,000,000
Equity Purchase Agreement, Commitment Fee Percentage										5.25%
Equity Purchase Agreement, Commitment Fee Installment Percentage										1.75%
Share price (in dollars per share)										$ 15.60
Stock Issued During Period, Shares, Issued for Services										11,381
Stock Issued During Period, Value, Issued for Services										$ 140,000
Accruals for potential obligations to the Investor															$ 700,000
Number of shares converted from debt instrument (in shares)															184,357
Conversion of debt into stock															$ 700,000
Leviston Resources LLC | Settled Litigation
Class of Stock [Line Items]
Issuance of convertible notes					$ 700,000
Lincoln Park [Member]
Class of Stock [Line Items]
Proceeds from sale of stock															$ 6,600,000	$ 1,400,000
New shares issued (in shares)			1,800,000	1,000,000		466,667	40,000
Value of shares issued							$ 10,000,000
Maximum percentage of shares issued							19.99%
Maximum number of shares issued							308,590
Beneficial Ownership Cap							4.99%
Shares sold in offering (in shares)															2,778,077	328,590
Issuance of common stock, net of issuance costs															$ 6,600,000	$ 1,400,000
Share price (in dollars per share)							$ 7.05
Shares issued (in shares)															1,680,000
Lincoln Park [Member] | Subsequent Events
Class of Stock [Line Items]
Proceeds from sale of stock												$ 1,300,000					$ 9,300,000
New shares issued (in shares)													780,012	120,000
Shares sold in offering (in shares)												900,012
Issuance of common stock, net of issuance costs		$ 9,300,000
Lincoln Park [Member] | Subsequent Events | Common Stock
Class of Stock [Line Items]
New shares issued (in shares)	920,654
Preferred Class B
Class of Stock [Line Items]
Common stock issued on conversion of preferred shares															208,000
Minimum | Settled Litigation
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs					$ 4,000,000
Minimum | Lincoln Park [Member]
Class of Stock [Line Items]
Share price (in dollars per share)							$ 1.50
Maximum | Lincoln Park [Member]
Class of Stock [Line Items]
Value of shares issued							$ 1,000,000								$ 10,000,000
Shares sold in offering based on market price							36,666
Shares sold in offering (in shares)							30,000

STOCKHOLDERS' EQUITY (Preferred

STOCKHOLDERS' EQUITY (Preferred Stock) (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000

STOCKHOLDERS' EQUITY (Series B

STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) - USD ($)	Nov. 29, 2018	Aug. 31, 2017	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 30, 2018	Apr. 30, 2018	Feb. 28, 2018	Feb. 12, 2018	Aug. 25, 2017
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)					$ 0.01	$ 0.01
Share price (in dollars per share)										$ 15.60
Preferred stock, shares authorized (in shares)					15,000,000	15,000,000
Preferred stock, shares outstanding (in shares)					47	47
Preferred stock, shares issued (in shares)					47	47
Offering Warrants
Class of Stock [Line Items]
Stock rights issued (in shares)		178,667
Exercise price (in dollars per share)		$ 45			$ 11.25		$ 2.25	$ 4.50	$ 15.60
Proceeds from issuance of warrants					$ 15,000	$ 795,000
Preferred Class B
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)											$ 0.01
Number of shares converted (in shares)					2,340
Preferred stock, shares authorized (in shares)					6,900	6,900					6,900
Preferred stock, shares outstanding (in shares)					47	47
Preferred stock, shares issued (in shares)					6,900	6,900
Preferred Stock, Liquidation Preference Per Share											$ 1,000
2018 Inducement Agreement | Preferred Class B
Class of Stock [Line Items]
Conversion price (in dollars per share)	$ 2.25				$ 11.25
2018 Inducement Agreement | Preferred Class B | Deemed Dividend B
Class of Stock [Line Items]
Beneficial conversion feature				$ 40,000
2018 Inducement Agreement | Preferred Class B | Deemed Dividend D
Class of Stock [Line Items]
Beneficial conversion feature	$ 300,000
2018 Inducement Agreement | Preferred Class B | Deemed Dividend C
Class of Stock [Line Items]
Beneficial conversion feature			$ 200,000
2018 Purchase Agreement | Preferred Class B
Class of Stock [Line Items]
Conversion price (in dollars per share)					$ 15.60
2018 Purchase Agreement | Preferred Class B | Deemed Dividend A
Class of Stock [Line Items]
Beneficial conversion feature					$ 1,400,000
2018 Note Agreement | Preferred Class B
Class of Stock [Line Items]
Conversion price (in dollars per share)					$ 4.50	$ 15.60
Preferred Class B
Class of Stock [Line Items]
Common stock issued on conversion of preferred shares					208,000

STOCKHOLDERS' EQUITY (Series C

STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Feb. 12, 2018	Nov. 30, 2017	Nov. 06, 2017
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Share price (in dollars per share)			$ 15.60
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares outstanding (in shares)	47	47
Preferred stock, shares issued (in shares)	47	47
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)					$ 0.01
Number of shares converted (in shares)	2,548
Preferred stock, shares authorized (in shares)	2,748				2,748
Preferred stock, shares outstanding (in shares)	0
Preferred Stock, Liquidation Preference Per Share				$ 1,000
Common stock issued on conversion of preferred shares	223,022
Placement Agreement | Series C Preferred Stock [Member]
Class of Stock [Line Items]
Conversion price (in dollars per share)		$ 21
2018 Purchase Agreement | Series C Preferred Stock [Member]
Class of Stock [Line Items]
Conversion price (in dollars per share)	$ 15.60
2018 Purchase Agreement | Series C Preferred Stock [Member] | Deemed Dividend E
Class of Stock [Line Items]
Beneficial conversion feature	$ 0.8

STOCKHOLDERS' EQUITY (Preferr_2

STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details) - USD ($)	Mar. 21, 2018	Feb. 12, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 29, 2018	Mar. 12, 2018	Aug. 25, 2017
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)			15,000,000	15,000,000
Preferred stock, par value (in dollars per share)			$ 0.01	$ 0.01
Number of shares converted from debt instrument (in shares)		120,983
Conversion of convertible debt plus interest into common stock		$ 1,900,000	$ 7,553,000	$ 2,356,000
Deemed dividend			$ 0	$ 4,222,000
Warrants exercised			20,000
Preferred stock, shares outstanding (in shares)			47	47
Preferred stock, shares issued (in shares)			47	47
2018 Inducement Agreement | Warrants After Conversion Price Reduction [Member] | Deemed Dividend F
Class of Stock [Line Items]
Warrants, fair value			$ 100,000
Preferred Stock [Member]
Class of Stock [Line Items]
Shares not converted			47
Preferred Stock [Member] | 2018 Inducement Agreement
Class of Stock [Line Items]
Conversion price (in dollars per share)						$ 11.25
Exercise price (in dollars per share)			$ 11.25	$ 15.60
Preferred Stock [Member] | 2018 Inducement Agreement | Deemed Dividend F
Class of Stock [Line Items]
Shares converted, value			$ 1,100,000
Warrants, fair value			$ 1,200,000
Common Stock
Class of Stock [Line Items]
Number of shares converted from debt instrument (in shares)			310,200	252,486
Conversion of convertible debt plus interest into common stock			$ 7,600,000	$ 2,400,000
Preferred Class B
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)			6,900	6,900			6,900
Preferred stock, par value (in dollars per share)							$ 0.01
Number of shares converted (in shares)			2,340
Preferred stock, shares outstanding (in shares)			47	47
Preferred stock, shares issued (in shares)			6,900	6,900
Preferred Class B | 2018 Inducement Agreement
Class of Stock [Line Items]
Conversion price (in dollars per share)			$ 11.25		$ 2.25
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)	$ 11.25		$ 11.25
Warrants Issued During Period, Maximum Allowed Percentage of Common Stock	4.99%
Convertible Preferred Stock [Member] | Preferred Stock Induced Conversions, First Investor [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Warrants or Rights Exercised	44,444
Convertible Preferred Stock [Member] | Preferred Stock Induced Conversions, Second Investor [Member]
Class of Stock [Line Items]
Issuance of warrants in conjunction with issuance of side agreement	$ 33,333

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)	Dec. 31, 2019$ / sharesshares
Class of Stock [Line Items]
Underlying shares (in shares)	909,189
Warrants Assumed in Merger, Expiring April 2020 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	832
Exercise price (in dollars per share) | $ / shares	$ 1,800
Warrants Assumed in Merger, Expiring February 2020 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	1,588
Exercise price (in dollars per share) | $ / shares	$ 1,008
Warrants Assumed in Merger, Expiring December 2020 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	272
Exercise price (in dollars per share) | $ / shares	$ 747
Warrants Assumed in Merger, Expiring January 2021, Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	596
Exercise price (in dollars per share) | $ / shares	$ 544.50
Warrants outstanding (in shares)	239
Warrants Not Assumed in Merger, Expiring June 2022, Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	2,540
Exercise price (in dollars per share) | $ / shares	$ 41.25
Warrants Not Assumed in Merger, Expiring June 2022, Group B [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	500
Exercise price (in dollars per share) | $ / shares	$ 7.50
Warrants Not Assumed In Merger, Expiring June 2022 Group C [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	6,095
Exercise price (in dollars per share) | $ / shares	$ 105
Warrants Not Assumed in Merger, Expiring August 2022, Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	25,201
Exercise price (in dollars per share) | $ / shares	$ 2.25
Warrants Not Assumed in Merger, Expiring August 2022, Group B [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	4,000
Exercise price (in dollars per share) | $ / shares	$ 46.88
Warrants Not Assumed in Merger, Expiring August 2022, Group C [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	47,995
Exercise price (in dollars per share) | $ / shares	$ 150
Warrants Not Assumed in Merger, Expiring August 2022, Group D [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	9,101
Exercise price (in dollars per share) | $ / shares	$ 7.50
Warrants Not Assumed In Merger, Expiring August 2022 Group E [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	16,664
Exercise price (in dollars per share) | $ / shares	$ 2.25
Warrants Not Assumed In Merger, Expiring August2022 Group F [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	7,335
Exercise price (in dollars per share) | $ / shares	$ 2.25
Warrants Not Assumed in Merger, Expiring October 2022 Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	666
Exercise price (in dollars per share) | $ / shares	$ 2.25
Warrants Not Assumed in Merger, Expiring May 2023 [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 2.25
Warrants Not Assumed in Merger, Expiring October 2022 Group B [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	7,207
Exercise price (in dollars per share) | $ / shares	$ 112.50
Warrants Not Assumed in Merger, Expiring April 2019 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	69,964
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed in Merger, Expiring April 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	121,552
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed in Merger, Expiring October 2022 Group C [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	15,466
Exercise price (in dollars per share) | $ / shares	$ 11.25
Warrants Not Assumed In Merger, Expiring July 2019 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	14,671
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring July 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	14,672
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring August 2019 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	36,334
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring August 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	36,334
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring September 2019 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	19,816
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring September 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	20,903
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring November 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	75,788
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring December 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	51,282
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring April 2024 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	147,472
Exercise price (in dollars per share) | $ / shares	$ 5.40
Warrants Not Assumed In Merger, Expiring May 2024 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)	154,343
Exercise price (in dollars per share) | $ / shares	$ 9.56
2016 Warrant Liability [Member]
Class of Stock [Line Items]
Warrants outstanding (in shares)	357

STOCKHOLDERS' EQUITY (New Bridg

STOCKHOLDERS' EQUITY (New Bridge Warrants) (Details) - USD ($)	Dec. 31, 2019	Aug. 31, 2017	Jun. 30, 2017
Class of Stock [Line Items]
Underlying shares (in shares)	909,189
2017 Bridge Notes | Common Stock
Class of Stock [Line Items]
Underlying shares (in shares)	500
Exercise price (in dollars per share)	$ 7.50	$ 41.25
Warrants, fair value	$ 1,000
Bridge Loan | Common Stock
Class of Stock [Line Items]
Exercise price (in dollars per share)			$ 112.50

STOCKHOLDERS' EQUITY (Side Warr

STOCKHOLDERS' EQUITY (Side Warrants) (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Underlying shares (in shares)	909,189
Side Warrants [Member]
Class of Warrant or Right [Line Items]
Underlying shares (in shares)	6,095
Exercise price (in dollars per share) | $ / shares	$ 105
Class of warrant or right, term	5 years

STOCKHOLDERS' EQUITY (Offering

STOCKHOLDERS' EQUITY (Offering Warrants) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Nov. 30, 2018	Apr. 30, 2018
Class of Stock [Line Items]
Deemed dividend			$ 0	$ 4,222,000
Warrants exercised			20,000
Offering Warrants
Class of Stock [Line Items]
Stock rights issued (in shares)		178,667
Exercise price (in dollars per share)	$ 15.60	$ 45	$ 11.25		$ 2.25	$ 4.50
Class of warrant or right, term		5 years
Warrants exercised			6,800	146,666
Proceeds from issuance of warrants			$ 15,000	$ 795,000
Intrinsic value of warrants exercisable			$ 36,000	$ 420,000
Offering Warrants | Deemed Dividend G
Class of Stock [Line Items]
Deemed dividend	$ 62,000

STOCKHOLDERS' EQUITY (Represent

STOCKHOLDERS' EQUITY (Representative Warrants) (Details) - shares	1 Months Ended
	Aug. 31, 2017	Dec. 31, 2019
Class of Stock [Line Items]
Underlying shares (in shares)		909,189
Representative Warrants [Member] | Minimum
Class of Stock [Line Items]
Class of warrant or right, term	1 year
Representative Warrants [Member] | Maximum
Class of Stock [Line Items]
Class of warrant or right, term	5 years

STOCKHOLDERS' EQUITY (Series A

STOCKHOLDERS' EQUITY (Series A Conversion Warrants) (Details) - shares	1 Months Ended
	Aug. 31, 2017	Dec. 31, 2019
Class of Stock [Line Items]
Underlying shares (in shares)		909,189
Series A Conversion Warrants [Member]
Class of Stock [Line Items]
Class of warrant or right, term	5 years

STOCKHOLDERS' EQUITY (Note Conv

STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details) - USD ($)	Feb. 12, 2018	Nov. 30, 2018	Apr. 30, 2018	Jul. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2018	Dec. 31, 2017	Aug. 31, 2017	Jun. 30, 2017
Class of Stock [Line Items]
Conversion of debt into stock	$ 1,900,000				$ 7,553,000	$ 2,356,000
Conversion of convertible notes into common stock (in shares)	120,983
Underlying shares (in shares)					909,189
Deemed dividend					$ 0	4,222,000
Series A Conversion Warrants [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)					$ 7.50
Underlying shares (in shares)					9,101
Warrants, fair value					$ 10,000
Note Conversion Warrants
Class of Stock [Line Items]
Class of warrant or right, term					5 years
2018 Inducement Agreement | Deemed Dividend K
Class of Stock [Line Items]
Deemed dividend						5,000
2018 Inducement Agreement | Deemed Dividend F
Class of Stock [Line Items]
Deemed dividend						1,154,000
2018 Inducement Agreement | Note Conversion Warrants | Deemed Dividend K
Class of Stock [Line Items]
Deemed dividend					$ 5,000
2018 Purchase Agreement | Deemed Dividend J
Class of Stock [Line Items]
Deemed dividend						8,000
2018 Purchase Agreement | Deemed Dividend G
Class of Stock [Line Items]
Deemed dividend						62,000
2018 Purchase Agreement | Note Conversion Warrants | Deemed Dividend J
Class of Stock [Line Items]
Deemed dividend					8,000
2018 Note Agreement
Class of Stock [Line Items]
Exercise price (in dollars per share)		$ 2.25	$ 4.50
2018 Note Agreement | Deemed Dividend L
Class of Stock [Line Items]
Deemed dividend						10,000
2018 Note Agreement | Note Conversion Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)		$ 2.25	$ 4.50
2018 Note Agreement | Note Conversion Warrants | Deemed Dividend L
Class of Stock [Line Items]
Deemed dividend			$ 10,000
2018 Note Agreement | Note Conversion Warrants | Deemed Dividend M
Class of Stock [Line Items]
Deemed dividend		$ 4,000
Common Stock
Class of Stock [Line Items]
Conversion of debt into stock					$ 7,600,000	$ 2,400,000
Conversion of convertible notes into common stock (in shares)					310,200	252,486
Common Stock | Note Conversion Warrants
Class of Stock [Line Items]
Conversion of convertible notes into common stock (in shares)				23,999
Exercise price (in dollars per share)								$ 21	$ 45
Common Stock | 2018 Inducement Agreement | Note Conversion Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)					$ 11.25
Common Stock | 2018 Purchase Agreement | Note Conversion Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)							$ 15.60
Bridge Loan | Common Stock
Class of Stock [Line Items]
Exercise price (in dollars per share)										$ 112.50

STOCKHOLDERS' EQUITY (Convertib

STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details) - USD ($)	1 Months Ended			12 Months Ended
	Nov. 30, 2018	Apr. 30, 2018	Aug. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2018	Oct. 03, 2017
Class of Stock [Line Items]
Deemed dividend				$ 0	$ 4,222,000
Convertible Promissory Note Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)				$ 21			$ 45
Offering Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)	$ 2.25	$ 4.50	$ 45	11.25		$ 15.60
Class of warrant or right, term			5 years
Offering Warrants | Deemed Dividend H
Class of Stock [Line Items]
Deemed dividend		$ 63,000
Offering Warrants | Deemed Dividend I
Class of Stock [Line Items]
Deemed dividend	$ 5,000
2018 Inducement Agreement | Convertible Promissory Note Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)				11.25
2018 Purchase Agreement | Convertible Promissory Note Warrants
Class of Stock [Line Items]
Exercise price (in dollars per share)				$ 15.60
2018 Note Agreement
Class of Stock [Line Items]
Exercise price (in dollars per share)	$ 2.25	$ 4.50
2018 Note Agreement | Deemed Dividend H
Class of Stock [Line Items]
Deemed dividend					$ 63,000
Maximum | 2018 Inducement Agreement | Convertible Promissory Note Warrants | Deemed Dividend O
Class of Stock [Line Items]
Deemed dividend				$ 1,000
Maximum | 2018 Purchase Agreement | Convertible Promissory Note Warrants | Deemed Dividend N
Class of Stock [Line Items]
Deemed dividend				$ 1,000

STOCKHOLDERS' EQUITY (Series _2

STOCKHOLDERS' EQUITY (Series C Warrants) (Details) - USD ($)	1 Months Ended				12 Months Ended
	Nov. 30, 2018	Apr. 30, 2018	Feb. 28, 2018	Nov. 30, 2017	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Underlying shares (in shares)					909,189
Deemed dividend					$ 0	$ 4,222,000
Warrants exercised					20,000
Series C Warrants [Member]
Class of Stock [Line Items]
Underlying shares (in shares)				130,857
Exercise price (in dollars per share)				$ 24.45
Class of warrant or right, term				5 years
Percentage of outstanding shares owned threshold prior to exercise of warrants				4.99%
Percentage of outstanding shares owned threshold after exercise of warrants				9.99%
2018 Purchase Agreement | Deemed Dividend R
Class of Stock [Line Items]
Deemed dividend						58,000
2018 Purchase Agreement | Deemed Dividend J
Class of Stock [Line Items]
Deemed dividend						8,000
2018 Purchase Agreement | Series C Warrants [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)			$ 15.60		$ 11.25
2018 Purchase Agreement | Series C Warrants [Member] | Deemed Dividend R
Class of Stock [Line Items]
Deemed dividend			$ 58,000
2018 Note Agreement
Class of Stock [Line Items]
Exercise price (in dollars per share)	$ 2.25	$ 4.50
2018 Note Agreement | Deemed Dividend S
Class of Stock [Line Items]
Deemed dividend						$ 45,000
2018 Note Agreement | Series C Warrants [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)	$ 2.25	$ 4.50
Warrants exercised					25,037	105,820
Proceeds from issuance of warrants					$ 56,000	$ 476,000
Intrinsic value of warrants exercised in period					$ 443,000	$ 294,000
2018 Note Agreement | Series C Warrants [Member] | Deemed Dividend S
Class of Stock [Line Items]
Deemed dividend		$ 45,000
2018 Note Agreement | Series C Warrants [Member] | Deemed Dividend T
Class of Stock [Line Items]
Deemed dividend	$ 4,000

STOCKHOLDERS' EQUITY (Remaining

STOCKHOLDERS' EQUITY (Remaining Warrants) (Details) - USD ($)

Apr. 30, 2018

May 31, 2019

Sep. 30, 2018

Apr. 30, 2018

Dec. 31, 2018

Sep. 30, 2018

Sep. 30, 2018

Dec. 31, 2019

Dec. 31, 2018

Apr. 30, 2019

Nov. 30, 2018

Aug. 31, 2018

Feb. 28, 2018

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

909,189

Loss on modification of warrants

$ (1,128,000)

Warrants exercised

20,000

Change in fair value due to repricing

$ (416,000)

$ (1,918,000)

Loss on issuance of convertible notes

$ 1,870,000

1,328,000

Creditor Warrants Relating to Secured Debt

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

7,207

Exercise price (in dollars per share)

$ 112.50

April 2018 Warrants

Class of Stock [Line Items]

Stock rights issued (in shares)

243,224

Exercise price (in dollars per share)

$ 11.25

$ 7.50

$ 11.25

$ 7.50

$ 7.50

Warrants, fair value

$ 1,100,000

$ 1,100,000

Warrants exercised

51,708

Proceeds from issuance of warrants

$ 279,000

Intrinsic value of warrants exercisable

$ 128,000

Change in fair value due to repricing

$ 100,000

April 2018 Warrants, First Half

Class of Stock [Line Items]

Class of warrant or right, term

5 years

5 years

5 years

Amended Warrants

Class of Stock [Line Items]

Exercise price (in dollars per share)

$ 5.40

Warrants term

5 years

Amended April 2018 Warrants

Class of Stock [Line Items]

Exercise price (in dollars per share)

$ 5.40

Warrants term

5 years

Loss on modification of warrants

$ 700,000

Amended Q3 2018 Warrants [Member]

Class of Stock [Line Items]

Loss on modification of warrants

$ 400,000

April 2018 Warrants, Second Half

Class of Stock [Line Items]

Class of warrant or right, term

1 year

1 year

1 year

Advisor Warrants

Class of Stock [Line Items]

Stock rights issued (in shares)

15,466

Warrants, fair value

$ 100,000

$ 100,000

Class of warrant or right, term

4 years

Quarter 3 2018 Warrants

Class of Stock [Line Items]

Stock rights issued (in shares)

196,340

Exercise price (in dollars per share)

$ 5.40

Warrants term

5 years

Warrants exercised

53,610

Proceeds from issuance of warrants

$ 289,000

Intrinsic value of warrants exercisable

$ 133,382

Quarter 3 2018 Warrants | Convertible Debt [Member]

Class of Stock [Line Items]

Number of Warrants issued

196,340

Exercise price (in dollars per share)

$ 11.25

Warrants, fair value

$ 700,000

$ 700,000

$ 700,000

Change in fair value due to repricing

$ 100,000

Modified exercise price

$ 7.50

Quarter 3 2018 Warrants, First Half [Member] | Convertible Debt [Member]

Class of Stock [Line Items]

Class of warrant or right, term

5 years

Quarter 3 2018 Warrants, Second Half [Member] | Convertible Debt [Member]

Class of Stock [Line Items]

Class of warrant or right, term

1 year

Warrants Not Assumed In Merger, Expiring November 2023 [Member]

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

75,788

Exercise price (in dollars per share)

$ 5.40

Warrants Not Assumed In Merger, Expiring December 2023 [Member]

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

51,282

Exercise price (in dollars per share)

$ 5.40

Quarter 4 2018 Warrants

Class of Stock [Line Items]

Stock rights issued (in shares)

300,115

Warrants exercised

173,045

Proceeds from issuance of warrants

$ 934,000

Intrinsic value of warrants exercisable

$ 489,000

Quarter 4 2018 Warrants | Convertible Debt [Member]

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

300,115

300,115

Exercise price (in dollars per share)

$ 5.40

$ 5.40

Warrants, fair value

$ 700,000

$ 700,000

Warrants term

5 years

5 years

April 2019 Bridge Notes | Convertible Debt [Member]

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

147,472

Exercise price (in dollars per share)

$ 5.40

Warrants, fair value

$ 1,000,000

Warrants term

5 years

May 2019 Warrants

Class of Stock [Line Items]

Stock rights issued (in shares)

154,343

May 2019 Warrants | Convertible Debt [Member]

Class of Stock [Line Items]

Class of warrant, number of securities called by warrants

154,343

Exercise price (in dollars per share)

$ 5.40

Warrants, fair value

$ 900,000

Warrants term

5 years

2018 Note Agreement

Class of Stock [Line Items]

Exercise price (in dollars per share)

$ 4.50

$ 4.50

$ 2.25

2018 Note Agreement | April 2018 Warrants, First Half

Class of Stock [Line Items]

Class of warrant or right, term

1 year

2018 Note Agreement | April 2018 Warrants, Second Half

Class of Stock [Line Items]

Class of warrant or right, term

5 years

2018 Note Agreement | Advisor Warrants

Class of Stock [Line Items]

Stock rights issued (in shares)

15,466

Exercise price (in dollars per share)

$ 11.25

$ 11.25

Warrants, fair value

$ 100,000

$ 100,000

STOCKHOLDERS' EQUITY (Deemed Di

STOCKHOLDERS' EQUITY (Deemed Dividends) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Nov. 30, 2018	Apr. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Amount Recorded			$ 0	$ 4,222,000
2018 Purchase Agreement | Deemed Dividend A
Class of Stock [Line Items]
Amount Recorded				1,358,000
2018 Purchase Agreement | Deemed Dividend E
Class of Stock [Line Items]
Amount Recorded				829,000
2018 Purchase Agreement | Deemed Dividend G
Class of Stock [Line Items]
Amount Recorded				62,000
2018 Purchase Agreement | Deemed Dividend J
Class of Stock [Line Items]
Amount Recorded				8,000
2018 Purchase Agreement | Deemed Dividend R
Class of Stock [Line Items]
Amount Recorded				58,000
2018 Inducement Agreement | Deemed Dividend B
Class of Stock [Line Items]
Amount Recorded				40,000
2018 Inducement Agreement | Deemed Dividend F
Class of Stock [Line Items]
Amount Recorded				1,154,000
2018 Inducement Agreement | Deemed Dividend K
Class of Stock [Line Items]
Amount Recorded				5,000
2018 Note Agreement | Deemed Dividend L
Class of Stock [Line Items]
Amount Recorded				10,000
2018 Note Agreement | Deemed Dividend C
Class of Stock [Line Items]
Amount Recorded				216,000
2018 Note Agreement | Deemed Dividend H
Class of Stock [Line Items]
Amount Recorded				63,000
2018 Note Agreement | Deemed Dividend P
Class of Stock [Line Items]
Amount Recorded		$ 1,000
2018 Note Agreement | Deemed Dividend S
Class of Stock [Line Items]
Amount Recorded				45,000
2018 Note Agreement | Deemed Dividend Q
Class of Stock [Line Items]
Amount Recorded	$ 1,000
Amendment Agreement | Deemed Dividend D
Class of Stock [Line Items]
Amount Recorded				361,000
Amendment Agreement | Deemed Dividend I
Class of Stock [Line Items]
Amount Recorded				5,000
Amendment Agreement | Deemed Dividend M
Class of Stock [Line Items]
Amount Recorded				4,000
Amendment Agreement | Deemed Dividend T
Class of Stock [Line Items]
Amount Recorded				$ 4,000

FAIR VALUE (Narratives) (Detail

FAIR VALUE (Narratives) (Details) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	May 31, 2019shares	Apr. 30, 2019shares	Apr. 30, 2018USD ($)shares	Dec. 31, 2018USD ($)Yshares	Sep. 30, 2018USD ($)shares	Dec. 31, 2019USD ($)Yshares	Dec. 31, 2018USD ($)Y	Feb. 12, 2018$ / shares	Dec. 31, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt settlement						$ 477
Share price (in dollars per share) | $ / shares								$ 15.60
Derivative asset (liability)				$ 62			$ 62
Bridge Notes Redemption Feature [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt settlement						438
Derivative asset (liability)				30			30
Conversion Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt settlement						39
Derivative asset (liability)				$ 32			32
Quarter 3 2018 Bridge Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities					$ 100
Derivative liability from debt discount					$ 100
April 2018 Bridge Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities			$ 300
Derivative liability from debt discount			$ 100
2016 Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares) | shares						357
(Decrease) in warrant liability						$ (400)
Warrants canceled in settlement agreement | shares						1,347
Debt settlement							$ 456
Measurement Input, Price Volatility [Member] | 2016 Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input						140
Measurement Input, Risk Free Interest Rate [Member] | 2016 Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input						1.59
Measurement Input, Expected Term [Member] | 2016 Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y						1
April 2018 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock rights issued (in shares) | shares			243,224
Advisor Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock rights issued (in shares) | shares			15,466
Quarter 3 2018 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock rights issued (in shares) | shares					196,340
Quarter 4 2018 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock rights issued (in shares) | shares				300,115
Quarter 4 2018 Warrants | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input				176			176
Quarter 4 2018 Warrants | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.48			2.48
Quarter 4 2018 Warrants | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected term							2 years
April 2019 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock rights issued (in shares) | shares		147,472
May 2019 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock rights issued (in shares) | shares	154,343
Minimum | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input						141
Minimum | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input						1.58
Minimum | April 2018 Warrants | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input				85			85
Minimum | April 2018 Warrants | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.45			2.45
Minimum | April 2018 Warrants | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y				0.3			0.3
Minimum | April 2019 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected term						2 years 3 months 18 days
Maximum | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input						163
Maximum | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input						1.65
Maximum | April 2018 Warrants | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input				162			162
Maximum | April 2018 Warrants | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.63			2.63
Maximum | April 2018 Warrants | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y				5			5
Maximum | April 2019 Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected term						4 years 4 months 24 days

FAIR VALUE (Schedule of Changes

FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total (gains) or losses:
Deductions - warrant liability settlement	$ (477)
Warrant Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1,132	$ 841
Additions	1,858	2,665
Total (gains) or losses:
Revaluation recognized in earnings	(416)	(2,061)
Modification recognized in earnings	1,128	143
Deductions - warrant liability settlement	(2,364)	(456)
Balance at end of period	1,338	1,132
2016 Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	116	841
Total (gains) or losses:
Revaluation recognized in earnings	(46)	(269)
Deductions - warrant liability settlement		(456)
Balance at end of period	70	116
2018 Warrant Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1,016
Additions	1,858	2,665
Total (gains) or losses:
Revaluation recognized in earnings	(370)	(1,792)
Modification recognized in earnings	1,128	143
Deductions - warrant liability settlement	(2,364)
Balance at end of period	$ 1,268	$ 1,016

FAIR VALUE (Schedule of Chang_2

FAIR VALUE (Schedule of Changes in Fair Value of Derivative Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability beginning balance	$ 62
Additions		652
Deductions - write-off in conjunction with convertible note conversions		(301)
Total (gains) or losses:
Extinguishment recognized in earnings		(22)
Revaluation recognized in earnings	415	(267)
Derivative liability ending balance		62
Bridge Notes Redemption Feature [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability beginning balance	30
Additions		269
Total (gains) or losses:
Extinguishment recognized in earnings		(22)
Revaluation recognized in earnings	408	(217)
Derivative liability ending balance		30
Conversion Option [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability beginning balance	32
Additions		383
Deductions - write-off in conjunction with convertible note conversions		(301)
Total (gains) or losses:
Revaluation recognized in earnings	7	(50)
Derivative liability ending balance		$ 32

EQUITY INCENTIVE PLAN (Narrativ

EQUITY INCENTIVE PLAN (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 700,000	$ (500,000)
Unrecognized compensation expense related to unvested stock awards		$ 1,700,000
Unvested stock options, unrecognized compensation expense weighted average recognition period		2 years
Share-based compensation arrangement by share-based payment award, expiration period		10 years
Accrued expenses		$ 1,268,000	$ 1,583,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expected to vest, outstanding (in shares)		413,174
Stock options, expected to vest, outstanding, aggregate intrinsic value		$ 0
Stock options, expected to vest remaining contractual term		8 years 8 months 12 days
Weighted average grant date fair value (in dollars per share)		$ 2.15
Risk free interest rate, minimum		1.60%
Risk free interest rate, maximum		2.53%
Term		6 years
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized	359,300
Number of shares authorized	403,744
Maximum number of shares per employee	66,667
Award plan, percentage of outstanding stock maximum	5.00%
Equity Incentive Plan 2017 [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, expiration period		10 years
Number of shares authorized		44,444
Pricing model used for fair value assumptions		Black-Scholes option pricing model
Minimum | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate		133.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period		4 years
Maximum | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period		4 years
Volatility rate		139.00%

EQUITY INCENTIVE PLAN (Summary

EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Weighted-Average Exercise Price
Stock-based compensation	$ 0.7	$ (0.5)
Stock Options [Member]
Number of Options
Outstanding at beginning of period (in shares)	224,895
Granted (in shares)	292,604	224,365
Forfeited (in shares)	(27,169)	(15,236)
Outstanding at end of period (in shares)	490,330	224,895
Exercisable at end of period (in shares)	181,705
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 15.90
Granted (in dollars per share)	2.36	$ 10.50
Forfeited (in dollars per share)	6.03	29.94
Outstanding at end of period (in dollars per share)	8.30	$ 15.90
Exercisable at end of period (in dollars per share)	$ 13.48

SALES SERVICE REVENUE, NET AN_3

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Concentration Risk [Line Items]
Deferred revenue	$ 35	$ 49

SALES SERVICE REVENUE, NET AN_4

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 4,095	$ 3,448
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	4,051	3,335
Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,456	2,148
Biomarker Testing and Clinical Project Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	595	1,187
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	28	50
Medicaid [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	28	50
Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,669	1,000
Medicare [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,669	1,000
Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	34	138
Self-Pay [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	34	138
Third Party Payer [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,725	960
Third Party Payer [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,725	960
Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	595	1,187
Contract Diagnostic Services [Member] | Biomarker Testing and Clinical Project Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 595	$ 1,187

SALES SERVICE REVENUE, NET AN_5

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Gross revenue	$ 8,175	$ 4,901
Contractual allowance and adjustments	(4,080)	(1,453)
Service revenue, net	4,095	3,448
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	31	86
Contractual allowance and adjustments	(3)	(36)
Service revenue, net	28	50
Medicare [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	1,686	1,019
Contractual allowance and adjustments	(17)	(19)
Service revenue, net	1,669	1,000
Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	34	138
Service revenue, net	34	138
Third Party Payer [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	5,785	2,358
Contractual allowance and adjustments	(4,060)	(1,398)
Service revenue, net	1,725	960
Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	595	1,187
Service revenue, net	595	1,187
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	8,131	4,788
Contractual allowance and adjustments	(4,080)	(1,453)
Service revenue, net	4,051	3,335
Clinical Research Grants and Other [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	44	113
Service revenue, net	$ 44	$ 113

SALES SERVICE REVENUE, NET AN_6

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 4,095	$ 3,448
less allowance for doubtful accounts	(968)	(584)
Net sales	3,127	2,864
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	28	50
less allowance for doubtful accounts	(28)	(50)
Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,669	1,000
less allowance for doubtful accounts	(251)	(150)
Net sales	1,418	850
Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	34	138
Net sales	34	138
Third Party Payer [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,725	960
less allowance for doubtful accounts	(689)	(384)
Net sales	1,036	576
Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	595	1,187
Net sales	595	1,187
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	4,051	3,335
less allowance for doubtful accounts	(968)	(584)
Net sales	3,083	2,751
Clinical Research Grants and Other [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	44	113
Net sales	$ 44	$ 113

SALES SERVICE REVENUE, NET AN_7

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts receivable, gross	$ 3,248	$ 2,398
Less allowance for doubtful accounts	(2,674)	(1,708)
Accounts receivable, net	574	690
Medicaid [Member]
Accounts receivable, gross	107	82
Medicare [Member]
Accounts receivable, gross	814	633
Self-Pay [Member]
Accounts receivable, gross	88	108
Third Party Payer [Member]
Accounts receivable, gross	2,203	1,382
Contract Diagnostic Services [Member]
Accounts receivable, gross	$ 36	$ 193

SALES SERVICE REVENUE, NET AN_8

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts, Beginning balance	$ (1,708)
less allowance for doubtful accounts	(968)	$ (584)
Allowances for doubtful accounts	(4,095)	(3,448)
Bad debt expense	(2)
Total charges	(966)
Allowance for doubtful accounts, Ending balance	(2,674)	(1,708)
Medicaid [Member]
less allowance for doubtful accounts	(28)	(50)
Allowances for doubtful accounts	(28)	(50)
Medicare [Member]
less allowance for doubtful accounts	(251)	(150)
Allowances for doubtful accounts	(1,669)	(1,000)
Third Party Payer [Member]
less allowance for doubtful accounts	(689)	(384)
Allowances for doubtful accounts	$ (1,725)	$ (960)

SALES SERVICE REVENUE, NET AN_9

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Detail) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Sales Revenue, Net [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	19.00%	33.00%
Sales Revenue, Net [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		23.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Events - USD ($)	Mar. 26, 2020	Mar. 26, 2020	Mar. 25, 2020
Bridge Notes [Member]
Subsequent Event [Line Items]
Guaranteed interest period	18 months
Floor price			$ 2.25
May 2019 Warrants
Subsequent Event [Line Items]
Floor price	$ 0.40	$ 0.40
LP 2020 Purchase Agreement [Member]
Subsequent Event [Line Items]
Maximum repurchase of common stock amount	$ 10,000,000	$ 10,000,000
Purchase agreement term		24 months
LP 2020 Purchase Agreement [Member] | Lincoln Park [Member]
Subsequent Event [Line Items]
Stock issued for commitment fees		250,000
Maximum repurchase of common stock	50,000	50,000
Maximum amount of single regular purchase		$ 1,000,000
LP 2020 Purchase Agreement [Member] | Lincoln Park [Member] | Closing Sale Price Above 1.00 [Member]
Subsequent Event [Line Items]
Maximum repurchase of common stock	80,000	80,000
LP 2020 Purchase Agreement [Member] | Lincoln Park [Member] | Closing Sale Price Above 1.50 [Member]
Subsequent Event [Line Items]
Maximum repurchase of common stock	100,000	100,000